#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Human Plasma BDNF Is Associated With Amygdala-Prefrontal Cortex Functional Connectivity and Problem Drinking Behaviors
#Text=Abstract
#Text=Background
#Text=Preclinical studies suggest that decreased levels of brain-derived neurotrophic factor in the amygdala play a role in anxiety and alcohol use disorder.
1-1	0-5	Human	_
1-2	6-12	Plasma	_
1-3	13-17	BDNF	_
1-4	18-20	Is	_
1-5	21-31	Associated	_
1-6	32-36	With	_
1-7	37-56	Amygdala-Prefrontal	_
1-8	57-63	Cortex	_
1-9	64-74	Functional	_
1-10	75-87	Connectivity	_
1-11	88-91	and	_
1-12	92-99	Problem	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-13	100-108	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-14	109-118	Behaviors	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-15	119-127	Abstract	_
1-16	128-138	Background	_
1-17	139-150	Preclinical	_
1-18	151-158	studies	_
1-19	159-166	suggest	_
1-20	167-171	that	_
1-21	172-181	decreased	_
1-22	182-188	levels	_
1-23	189-191	of	_
1-24	192-205	brain-derived	_
1-25	206-218	neurotrophic	_
1-26	219-225	factor	_
1-27	226-228	in	_
1-28	229-232	the	_
1-29	233-241	amygdala	_
1-30	242-246	play	_
1-31	247-248	a	_
1-32	249-253	role	_
1-33	254-256	in	_
1-34	257-264	anxiety	_
1-35	265-268	and	_
1-36	269-276	alcohol	_
1-37	277-280	use	_
1-38	281-289	disorder	_
1-39	289-290	.	_

#Text=The association between brain-derived neurotrophic factor levels and amygdala function in humans with alcohol use disorder is still unclear, although neuroimaging studies have also implicated the amygdala in alcohol use disorder and suggest that alcohol use disorder is associated with disrupted functional connectivity between the amygdala and prefrontal cortex during aversive states.
2-1	291-294	The	_
2-2	295-306	association	_
2-3	307-314	between	_
2-4	315-328	brain-derived	_
2-5	329-341	neurotrophic	_
2-6	342-348	factor	_
2-7	349-355	levels	_
2-8	356-359	and	_
2-9	360-368	amygdala	_
2-10	369-377	function	_
2-11	378-380	in	_
2-12	381-387	humans	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
2-13	388-392	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
2-14	393-400	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
2-15	401-404	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
2-16	405-413	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
2-17	414-416	is	_
2-18	417-422	still	_
2-19	423-430	unclear	_
2-20	430-431	,	_
2-21	432-440	although	_
2-22	441-453	neuroimaging	_
2-23	454-461	studies	_
2-24	462-466	have	_
2-25	467-471	also	_
2-26	472-482	implicated	_
2-27	483-486	the	_
2-28	487-495	amygdala	_
2-29	496-498	in	_
2-30	499-506	alcohol	_
2-31	507-510	use	_
2-32	511-519	disorder	_
2-33	520-523	and	_
2-34	524-531	suggest	_
2-35	532-536	that	_
2-36	537-544	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-37	545-548	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-38	549-557	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-39	558-560	is	_
2-40	561-571	associated	_
2-41	572-576	with	_
2-42	577-586	disrupted	_
2-43	587-597	functional	_
2-44	598-610	connectivity	_
2-45	611-618	between	_
2-46	619-622	the	_
2-47	623-631	amygdala	_
2-48	632-635	and	_
2-49	636-646	prefrontal	_
2-50	647-653	cortex	_
2-51	654-660	during	_
2-52	661-669	aversive	_
2-53	670-676	states	_
2-54	676-677	.	_

#Text=Methods
#Text=The current study investigated whether plasma brain-derived neurotrophic factor levels in individuals with and without alcohol use disorder (n = 57) were associated with individual differences in amygdala reactivity and amygdala-prefrontal cortex functional connectivity during 2 forms of aversive responding captured via functional magnetic resonance imaging: anxiety elicited by unpredictable threat of shock and fear elicited by predictable threat of shock.
3-1	678-685	Methods	_
3-2	686-689	The	_
3-3	690-697	current	_
3-4	698-703	study	_
3-5	704-716	investigated	_
3-6	717-724	whether	_
3-7	725-731	plasma	_
3-8	732-745	brain-derived	_
3-9	746-758	neurotrophic	_
3-10	759-765	factor	_
3-11	766-772	levels	_
3-12	773-775	in	_
3-13	776-787	individuals	_
3-14	788-792	with	_
3-15	793-796	and	_
3-16	797-804	without	_
3-17	805-812	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
3-18	813-816	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
3-19	817-825	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
3-20	826-827	(	_
3-21	827-828	n	_
3-22	829-830	=	_
3-23	831-833	57	_
3-24	833-834	)	_
3-25	835-839	were	_
3-26	840-850	associated	_
3-27	851-855	with	_
3-28	856-866	individual	_
3-29	867-878	differences	_
3-30	879-881	in	_
3-31	882-890	amygdala	_
3-32	891-901	reactivity	_
3-33	902-905	and	_
3-34	906-925	amygdala-prefrontal	_
3-35	926-932	cortex	_
3-36	933-943	functional	_
3-37	944-956	connectivity	_
3-38	957-963	during	_
3-39	964-965	2	_
3-40	966-971	forms	_
3-41	972-974	of	_
3-42	975-983	aversive	_
3-43	984-994	responding	_
3-44	995-1003	captured	_
3-45	1004-1007	via	_
3-46	1008-1018	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]
3-47	1019-1027	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]
3-48	1028-1037	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]
3-49	1038-1045	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]
3-50	1045-1046	:	_
3-51	1047-1054	anxiety	_
3-52	1055-1063	elicited	_
3-53	1064-1066	by	_
3-54	1067-1080	unpredictable	_
3-55	1081-1087	threat	_
3-56	1088-1090	of	_
3-57	1091-1096	shock	_
3-58	1097-1100	and	_
3-59	1101-1105	fear	_
3-60	1106-1114	elicited	_
3-61	1115-1117	by	_
3-62	1118-1129	predictable	_
3-63	1130-1136	threat	_
3-64	1137-1139	of	_
3-65	1140-1145	shock	_
3-66	1145-1146	.	_

#Text=We also examined whether brain-derived neurotrophic factor and brain function were associated with binge drinking episodes and alcohol use disorder age of onset.
4-1	1147-1149	We	_
4-2	1150-1154	also	_
4-3	1155-1163	examined	_
4-4	1164-1171	whether	_
4-5	1172-1185	brain-derived	_
4-6	1186-1198	neurotrophic	_
4-7	1199-1205	factor	_
4-8	1206-1209	and	_
4-9	1210-1215	brain	_
4-10	1216-1224	function	_
4-11	1225-1229	were	_
4-12	1230-1240	associated	_
4-13	1241-1245	with	_
4-14	1246-1251	binge	_
4-15	1252-1260	drinking	_
4-16	1261-1269	episodes	_
4-17	1270-1273	and	_
4-18	1274-1281	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]
4-19	1282-1285	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]
4-20	1286-1294	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]
4-21	1295-1298	age	_
4-22	1299-1301	of	_
4-23	1302-1307	onset	_
4-24	1307-1308	.	_

#Text=Results
#Text=During anxiety, but not fear, lower levels of plasma brain-derived neurotrophic factor were associated with less connectivity between the left amygdala and the medial prefrontal cortex and the inferior frontal gyrus.
5-1	1309-1316	Results	_
5-2	1317-1323	During	_
5-3	1324-1331	anxiety	_
5-4	1331-1332	,	_
5-5	1333-1336	but	_
5-6	1337-1340	not	_
5-7	1341-1345	fear	_
5-8	1345-1346	,	_
5-9	1347-1352	lower	_
5-10	1353-1359	levels	_
5-11	1360-1362	of	_
5-12	1363-1369	plasma	_
5-13	1370-1383	brain-derived	_
5-14	1384-1396	neurotrophic	_
5-15	1397-1403	factor	_
5-16	1404-1408	were	_
5-17	1409-1419	associated	_
5-18	1420-1424	with	_
5-19	1425-1429	less	_
5-20	1430-1442	connectivity	_
5-21	1443-1450	between	_
5-22	1451-1454	the	_
5-23	1455-1459	left	_
5-24	1460-1468	amygdala	_
5-25	1469-1472	and	_
5-26	1473-1476	the	_
5-27	1477-1483	medial	_
5-28	1484-1494	prefrontal	_
5-29	1495-1501	cortex	_
5-30	1502-1505	and	_
5-31	1506-1509	the	_
5-32	1510-1518	inferior	_
5-33	1519-1526	frontal	_
5-34	1527-1532	gyrus	_
5-35	1532-1533	.	_

#Text=In addition, within individuals with alcohol use disorder (only), lower levels of brain-derived neurotrophic factor and amygdala-medial prefrontal cortex functional connectivity during anxiety were associated with more binge episodes within the past 60 days and a lower age of alcohol use disorder onset.
6-1	1534-1536	In	_
6-2	1537-1545	addition	_
6-3	1545-1546	,	_
6-4	1547-1553	within	_
6-5	1554-1565	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-6	1566-1570	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-7	1571-1578	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-8	1579-1582	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-9	1583-1591	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-10	1592-1593	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-11	1593-1597	only	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-12	1597-1598	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
6-13	1598-1599	,	_
6-14	1600-1605	lower	_
6-15	1606-1612	levels	_
6-16	1613-1615	of	_
6-17	1616-1629	brain-derived	_
6-18	1630-1642	neurotrophic	_
6-19	1643-1649	factor	_
6-20	1650-1653	and	_
6-21	1654-1669	amygdala-medial	_
6-22	1670-1680	prefrontal	_
6-23	1681-1687	cortex	_
6-24	1688-1698	functional	_
6-25	1699-1711	connectivity	_
6-26	1712-1718	during	_
6-27	1719-1726	anxiety	_
6-28	1727-1731	were	_
6-29	1732-1742	associated	_
6-30	1743-1747	with	_
6-31	1748-1752	more	_
6-32	1753-1758	binge	_
6-33	1759-1767	episodes	_
6-34	1768-1774	within	_
6-35	1775-1778	the	_
6-36	1779-1783	past	_
6-37	1784-1786	60	_
6-38	1787-1791	days	_
6-39	1792-1795	and	_
6-40	1796-1797	a	_
6-41	1798-1803	lower	_
6-42	1804-1807	age	_
6-43	1808-1810	of	_
6-44	1811-1818	alcohol	_
6-45	1819-1822	use	_
6-46	1823-1831	disorder	_
6-47	1832-1837	onset	_
6-48	1837-1838	.	_

#Text=There were no associations between brain-derived neurotrophic factor levels and focal amygdala task reactivity.
7-1	1839-1844	There	_
7-2	1845-1849	were	_
7-3	1850-1852	no	_
7-4	1853-1865	associations	_
7-5	1866-1873	between	_
7-6	1874-1887	brain-derived	_
7-7	1888-1900	neurotrophic	_
7-8	1901-1907	factor	_
7-9	1908-1914	levels	_
7-10	1915-1918	and	_
7-11	1919-1924	focal	_
7-12	1925-1933	amygdala	_
7-13	1934-1938	task	_
7-14	1939-1949	reactivity	_
7-15	1949-1950	.	_

#Text=Conclusions
#Text=Together, the results indicate that plasma brain-derived neurotrophic factor levels are related to amygdala circuit functioning in humans, particularly during anxiety, and these individual differences may relate to drinking behaviors.
8-1	1951-1962	Conclusions	_
8-2	1963-1971	Together	_
8-3	1971-1972	,	_
8-4	1973-1976	the	_
8-5	1977-1984	results	_
8-6	1985-1993	indicate	_
8-7	1994-1998	that	_
8-8	1999-2005	plasma	_
8-9	2006-2019	brain-derived	_
8-10	2020-2032	neurotrophic	_
8-11	2033-2039	factor	_
8-12	2040-2046	levels	_
8-13	2047-2050	are	_
8-14	2051-2058	related	_
8-15	2059-2061	to	_
8-16	2062-2070	amygdala	_
8-17	2071-2078	circuit	_
8-18	2079-2090	functioning	_
8-19	2091-2093	in	_
8-20	2094-2100	humans	_
8-21	2100-2101	,	_
8-22	2102-2114	particularly	_
8-23	2115-2121	during	_
8-24	2122-2129	anxiety	_
8-25	2129-2130	,	_
8-26	2131-2134	and	_
8-27	2135-2140	these	_
8-28	2141-2151	individual	_
8-29	2152-2163	differences	_
8-30	2164-2167	may	_
8-31	2168-2174	relate	_
8-32	2175-2177	to	_
8-33	2178-2186	drinking	_
8-34	2187-2196	behaviors	_
8-35	2196-2197	.	_

#Text=Significance Statement
#Text=Animal research indicates that decreased expression of brain-derived neurotrophic factor (BDNF) in the amygdala is involved in regulating anxiety and alcohol drinking behaviors.
9-1	2198-2210	Significance	_
9-2	2211-2220	Statement	_
9-3	2221-2227	Animal	_
9-4	2228-2236	research	_
9-5	2237-2246	indicates	_
9-6	2247-2251	that	_
9-7	2252-2261	decreased	_
9-8	2262-2272	expression	_
9-9	2273-2275	of	_
9-10	2276-2289	brain-derived	_
9-11	2290-2302	neurotrophic	_
9-12	2303-2309	factor	_
9-13	2310-2311	(	_
9-14	2311-2315	BDNF	_
9-15	2315-2316	)	_
9-16	2317-2319	in	_
9-17	2320-2323	the	_
9-18	2324-2332	amygdala	_
9-19	2333-2335	is	_
9-20	2336-2344	involved	_
9-21	2345-2347	in	_
9-22	2348-2358	regulating	_
9-23	2359-2366	anxiety	_
9-24	2367-2370	and	_
9-25	2371-2378	alcohol	_
9-26	2379-2387	drinking	_
9-27	2388-2397	behaviors	_
9-28	2397-2398	.	_

#Text=Within humans with alcohol use disorder (AUD), the relationship between BDNF levels and amygdala functioning has been unclear.
10-1	2399-2405	Within	_
10-2	2406-2412	humans	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-3	2413-2417	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-4	2418-2425	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-5	2426-2429	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-6	2430-2438	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-7	2439-2440	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-8	2440-2443	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-9	2443-2444	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
10-10	2444-2445	,	_
10-11	2446-2449	the	_
10-12	2450-2462	relationship	_
10-13	2463-2470	between	_
10-14	2471-2475	BDNF	_
10-15	2476-2482	levels	_
10-16	2483-2486	and	_
10-17	2487-2495	amygdala	_
10-18	2496-2507	functioning	_
10-19	2508-2511	has	_
10-20	2512-2516	been	_
10-21	2517-2524	unclear	_
10-22	2524-2525	.	_

#Text=The goal of the current study was to explore the links between peripheral BDNF levels, amygdala circuit function during anxiety, and drinking behaviors in humans.
11-1	2526-2529	The	_
11-2	2530-2534	goal	_
11-3	2535-2537	of	_
11-4	2538-2541	the	_
11-5	2542-2549	current	_
11-6	2550-2555	study	_
11-7	2556-2559	was	_
11-8	2560-2562	to	_
11-9	2563-2570	explore	_
11-10	2571-2574	the	_
11-11	2575-2580	links	_
11-12	2581-2588	between	_
11-13	2589-2599	peripheral	_
11-14	2600-2604	BDNF	_
11-15	2605-2611	levels	_
11-16	2611-2612	,	_
11-17	2613-2621	amygdala	_
11-18	2622-2629	circuit	_
11-19	2630-2638	function	_
11-20	2639-2645	during	_
11-21	2646-2653	anxiety	_
11-22	2653-2654	,	_
11-23	2655-2658	and	_
11-24	2659-2667	drinking	_
11-25	2668-2677	behaviors	_
11-26	2678-2680	in	_
11-27	2681-2687	humans	_
11-28	2687-2688	.	_

#Text=Results revealed that lower levels of plasma BDNF were associated with decreased functional connectivity between the amygdala and regulatory regions of the prefrontal cortex (PFC), captured via functional magnetic resonance imaging (fMRI).
12-1	2689-2696	Results	_
12-2	2697-2705	revealed	_
12-3	2706-2710	that	_
12-4	2711-2716	lower	_
12-5	2717-2723	levels	_
12-6	2724-2726	of	_
12-7	2727-2733	plasma	_
12-8	2734-2738	BDNF	_
12-9	2739-2743	were	_
12-10	2744-2754	associated	_
12-11	2755-2759	with	_
12-12	2760-2769	decreased	_
12-13	2770-2780	functional	_
12-14	2781-2793	connectivity	_
12-15	2794-2801	between	_
12-16	2802-2805	the	_
12-17	2806-2814	amygdala	_
12-18	2815-2818	and	_
12-19	2819-2829	regulatory	_
12-20	2830-2837	regions	_
12-21	2838-2840	of	_
12-22	2841-2844	the	_
12-23	2845-2855	prefrontal	_
12-24	2856-2862	cortex	_
12-25	2863-2864	(	_
12-26	2864-2867	PFC	_
12-27	2867-2868	)	_
12-28	2868-2869	,	_
12-29	2870-2878	captured	_
12-30	2879-2882	via	_
12-31	2883-2893	functional	_
12-32	2894-2902	magnetic	_
12-33	2903-2912	resonance	_
12-34	2913-2920	imaging	_
12-35	2921-2922	(	_
12-36	2922-2926	fMRI	_
12-37	2926-2927	)	_
12-38	2927-2928	.	_

#Text=Within individuals with AUD, lower levels of BDNF and less amygdala-PFC connectivity during anxiety were associated with more recent binge episodes and lower age of AUD onset.
13-1	2929-2935	Within	_
13-2	2936-2947	individuals	_
13-3	2948-2952	with	_
13-4	2953-2956	AUD	_
13-5	2956-2957	,	_
13-6	2958-2963	lower	_
13-7	2964-2970	levels	_
13-8	2971-2973	of	_
13-9	2974-2978	BDNF	_
13-10	2979-2982	and	_
13-11	2983-2987	less	_
13-12	2988-3000	amygdala-PFC	_
13-13	3001-3013	connectivity	_
13-14	3014-3020	during	_
13-15	3021-3028	anxiety	_
13-16	3029-3033	were	_
13-17	3034-3044	associated	_
13-18	3045-3049	with	_
13-19	3050-3054	more	_
13-20	3055-3061	recent	_
13-21	3062-3067	binge	_
13-22	3068-3076	episodes	_
13-23	3077-3080	and	_
13-24	3081-3086	lower	_
13-25	3087-3090	age	_
13-26	3091-3093	of	_
13-27	3094-3097	AUD	_
13-28	3098-3103	onset	_
13-29	3103-3104	.	_

#Text=The study provides evidence to suggest that plasma BDNF levels may serve as a biomarker in relation to amygdala circuit function in humans.
14-1	3105-3108	The	_
14-2	3109-3114	study	_
14-3	3115-3123	provides	_
14-4	3124-3132	evidence	_
14-5	3133-3135	to	_
14-6	3136-3143	suggest	_
14-7	3144-3148	that	_
14-8	3149-3155	plasma	_
14-9	3156-3160	BDNF	_
14-10	3161-3167	levels	_
14-11	3168-3171	may	_
14-12	3172-3177	serve	_
14-13	3178-3180	as	_
14-14	3181-3182	a	_
14-15	3183-3192	biomarker	_
14-16	3193-3195	in	_
14-17	3196-3204	relation	_
14-18	3205-3207	to	_
14-19	3208-3216	amygdala	_
14-20	3217-3224	circuit	_
14-21	3225-3233	function	_
14-22	3234-3236	in	_
14-23	3237-3243	humans	_
14-24	3243-3244	.	_

#Text=Alcohol use is the leading risk factor for global disease burden and has a substantial impact on physical and mental health.
15-1	3245-3252	Alcohol	_
15-2	3253-3256	use	_
15-3	3257-3259	is	_
15-4	3260-3263	the	_
15-5	3264-3271	leading	_
15-6	3272-3276	risk	_
15-7	3277-3283	factor	_
15-8	3284-3287	for	_
15-9	3288-3294	global	_
15-10	3295-3302	disease	_
15-11	3303-3309	burden	_
15-12	3310-3313	and	_
15-13	3314-3317	has	_
15-14	3318-3319	a	_
15-15	3320-3331	substantial	_
15-16	3332-3338	impact	_
15-17	3339-3341	on	_
15-18	3342-3350	physical	_
15-19	3351-3354	and	_
15-20	3355-3361	mental	_
15-21	3362-3368	health	_
15-22	3368-3369	.	_

#Text=In the United States, alcohol use disorder (AUD) is also highly prevalent with approximately 30% of individuals meeting criteria for the disorder at some point in their lifetime.
16-1	3370-3372	In	_
16-2	3373-3376	the	_
16-3	3377-3383	United	_
16-4	3384-3390	States	_
16-5	3390-3391	,	_
16-6	3392-3399	alcohol	_
16-7	3400-3403	use	_
16-8	3404-3412	disorder	_
16-9	3413-3414	(	_
16-10	3414-3417	AUD	_
16-11	3417-3418	)	_
16-12	3419-3421	is	_
16-13	3422-3426	also	_
16-14	3427-3433	highly	_
16-15	3434-3443	prevalent	_
16-16	3444-3448	with	_
16-17	3449-3462	approximately	_
16-18	3463-3466	30%	_
16-19	3467-3469	of	_
16-20	3470-3481	individuals	_
16-21	3482-3489	meeting	_
16-22	3490-3498	criteria	_
16-23	3499-3502	for	_
16-24	3503-3506	the	_
16-25	3507-3515	disorder	_
16-26	3516-3518	at	_
16-27	3519-3523	some	_
16-28	3524-3529	point	_
16-29	3530-3532	in	_
16-30	3533-3538	their	_
16-31	3539-3547	lifetime	_
16-32	3547-3548	.	_

#Text=Consequently, there is an urgent need to better understand the pathophysiology of AUD to aid in the development of novel prevention and intervention efforts.
17-1	3549-3561	Consequently	_
17-2	3561-3562	,	_
17-3	3563-3568	there	_
17-4	3569-3571	is	_
17-5	3572-3574	an	_
17-6	3575-3581	urgent	_
17-7	3582-3586	need	_
17-8	3587-3589	to	_
17-9	3590-3596	better	_
17-10	3597-3607	understand	_
17-11	3608-3611	the	_
17-12	3612-3627	pathophysiology	_
17-13	3628-3630	of	_
17-14	3631-3634	AUD	_
17-15	3635-3637	to	_
17-16	3638-3641	aid	_
17-17	3642-3644	in	_
17-18	3645-3648	the	_
17-19	3649-3660	development	_
17-20	3661-3663	of	_
17-21	3664-3669	novel	_
17-22	3670-3680	prevention	_
17-23	3681-3684	and	_
17-24	3685-3697	intervention	_
17-25	3698-3705	efforts	_
17-26	3705-3706	.	_

#Text=Translational, mechanistic research designed to bridge the gap between human and nonhuman findings are especially key to move towards greater understanding and improved treatment of AUD.
18-1	3707-3720	Translational	_
18-2	3720-3721	,	_
18-3	3722-3733	mechanistic	_
18-4	3734-3742	research	_
18-5	3743-3751	designed	_
18-6	3752-3754	to	_
18-7	3755-3761	bridge	_
18-8	3762-3765	the	_
18-9	3766-3769	gap	_
18-10	3770-3777	between	_
18-11	3778-3783	human	_
18-12	3784-3787	and	_
18-13	3788-3796	nonhuman	_
18-14	3797-3805	findings	_
18-15	3806-3809	are	_
18-16	3810-3820	especially	_
18-17	3821-3824	key	_
18-18	3825-3827	to	_
18-19	3828-3832	move	_
18-20	3833-3840	towards	_
18-21	3841-3848	greater	_
18-22	3849-3862	understanding	_
18-23	3863-3866	and	_
18-24	3867-3875	improved	_
18-25	3876-3885	treatment	_
18-26	3886-3888	of	_
18-27	3889-3892	AUD	_
18-28	3892-3893	.	_

#Text=Preclinical models indicate that brain-derived neurotrophic factor (BDNF) is involved in the development of AUD.
19-1	3894-3905	Preclinical	_
19-2	3906-3912	models	_
19-3	3913-3921	indicate	_
19-4	3922-3926	that	_
19-5	3927-3940	brain-derived	_
19-6	3941-3953	neurotrophic	_
19-7	3954-3960	factor	_
19-8	3961-3962	(	_
19-9	3962-3966	BDNF	_
19-10	3966-3967	)	_
19-11	3968-3970	is	_
19-12	3971-3979	involved	_
19-13	3980-3982	in	_
19-14	3983-3986	the	_
19-15	3987-3998	development	_
19-16	3999-4001	of	_
19-17	4002-4005	AUD	_
19-18	4005-4006	.	_

#Text=BDNF is a neurotrophin that mediates neuroplasticity and the formation, survival, and differentiation of neurons in the brain through interactions with the tropomyosin-related kinase B receptor and several signaling cascades.
20-1	4007-4011	BDNF	_
20-2	4012-4014	is	_
20-3	4015-4016	a	_
20-4	4017-4029	neurotrophin	_
20-5	4030-4034	that	_
20-6	4035-4043	mediates	_
20-7	4044-4059	neuroplasticity	_
20-8	4060-4063	and	_
20-9	4064-4067	the	_
20-10	4068-4077	formation	_
20-11	4077-4078	,	_
20-12	4079-4087	survival	_
20-13	4087-4088	,	_
20-14	4089-4092	and	_
20-15	4093-4108	differentiation	_
20-16	4109-4111	of	_
20-17	4112-4119	neurons	_
20-18	4120-4122	in	_
20-19	4123-4126	the	_
20-20	4127-4132	brain	_
20-21	4133-4140	through	_
20-22	4141-4153	interactions	_
20-23	4154-4158	with	_
20-24	4159-4162	the	_
20-25	4163-4182	tropomyosin-related	_
20-26	4183-4189	kinase	_
20-27	4190-4191	B	_
20-28	4192-4200	receptor	_
20-29	4201-4204	and	_
20-30	4205-4212	several	_
20-31	4213-4222	signaling	_
20-32	4223-4231	cascades	_
20-33	4231-4232	.	_

#Text=In rodents, acute alcohol administration increases BDNF messenger RNA (mRNA) expression, whereas prolonged excessive alcohol intake reduces BDNF, particularly in the amygdala, striatum, and medial prefrontal cortex (mPFC).
21-1	4233-4235	In	_
21-2	4236-4243	rodents	_
21-3	4243-4244	,	_
21-4	4245-4250	acute	_
21-5	4251-4258	alcohol	_
21-6	4259-4273	administration	_
21-7	4274-4283	increases	_
21-8	4284-4288	BDNF	_
21-9	4289-4298	messenger	_
21-10	4299-4302	RNA	_
21-11	4303-4304	(	_
21-12	4304-4308	mRNA	_
21-13	4308-4309	)	_
21-14	4310-4320	expression	_
21-15	4320-4321	,	_
21-16	4322-4329	whereas	_
21-17	4330-4339	prolonged	_
21-18	4340-4349	excessive	_
21-19	4350-4357	alcohol	_
21-20	4358-4364	intake	_
21-21	4365-4372	reduces	_
21-22	4373-4377	BDNF	_
21-23	4377-4378	,	_
21-24	4379-4391	particularly	_
21-25	4392-4394	in	_
21-26	4395-4398	the	_
21-27	4399-4407	amygdala	_
21-28	4407-4408	,	_
21-29	4409-4417	striatum	_
21-30	4417-4418	,	_
21-31	4419-4422	and	_
21-32	4423-4429	medial	_
21-33	4430-4440	prefrontal	_
21-34	4441-4447	cortex	_
21-35	4448-4449	(	_
21-36	4449-4453	mPFC	_
21-37	4453-4454	)	_
21-38	4454-4455	.	_

#Text=Studies have also shown that haplodeficient BDNF and cyclic adenosine monophosphate (AMP) responsive-element binding protein mice showing about 50% lower BDNF levels have an increased preference for alcohol and display exaggerated anxiety-like behaviors.
22-1	4456-4463	Studies	_
22-2	4464-4468	have	_
22-3	4469-4473	also	_
22-4	4474-4479	shown	_
22-5	4480-4484	that	_
22-6	4485-4499	haplodeficient	_
22-7	4500-4504	BDNF	_
22-8	4505-4508	and	_
22-9	4509-4515	cyclic	_
22-10	4516-4525	adenosine	_
22-11	4526-4539	monophosphate	_
22-12	4540-4541	(	_
22-13	4541-4544	AMP	_
22-14	4544-4545	)	_
22-15	4546-4564	responsive-element	_
22-16	4565-4572	binding	_
22-17	4573-4580	protein	_
22-18	4581-4585	mice	_
22-19	4586-4593	showing	_
22-20	4594-4599	about	_
22-21	4600-4603	50%	_
22-22	4604-4609	lower	_
22-23	4610-4614	BDNF	_
22-24	4615-4621	levels	_
22-25	4622-4626	have	_
22-26	4627-4629	an	_
22-27	4630-4639	increased	_
22-28	4640-4650	preference	_
22-29	4651-4654	for	_
22-30	4655-4662	alcohol	_
22-31	4663-4666	and	_
22-32	4667-4674	display	_
22-33	4675-4686	exaggerated	_
22-34	4687-4699	anxiety-like	_
22-35	4700-4709	behaviors	_
22-36	4709-4710	.	_

#Text=Inhibition of BDNF expression in the central nucleus of amygdala via administration of BDNF antisense oligodeoxynucleotides increases both alcohol consumption and anxiety, which can be rescued by subsequent BDNF co-infusion.
23-1	4711-4721	Inhibition	_
23-2	4722-4724	of	_
23-3	4725-4729	BDNF	_
23-4	4730-4740	expression	_
23-5	4741-4743	in	_
23-6	4744-4747	the	_
23-7	4748-4755	central	_
23-8	4756-4763	nucleus	_
23-9	4764-4766	of	_
23-10	4767-4775	amygdala	_
23-11	4776-4779	via	_
23-12	4780-4794	administration	_
23-13	4795-4797	of	_
23-14	4798-4802	BDNF	_
23-15	4803-4812	antisense	_
23-16	4813-4834	oligodeoxynucleotides	_
23-17	4835-4844	increases	_
23-18	4845-4849	both	_
23-19	4850-4857	alcohol	_
23-20	4858-4869	consumption	_
23-21	4870-4873	and	_
23-22	4874-4881	anxiety	_
23-23	4881-4882	,	_
23-24	4883-4888	which	_
23-25	4889-4892	can	_
23-26	4893-4895	be	_
23-27	4896-4903	rescued	_
23-28	4904-4906	by	_
23-29	4907-4917	subsequent	_
23-30	4918-4922	BDNF	_
23-31	4923-4934	co-infusion	_
23-32	4934-4935	.	_

#Text=It has therefore been suggested that decreased BDNF levels in the amygdala are involved in regulating anxiety and alcohol consumption.
24-1	4936-4938	It	_
24-2	4939-4942	has	_
24-3	4943-4952	therefore	_
24-4	4953-4957	been	_
24-5	4958-4967	suggested	_
24-6	4968-4972	that	_
24-7	4973-4982	decreased	_
24-8	4983-4987	BDNF	_
24-9	4988-4994	levels	_
24-10	4995-4997	in	_
24-11	4998-5001	the	_
24-12	5002-5010	amygdala	_
24-13	5011-5014	are	_
24-14	5015-5023	involved	_
24-15	5024-5026	in	_
24-16	5027-5037	regulating	_
24-17	5038-5045	anxiety	_
24-18	5046-5049	and	_
24-19	5050-5057	alcohol	_
24-20	5058-5069	consumption	_
24-21	5069-5070	.	_

#Text=With regard to clinical models, our recent study using human postmortem amygdala found that individuals with early onset-AUD (i.e., onset prior to age 21 years) but not late-onset AUD (i.e., onset after age 21 years) exhibited an upregulation of BDNF antisense and a decrease in amygdala BDNF expression relative to control participants.
25-1	5071-5075	With	_
25-2	5076-5082	regard	_
25-3	5083-5085	to	_
25-4	5086-5094	clinical	_
25-5	5095-5101	models	_
25-6	5101-5102	,	_
25-7	5103-5106	our	_
25-8	5107-5113	recent	_
25-9	5114-5119	study	_
25-10	5120-5125	using	_
25-11	5126-5131	human	_
25-12	5132-5142	postmortem	_
25-13	5143-5151	amygdala	_
25-14	5152-5157	found	_
25-15	5158-5162	that	_
25-16	5163-5174	individuals	_
25-17	5175-5179	with	_
25-18	5180-5185	early	_
25-19	5186-5195	onset-AUD	_
25-20	5196-5197	(	_
25-21	5197-5200	i.e	_
25-22	5200-5201	.	_
25-23	5201-5202	,	_
25-24	5203-5208	onset	_
25-25	5209-5214	prior	_
25-26	5215-5217	to	_
25-27	5218-5221	age	_
25-28	5222-5224	21	_
25-29	5225-5230	years	_
25-30	5230-5231	)	_
25-31	5232-5235	but	_
25-32	5236-5239	not	_
25-33	5240-5250	late-onset	_
25-34	5251-5254	AUD	_
25-35	5255-5256	(	_
25-36	5256-5259	i.e	_
25-37	5259-5260	.	_
25-38	5260-5261	,	_
25-39	5262-5267	onset	_
25-40	5268-5273	after	_
25-41	5274-5277	age	_
25-42	5278-5280	21	_
25-43	5281-5286	years	_
25-44	5286-5287	)	_
25-45	5288-5297	exhibited	_
25-46	5298-5300	an	_
25-47	5301-5313	upregulation	_
25-48	5314-5316	of	_
25-49	5317-5321	BDNF	_
25-50	5322-5331	antisense	_
25-51	5332-5335	and	_
25-52	5336-5337	a	_
25-53	5338-5346	decrease	_
25-54	5347-5349	in	_
25-55	5350-5358	amygdala	_
25-56	5359-5363	BDNF	_
25-57	5364-5374	expression	_
25-58	5375-5383	relative	_
25-59	5384-5386	to	_
25-60	5387-5394	control	_
25-61	5395-5407	participants	_
25-62	5407-5408	.	_

#Text=No other studies to our knowledge have directly measured BDNF levels in the human amygdala, although fortunately, peripheral measures of BDNF have been shown to correlate with brain levels in rodents; thus, it is purported that BDNF measured via serum or plasma reflects (to some extent) central BDNF activity.
26-1	5409-5411	No	_
26-2	5412-5417	other	_
26-3	5418-5425	studies	_
26-4	5426-5428	to	_
26-5	5429-5432	our	_
26-6	5433-5442	knowledge	_
26-7	5443-5447	have	_
26-8	5448-5456	directly	_
26-9	5457-5465	measured	_
26-10	5466-5470	BDNF	_
26-11	5471-5477	levels	_
26-12	5478-5480	in	_
26-13	5481-5484	the	_
26-14	5485-5490	human	_
26-15	5491-5499	amygdala	_
26-16	5499-5500	,	_
26-17	5501-5509	although	_
26-18	5510-5521	fortunately	_
26-19	5521-5522	,	_
26-20	5523-5533	peripheral	_
26-21	5534-5542	measures	_
26-22	5543-5545	of	_
26-23	5546-5550	BDNF	_
26-24	5551-5555	have	_
26-25	5556-5560	been	_
26-26	5561-5566	shown	_
26-27	5567-5569	to	_
26-28	5570-5579	correlate	_
26-29	5580-5584	with	_
26-30	5585-5590	brain	_
26-31	5591-5597	levels	_
26-32	5598-5600	in	_
26-33	5601-5608	rodents	_
26-34	5608-5609	;	_
26-35	5610-5614	thus	_
26-36	5614-5615	,	_
26-37	5616-5618	it	_
26-38	5619-5621	is	_
26-39	5622-5631	purported	_
26-40	5632-5636	that	_
26-41	5637-5641	BDNF	_
26-42	5642-5650	measured	_
26-43	5651-5654	via	_
26-44	5655-5660	serum	_
26-45	5661-5663	or	_
26-46	5664-5670	plasma	_
26-47	5671-5679	reflects	_
26-48	5680-5681	(	_
26-49	5681-5683	to	_
26-50	5684-5688	some	_
26-51	5689-5695	extent	_
26-52	5695-5696	)	_
26-53	5697-5704	central	_
26-54	5705-5709	BDNF	_
26-55	5710-5718	activity	_
26-56	5718-5719	.	_

#Text=To date, numerous studies have tested differences in serum and/or plasma BDNF levels between individuals with and without AUD and have shown that AUD is associated with both increased BDNF and decreased BDNF compared with controls.
27-1	5720-5722	To	_
27-2	5723-5727	date	_
27-3	5727-5728	,	_
27-4	5729-5737	numerous	_
27-5	5738-5745	studies	_
27-6	5746-5750	have	_
27-7	5751-5757	tested	_
27-8	5758-5769	differences	_
27-9	5770-5772	in	_
27-10	5773-5778	serum	_
27-11	5779-5782	and	_
27-12	5782-5783	/	_
27-13	5783-5785	or	_
27-14	5786-5792	plasma	_
27-15	5793-5797	BDNF	_
27-16	5798-5804	levels	_
27-17	5805-5812	between	_
27-18	5813-5824	individuals	_
27-19	5825-5829	with	_
27-20	5830-5833	and	_
27-21	5834-5841	without	_
27-22	5842-5845	AUD	_
27-23	5846-5849	and	_
27-24	5850-5854	have	_
27-25	5855-5860	shown	_
27-26	5861-5865	that	_
27-27	5866-5869	AUD	_
27-28	5870-5872	is	_
27-29	5873-5883	associated	_
27-30	5884-5888	with	_
27-31	5889-5893	both	_
27-32	5894-5903	increased	_
27-33	5904-5908	BDNF	_
27-34	5909-5912	and	_
27-35	5913-5922	decreased	_
27-36	5923-5927	BDNF	_
27-37	5928-5936	compared	_
27-38	5937-5941	with	_
27-39	5942-5950	controls	_
27-40	5950-5951	.	_

#Text=An even larger set of studies showed no association between BDNF and AUD diagnoses.
28-1	5952-5954	An	_
28-2	5955-5959	even	_
28-3	5960-5966	larger	_
28-4	5967-5970	set	_
28-5	5971-5973	of	_
28-6	5974-5981	studies	_
28-7	5982-5988	showed	_
28-8	5989-5991	no	_
28-9	5992-6003	association	_
28-10	6004-6011	between	_
28-11	6012-6016	BDNF	_
28-12	6017-6020	and	_
28-13	6021-6024	AUD	_
28-14	6025-6034	diagnoses	_
28-15	6034-6035	.	_

#Text=These discrepant findings are likely related to the fact that AUD is a heterogeneous diagnosis that can include varying symptom combinations and patterns of drinking behavior.
29-1	6036-6041	These	_
29-2	6042-6052	discrepant	_
29-3	6053-6061	findings	_
29-4	6062-6065	are	_
29-5	6066-6072	likely	_
29-6	6073-6080	related	_
29-7	6081-6083	to	_
29-8	6084-6087	the	_
29-9	6088-6092	fact	_
29-10	6093-6097	that	_
29-11	6098-6101	AUD	_
29-12	6102-6104	is	_
29-13	6105-6106	a	_
29-14	6107-6120	heterogeneous	_
29-15	6121-6130	diagnosis	_
29-16	6131-6135	that	_
29-17	6136-6139	can	_
29-18	6140-6147	include	_
29-19	6148-6155	varying	_
29-20	6156-6163	symptom	_
29-21	6164-6176	combinations	_
29-22	6177-6180	and	_
29-23	6181-6189	patterns	_
29-24	6190-6192	of	_
29-25	6193-6201	drinking	_
29-26	6202-6210	behavior	_
29-27	6210-6211	.	_

#Text=More robust and consistent associations with BDNF may therefore be found at the level of individual differences, particularly biologically based individual differences.
30-1	6212-6216	More	_
30-2	6217-6223	robust	_
30-3	6224-6227	and	_
30-4	6228-6238	consistent	_
30-5	6239-6251	associations	_
30-6	6252-6256	with	_
30-7	6257-6261	BDNF	_
30-8	6262-6265	may	_
30-9	6266-6275	therefore	_
30-10	6276-6278	be	_
30-11	6279-6284	found	_
30-12	6285-6287	at	_
30-13	6288-6291	the	_
30-14	6292-6297	level	_
30-15	6298-6300	of	_
30-16	6301-6311	individual	_
30-17	6312-6323	differences	_
30-18	6323-6324	,	_
30-19	6325-6337	particularly	_
30-20	6338-6350	biologically	_
30-21	6351-6356	based	_
30-22	6357-6367	individual	_
30-23	6368-6379	differences	_
30-24	6379-6380	.	_

#Text=As has been discussed extensively in the field of genetics, the identification of intermediate biological phenotypes that serve as a link between molecular variables and human behavior may be a way to reduce heterogeneity and improve our understanding of the role of BDNF in AUD.
31-1	6381-6383	As	_
31-2	6384-6387	has	_
31-3	6388-6392	been	_
31-4	6393-6402	discussed	_
31-5	6403-6414	extensively	_
31-6	6415-6417	in	_
31-7	6418-6421	the	_
31-8	6422-6427	field	_
31-9	6428-6430	of	_
31-10	6431-6439	genetics	_
31-11	6439-6440	,	_
31-12	6441-6444	the	_
31-13	6445-6459	identification	_
31-14	6460-6462	of	_
31-15	6463-6475	intermediate	_
31-16	6476-6486	biological	_
31-17	6487-6497	phenotypes	_
31-18	6498-6502	that	_
31-19	6503-6508	serve	_
31-20	6509-6511	as	_
31-21	6512-6513	a	_
31-22	6514-6518	link	_
31-23	6519-6526	between	_
31-24	6527-6536	molecular	_
31-25	6537-6546	variables	_
31-26	6547-6550	and	_
31-27	6551-6556	human	_
31-28	6557-6565	behavior	_
31-29	6566-6569	may	_
31-30	6570-6572	be	_
31-31	6573-6574	a	_
31-32	6575-6578	way	_
31-33	6579-6581	to	_
31-34	6582-6588	reduce	_
31-35	6589-6602	heterogeneity	_
31-36	6603-6606	and	_
31-37	6607-6614	improve	_
31-38	6615-6618	our	_
31-39	6619-6632	understanding	_
31-40	6633-6635	of	_
31-41	6636-6639	the	_
31-42	6640-6644	role	_
31-43	6645-6647	of	_
31-44	6648-6652	BDNF	_
31-45	6653-6655	in	_
31-46	6656-6659	AUD	_
31-47	6659-6660	.	_

#Text=BDNF promotes synaptic plasticity and connectivity in the brain.
32-1	6661-6665	BDNF	_
32-2	6666-6674	promotes	_
32-3	6675-6683	synaptic	_
32-4	6684-6694	plasticity	_
32-5	6695-6698	and	_
32-6	6699-6711	connectivity	_
32-7	6712-6714	in	_
32-8	6715-6718	the	_
32-9	6719-6724	brain	_
32-10	6724-6725	.	_

#Text=Therefore, neural reactivity and functional connectivity measured via functional magnetic resonance imaging (fMRI) may be an important individual difference factor in humans that acts transiently and is associated with both BDNF levels and drinking behaviors.
33-1	6726-6735	Therefore	_
33-2	6735-6736	,	_
33-3	6737-6743	neural	_
33-4	6744-6754	reactivity	_
33-5	6755-6758	and	_
33-6	6759-6769	functional	_
33-7	6770-6782	connectivity	_
33-8	6783-6791	measured	_
33-9	6792-6795	via	_
33-10	6796-6806	functional	_
33-11	6807-6815	magnetic	_
33-12	6816-6825	resonance	_
33-13	6826-6833	imaging	_
33-14	6834-6835	(	_
33-15	6835-6839	fMRI	_
33-16	6839-6840	)	_
33-17	6841-6844	may	_
33-18	6845-6847	be	_
33-19	6848-6850	an	_
33-20	6851-6860	important	_
33-21	6861-6871	individual	_
33-22	6872-6882	difference	_
33-23	6883-6889	factor	_
33-24	6890-6892	in	_
33-25	6893-6899	humans	_
33-26	6900-6904	that	_
33-27	6905-6909	acts	_
33-28	6910-6921	transiently	_
33-29	6922-6925	and	_
33-30	6926-6928	is	_
33-31	6929-6939	associated	_
33-32	6940-6944	with	_
33-33	6945-6949	both	_
33-34	6950-6954	BDNF	_
33-35	6955-6961	levels	_
33-36	6962-6965	and	_
33-37	6966-6974	drinking	_
33-38	6975-6984	behaviors	_
33-39	6984-6985	.	_

#Text=Indeed, a functional polymorphism in the BDNF gene, specifically, the valine-to-methionine substitution at codon 66 (Val66Met), is associated with alterations in functional connectivity within several large-scale neural networks during resting state and emotion processing.
34-1	6986-6992	Indeed	_
34-2	6992-6993	,	_
34-3	6994-6995	a	_
34-4	6996-7006	functional	_
34-5	7007-7019	polymorphism	_
34-6	7020-7022	in	_
34-7	7023-7026	the	_
34-8	7027-7031	BDNF	_
34-9	7032-7036	gene	_
34-10	7036-7037	,	_
34-11	7038-7050	specifically	_
34-12	7050-7051	,	_
34-13	7052-7055	the	_
34-14	7056-7076	valine-to-methionine	_
34-15	7077-7089	substitution	_
34-16	7090-7092	at	_
34-17	7093-7098	codon	_
34-18	7099-7101	66	_
34-19	7102-7103	(	_
34-20	7103-7111	Val66Met	_
34-21	7111-7112	)	_
34-22	7112-7113	,	_
34-23	7114-7116	is	_
34-24	7117-7127	associated	_
34-25	7128-7132	with	_
34-26	7133-7144	alterations	_
34-27	7145-7147	in	_
34-28	7148-7158	functional	_
34-29	7159-7171	connectivity	_
34-30	7172-7178	within	_
34-31	7179-7186	several	_
34-32	7187-7198	large-scale	_
34-33	7199-7205	neural	_
34-34	7206-7214	networks	_
34-35	7215-7221	during	_
34-36	7222-7229	resting	_
34-37	7230-7235	state	_
34-38	7236-7239	and	_
34-39	7240-7247	emotion	_
34-40	7248-7258	processing	_
34-41	7258-7259	.	_

#Text=More broadly, Val66Met is associated with reductions in gray matter in memory and emotion regions, exaggerated limbic activation to negative stimuli, and deficits in cognitive function.
35-1	7260-7264	More	_
35-2	7265-7272	broadly	_
35-3	7272-7273	,	_
35-4	7274-7282	Val66Met	_
35-5	7283-7285	is	_
35-6	7286-7296	associated	_
35-7	7297-7301	with	_
35-8	7302-7312	reductions	_
35-9	7313-7315	in	_
35-10	7316-7320	gray	_
35-11	7321-7327	matter	_
35-12	7328-7330	in	_
35-13	7331-7337	memory	_
35-14	7338-7341	and	_
35-15	7342-7349	emotion	_
35-16	7350-7357	regions	_
35-17	7357-7358	,	_
35-18	7359-7370	exaggerated	_
35-19	7371-7377	limbic	_
35-20	7378-7388	activation	_
35-21	7389-7391	to	_
35-22	7392-7400	negative	_
35-23	7401-7408	stimuli	_
35-24	7408-7409	,	_
35-25	7410-7413	and	_
35-26	7414-7422	deficits	_
35-27	7423-7425	in	_
35-28	7426-7435	cognitive	_
35-29	7436-7444	function	_
35-30	7444-7445	.	_

#Text=There has been only 1 prior study to our knowledge that has investigated the impact of peripheral BDNF, measured in blood plasma, on functional connectivity associating increased levels of plasma BDNF with increased resting-state connectivity between motor areas in healthy older adults.
36-1	7446-7451	There	_
36-2	7452-7455	has	_
36-3	7456-7460	been	_
36-4	7461-7465	only	_
36-5	7466-7467	1	_
36-6	7468-7473	prior	_
36-7	7474-7479	study	_
36-8	7480-7482	to	_
36-9	7483-7486	our	_
36-10	7487-7496	knowledge	_
36-11	7497-7501	that	_
36-12	7502-7505	has	_
36-13	7506-7518	investigated	_
36-14	7519-7522	the	_
36-15	7523-7529	impact	_
36-16	7530-7532	of	_
36-17	7533-7543	peripheral	_
36-18	7544-7548	BDNF	_
36-19	7548-7549	,	_
36-20	7550-7558	measured	_
36-21	7559-7561	in	_
36-22	7562-7567	blood	_
36-23	7568-7574	plasma	_
36-24	7574-7575	,	_
36-25	7576-7578	on	_
36-26	7579-7589	functional	_
36-27	7590-7602	connectivity	_
36-28	7603-7614	associating	_
36-29	7615-7624	increased	_
36-30	7625-7631	levels	_
36-31	7632-7634	of	_
36-32	7635-7641	plasma	_
36-33	7642-7646	BDNF	_
36-34	7647-7651	with	_
36-35	7652-7661	increased	_
36-36	7662-7675	resting-state	_
36-37	7676-7688	connectivity	_
36-38	7689-7696	between	_
36-39	7697-7702	motor	_
36-40	7703-7708	areas	_
36-41	7709-7711	in	_
36-42	7712-7719	healthy	_
36-43	7720-7725	older	_
36-44	7726-7732	adults	_
36-45	7732-7733	.	_

#Text=Together these data highlight BDNF’s key role in neural function; however, no study to date has specifically examined the association between peripheral measures of BDNF and amygdalar functioning in humans despite the plethora of animal studies demonstrating the impact of BDNF levels in the amygdala on alcohol consumption and anxiety-like behaviors.
37-1	7734-7742	Together	_
37-2	7743-7748	these	_
37-3	7749-7753	data	_
37-4	7754-7763	highlight	_
37-5	7764-7768	BDNF	_
37-6	7768-7769	’	_
37-7	7769-7770	s	_
37-8	7771-7774	key	_
37-9	7775-7779	role	_
37-10	7780-7782	in	_
37-11	7783-7789	neural	_
37-12	7790-7798	function	_
37-13	7798-7799	;	_
37-14	7800-7807	however	_
37-15	7807-7808	,	_
37-16	7809-7811	no	_
37-17	7812-7817	study	_
37-18	7818-7820	to	_
37-19	7821-7825	date	_
37-20	7826-7829	has	_
37-21	7830-7842	specifically	_
37-22	7843-7851	examined	_
37-23	7852-7855	the	_
37-24	7856-7867	association	_
37-25	7868-7875	between	_
37-26	7876-7886	peripheral	_
37-27	7887-7895	measures	_
37-28	7896-7898	of	_
37-29	7899-7903	BDNF	_
37-30	7904-7907	and	_
37-31	7908-7917	amygdalar	_
37-32	7918-7929	functioning	_
37-33	7930-7932	in	_
37-34	7933-7939	humans	_
37-35	7940-7947	despite	_
37-36	7948-7951	the	_
37-37	7952-7960	plethora	_
37-38	7961-7963	of	_
37-39	7964-7970	animal	_
37-40	7971-7978	studies	_
37-41	7979-7992	demonstrating	_
37-42	7993-7996	the	_
37-43	7997-8003	impact	_
37-44	8004-8006	of	_
37-45	8007-8011	BDNF	_
37-46	8012-8018	levels	_
37-47	8019-8021	in	_
37-48	8022-8025	the	_
37-49	8026-8034	amygdala	_
37-50	8035-8037	on	_
37-51	8038-8045	alcohol	_
37-52	8046-8057	consumption	_
37-53	8058-8061	and	_
37-54	8062-8074	anxiety-like	_
37-55	8075-8084	behaviors	_
37-56	8084-8085	.	_

#Text=The broader human neuroimaging literature clearly indicates that anxiety and alcohol abuse are associated with abnormalities in amygdala-based neural networks.
38-1	8086-8089	The	_
38-2	8090-8097	broader	_
38-3	8098-8103	human	_
38-4	8104-8116	neuroimaging	_
38-5	8117-8127	literature	_
38-6	8128-8135	clearly	_
38-7	8136-8145	indicates	_
38-8	8146-8150	that	_
38-9	8151-8158	anxiety	_
38-10	8159-8162	and	_
38-11	8163-8170	alcohol	_
38-12	8171-8176	abuse	_
38-13	8177-8180	are	_
38-14	8181-8191	associated	_
38-15	8192-8196	with	_
38-16	8197-8210	abnormalities	_
38-17	8211-8213	in	_
38-18	8214-8228	amygdala-based	_
38-19	8229-8235	neural	_
38-20	8236-8244	networks	_
38-21	8244-8245	.	_

#Text=Alcohol acutely dampens amygdala reactivity and uncouples functional connections between the amygdala and regulatory prefrontal cortex (PFC) regions during threat perception.
39-1	8246-8253	Alcohol	_
39-2	8254-8261	acutely	_
39-3	8262-8269	dampens	_
39-4	8270-8278	amygdala	_
39-5	8279-8289	reactivity	_
39-6	8290-8293	and	_
39-7	8294-8303	uncouples	_
39-8	8304-8314	functional	_
39-9	8315-8326	connections	_
39-10	8327-8334	between	_
39-11	8335-8338	the	_
39-12	8339-8347	amygdala	_
39-13	8348-8351	and	_
39-14	8352-8362	regulatory	_
39-15	8363-8373	prefrontal	_
39-16	8374-8380	cortex	_
39-17	8381-8382	(	_
39-18	8382-8385	PFC	_
39-19	8385-8386	)	_
39-20	8387-8394	regions	_
39-21	8395-8401	during	_
39-22	8402-8408	threat	_
39-23	8409-8419	perception	_
39-24	8419-8420	.	_

#Text=When sober, individuals with AUD, and individuals at risk for AUD, show decreased amygdala reactivity to threatening stimuli (; Marinkovi et al., 2009).
40-1	8421-8425	When	_
40-2	8426-8431	sober	_
40-3	8431-8432	,	_
40-4	8433-8444	individuals	_
40-5	8445-8449	with	_
40-6	8450-8453	AUD	_
40-7	8453-8454	,	_
40-8	8455-8458	and	_
40-9	8459-8470	individuals	_
40-10	8471-8473	at	_
40-11	8474-8478	risk	_
40-12	8479-8482	for	_
40-13	8483-8486	AUD	_
40-14	8486-8487	,	_
40-15	8488-8492	show	_
40-16	8493-8502	decreased	_
40-17	8503-8511	amygdala	_
40-18	8512-8522	reactivity	_
40-19	8523-8525	to	_
40-20	8526-8537	threatening	_
40-21	8538-8545	stimuli	_
40-22	8546-8547	(	_
40-23	8547-8548	;	_
40-24	8549-8558	Marinkovi	_
40-25	8559-8561	et	_
40-26	8562-8564	al	_
40-27	8564-8565	.	_
40-28	8565-8566	,	_
40-29	8567-8571	2009	_
40-30	8571-8572	)	_
40-31	8572-8573	.	_

#Text=Decreased amygdala-PFC connectivity at rest has also been shown to longitudinally predict increases in alcohol use in adolescents.
41-1	8574-8583	Decreased	_
41-2	8584-8596	amygdala-PFC	_
41-3	8597-8609	connectivity	_
41-4	8610-8612	at	_
41-5	8613-8617	rest	_
41-6	8618-8621	has	_
41-7	8622-8626	also	_
41-8	8627-8631	been	_
41-9	8632-8637	shown	_
41-10	8638-8640	to	_
41-11	8641-8655	longitudinally	_
41-12	8656-8663	predict	_
41-13	8664-8673	increases	_
41-14	8674-8676	in	_
41-15	8677-8684	alcohol	_
41-16	8685-8688	use	_
41-17	8689-8691	in	_
41-18	8692-8703	adolescents	_
41-19	8703-8704	.	_

#Text=Taken together, the amygdala is implicated in alcohol dependence in both human and animal research, and the amygdala-PFC circuit, in particular, is a well-positioned target for the effects of varying BDNF levels.
42-1	8705-8710	Taken	_
42-2	8711-8719	together	_
42-3	8719-8720	,	_
42-4	8721-8724	the	_
42-5	8725-8733	amygdala	_
42-6	8734-8736	is	_
42-7	8737-8747	implicated	_
42-8	8748-8750	in	_
42-9	8751-8758	alcohol	_
42-10	8759-8769	dependence	_
42-11	8770-8772	in	_
42-12	8773-8777	both	_
42-13	8778-8783	human	_
42-14	8784-8787	and	_
42-15	8788-8794	animal	_
42-16	8795-8803	research	_
42-17	8803-8804	,	_
42-18	8805-8808	and	_
42-19	8809-8812	the	_
42-20	8813-8825	amygdala-PFC	_
42-21	8826-8833	circuit	_
42-22	8833-8834	,	_
42-23	8835-8837	in	_
42-24	8838-8848	particular	_
42-25	8848-8849	,	_
42-26	8850-8852	is	_
42-27	8853-8854	a	_
42-28	8855-8870	well-positioned	_
42-29	8871-8877	target	_
42-30	8878-8881	for	_
42-31	8882-8885	the	_
42-32	8886-8893	effects	_
42-33	8894-8896	of	_
42-34	8897-8904	varying	_
42-35	8905-8909	BDNF	_
42-36	8910-8916	levels	_
42-37	8916-8917	.	_

#Text=The current study examined whether human plasma BDNF was related to individual differences in amygdala reactivity and amygdala-PFC functional connectivity during a task specifically designed to elicit anxiety and whether both BDNF levels and amygdala-circuit function were associated with real-world drinking behaviors.
43-1	8918-8921	The	_
43-2	8922-8929	current	_
43-3	8930-8935	study	_
43-4	8936-8944	examined	_
43-5	8945-8952	whether	_
43-6	8953-8958	human	_
43-7	8959-8965	plasma	_
43-8	8966-8970	BDNF	_
43-9	8971-8974	was	_
43-10	8975-8982	related	_
43-11	8983-8985	to	_
43-12	8986-8996	individual	_
43-13	8997-9008	differences	_
43-14	9009-9011	in	_
43-15	9012-9020	amygdala	_
43-16	9021-9031	reactivity	_
43-17	9032-9035	and	_
43-18	9036-9048	amygdala-PFC	_
43-19	9049-9059	functional	_
43-20	9060-9072	connectivity	_
43-21	9073-9079	during	_
43-22	9080-9081	a	_
43-23	9082-9086	task	_
43-24	9087-9099	specifically	_
43-25	9100-9108	designed	_
43-26	9109-9111	to	_
43-27	9112-9118	elicit	_
43-28	9119-9126	anxiety	_
43-29	9127-9130	and	_
43-30	9131-9138	whether	_
43-31	9139-9143	both	_
43-32	9144-9148	BDNF	_
43-33	9149-9155	levels	_
43-34	9156-9159	and	_
43-35	9160-9176	amygdala-circuit	_
43-36	9177-9185	function	_
43-37	9186-9190	were	_
43-38	9191-9201	associated	_
43-39	9202-9206	with	_
43-40	9207-9217	real-world	_
43-41	9218-9226	drinking	_
43-42	9227-9236	behaviors	_
43-43	9236-9237	.	_

#Text=The sample included individuals with and without AUD in order to capture a full distribution of drinking behaviors, BDNF levels, and individual differences in amygdala reactivity and functional connectivity.
44-1	9238-9241	The	_
44-2	9242-9248	sample	_
44-3	9249-9257	included	_
44-4	9258-9269	individuals	_
44-5	9270-9274	with	_
44-6	9275-9278	and	_
44-7	9279-9286	without	_
44-8	9287-9290	AUD	_
44-9	9291-9293	in	_
44-10	9294-9299	order	_
44-11	9300-9302	to	_
44-12	9303-9310	capture	_
44-13	9311-9312	a	_
44-14	9313-9317	full	_
44-15	9318-9330	distribution	_
44-16	9331-9333	of	_
44-17	9334-9342	drinking	_
44-18	9343-9352	behaviors	_
44-19	9352-9353	,	_
44-20	9354-9358	BDNF	_
44-21	9359-9365	levels	_
44-22	9365-9366	,	_
44-23	9367-9370	and	_
44-24	9371-9381	individual	_
44-25	9382-9393	differences	_
44-26	9394-9396	in	_
44-27	9397-9405	amygdala	_
44-28	9406-9416	reactivity	_
44-29	9417-9420	and	_
44-30	9421-9431	functional	_
44-31	9432-9444	connectivity	_
44-32	9444-9445	.	_

#Text=Individuals completed a neuroimaging paradigm designed to probe both reactivity during anticipatory anxiety and fear using unpredictable (U-) and predictable (P-) threat of electric shock, respectively.
45-1	9446-9457	Individuals	_
45-2	9458-9467	completed	_
45-3	9468-9469	a	_
45-4	9470-9482	neuroimaging	_
45-5	9483-9491	paradigm	_
45-6	9492-9500	designed	_
45-7	9501-9503	to	_
45-8	9504-9509	probe	_
45-9	9510-9514	both	_
45-10	9515-9525	reactivity	_
45-11	9526-9532	during	_
45-12	9533-9545	anticipatory	_
45-13	9546-9553	anxiety	_
45-14	9554-9557	and	_
45-15	9558-9562	fear	_
45-16	9563-9568	using	_
45-17	9569-9582	unpredictable	_
45-18	9583-9584	(	_
45-19	9584-9585	U	_
45-20	9585-9586	-	_
45-21	9586-9587	)	_
45-22	9588-9591	and	_
45-23	9592-9603	predictable	_
45-24	9604-9605	(	_
45-25	9605-9606	P	_
45-26	9606-9607	-	_
45-27	9607-9608	)	_
45-28	9609-9615	threat	_
45-29	9616-9618	of	_
45-30	9619-9627	electric	_
45-31	9628-9633	shock	_
45-32	9633-9634	,	_
45-33	9635-9647	respectively	_
45-34	9647-9648	.	_

#Text=Human and animal studies show that anticipatory anxiety and fear are separable aversive states that have overlapping, yet distinct, neural correlates.
46-1	9649-9654	Human	_
46-2	9655-9658	and	_
46-3	9659-9665	animal	_
46-4	9666-9673	studies	_
46-5	9674-9678	show	_
46-6	9679-9683	that	_
46-7	9684-9696	anticipatory	_
46-8	9697-9704	anxiety	_
46-9	9705-9708	and	_
46-10	9709-9713	fear	_
46-11	9714-9717	are	_
46-12	9718-9727	separable	_
46-13	9728-9736	aversive	_
46-14	9737-9743	states	_
46-15	9744-9748	that	_
46-16	9749-9753	have	_
46-17	9754-9765	overlapping	_
46-18	9765-9766	,	_
46-19	9767-9770	yet	_
46-20	9771-9779	distinct	_
46-21	9779-9780	,	_
46-22	9781-9787	neural	_
46-23	9788-9798	correlates	_
46-24	9798-9799	.	_

#Text=Notably, recent research found that the BDNF Val66Met polymorphism is associated with exaggerated anticipatory anxiety to an upcoming stressor, and exaggerated anticipatory anxiety, but not fear reactivity, distinguished individuals with AUD from controls.
47-1	9800-9807	Notably	_
47-2	9807-9808	,	_
47-3	9809-9815	recent	_
47-4	9816-9824	research	_
47-5	9825-9830	found	_
47-6	9831-9835	that	_
47-7	9836-9839	the	_
47-8	9840-9844	BDNF	_
47-9	9845-9853	Val66Met	_
47-10	9854-9866	polymorphism	_
47-11	9867-9869	is	_
47-12	9870-9880	associated	_
47-13	9881-9885	with	_
47-14	9886-9897	exaggerated	_
47-15	9898-9910	anticipatory	_
47-16	9911-9918	anxiety	_
47-17	9919-9921	to	_
47-18	9922-9924	an	_
47-19	9925-9933	upcoming	_
47-20	9934-9942	stressor	_
47-21	9942-9943	,	_
47-22	9944-9947	and	_
47-23	9948-9959	exaggerated	_
47-24	9960-9972	anticipatory	_
47-25	9973-9980	anxiety	_
47-26	9980-9981	,	_
47-27	9982-9985	but	_
47-28	9986-9989	not	_
47-29	9990-9994	fear	_
47-30	9995-10005	reactivity	_
47-31	10005-10006	,	_
47-32	10007-10020	distinguished	_
47-33	10021-10032	individuals	_
47-34	10033-10037	with	_
47-35	10038-10041	AUD	_
47-36	10042-10046	from	_
47-37	10047-10055	controls	_
47-38	10055-10056	.	_

#Text=Here, we investigated changes in plasma BDNF levels and amygdala reactivity and amygdala-PFC functional connectivity, particularly during anticipatory anxiety (i.e., U-threat) and their association with greater real-world problem-drinking behaviors.
48-1	10057-10061	Here	_
48-2	10061-10062	,	_
48-3	10063-10065	we	_
48-4	10066-10078	investigated	_
48-5	10079-10086	changes	_
48-6	10087-10089	in	_
48-7	10090-10096	plasma	_
48-8	10097-10101	BDNF	_
48-9	10102-10108	levels	_
48-10	10109-10112	and	_
48-11	10113-10121	amygdala	_
48-12	10122-10132	reactivity	_
48-13	10133-10136	and	_
48-14	10137-10149	amygdala-PFC	_
48-15	10150-10160	functional	_
48-16	10161-10173	connectivity	_
48-17	10173-10174	,	_
48-18	10175-10187	particularly	_
48-19	10188-10194	during	_
48-20	10195-10207	anticipatory	_
48-21	10208-10215	anxiety	_
48-22	10216-10217	(	_
48-23	10217-10220	i.e	_
48-24	10220-10221	.	_
48-25	10221-10222	,	_
48-26	10223-10231	U-threat	_
48-27	10231-10232	)	_
48-28	10233-10236	and	_
48-29	10237-10242	their	_
48-30	10243-10254	association	_
48-31	10255-10259	with	_
48-32	10260-10267	greater	_
48-33	10268-10278	real-world	_
48-34	10279-10295	problem-drinking	_
48-35	10296-10305	behaviors	_
48-36	10305-10306	.	_

#Text=METHODS
#Text=Participants
#Text=Volunteers were recruited via advertisements posted in the Chicago community, local psychiatric clinics, and nearby college campuses.
49-1	10307-10314	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod
49-2	10315-10327	Participants	_
49-3	10328-10338	Volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-4	10339-10343	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-5	10344-10353	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-6	10354-10357	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-7	10358-10372	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-8	10373-10379	posted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-9	10380-10382	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-10	10383-10386	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-11	10387-10394	Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-12	10395-10404	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-13	10404-10405	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-14	10406-10411	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-15	10412-10423	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-16	10424-10431	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-17	10431-10432	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-18	10433-10436	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-19	10437-10443	nearby	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-20	10444-10451	college	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-21	10452-10460	campuses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
49-22	10460-10461	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=To be included in the study, individuals were required to be between 21 and 30 years old and able to provide written informed consent.
50-1	10462-10464	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-2	10465-10467	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-3	10468-10476	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-4	10477-10479	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-5	10480-10483	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-6	10484-10489	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-7	10489-10490	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-8	10491-10502	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-9	10503-10507	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-10	10508-10516	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-11	10517-10519	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-12	10520-10522	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-13	10523-10530	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-14	10531-10533	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-15	10534-10537	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-16	10538-10540	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-17	10541-10546	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-18	10547-10550	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-19	10551-10554	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-20	10555-10559	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-21	10560-10562	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-22	10563-10570	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-23	10571-10578	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-24	10579-10587	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-25	10588-10595	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
50-26	10595-10596	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=Individuals also had to (1) have no personal or family history of AUD (i.e., controls) or (2) meet criteria for AUD within the past 2 years.
51-1	10597-10608	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-2	10609-10613	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-3	10614-10617	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-4	10618-10620	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-5	10621-10622	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-6	10622-10623	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-7	10623-10624	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-8	10625-10629	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-9	10630-10632	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-10	10633-10641	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-11	10642-10644	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-12	10645-10651	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-13	10652-10659	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-14	10660-10662	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-15	10663-10666	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
51-16	10667-10668	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-17	10668-10671	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-18	10671-10672	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-19	10672-10673	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-20	10674-10682	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-21	10682-10683	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-22	10684-10686	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-23	10687-10688	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-24	10688-10689	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-25	10689-10690	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
51-26	10691-10695	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-27	10696-10704	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-28	10705-10708	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-29	10709-10712	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-30	10713-10719	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-31	10720-10723	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-32	10724-10728	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-33	10729-10730	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-34	10731-10736	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
51-35	10736-10737	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]

#Text=Exclusion criteria included any serious medical condition, psychotropic medication use, deafness, contraindication for neuroimaging, pregnancy, lifetime moderate or severe substance use disorder (other than alcohol and nicotine), daily cigarette smoking, and psychosis.
52-1	10738-10747	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-2	10748-10756	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-3	10757-10765	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-4	10766-10769	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-5	10770-10777	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-6	10778-10785	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-7	10786-10795	condition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-8	10795-10796	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-9	10797-10809	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-10	10810-10820	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-11	10821-10824	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-12	10824-10825	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-13	10826-10834	deafness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-14	10834-10835	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-15	10836-10852	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-16	10853-10856	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-17	10857-10869	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-18	10869-10870	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-19	10871-10880	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-20	10880-10881	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-21	10882-10890	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-22	10891-10899	moderate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-23	10900-10902	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-24	10903-10909	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-25	10910-10919	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-26	10920-10923	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-27	10924-10932	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-28	10933-10934	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-29	10934-10939	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-30	10940-10944	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-31	10945-10952	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-32	10953-10956	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-33	10957-10965	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-34	10965-10966	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-35	10966-10967	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-36	10968-10973	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-37	10974-10983	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-38	10984-10991	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-39	10991-10992	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-40	10993-10996	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-41	10997-11006	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
52-42	11006-11007	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]

#Text=The protocol was approved by the university institutional review board and participants provided written informed consent.
53-1	11008-11011	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-2	11012-11020	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-3	11021-11024	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-4	11025-11033	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-5	11034-11036	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-6	11037-11040	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-7	11041-11051	university	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-8	11052-11065	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-9	11066-11072	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-10	11073-11078	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-11	11079-11082	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-12	11083-11095	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-13	11096-11104	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-14	11105-11112	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-15	11113-11121	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-16	11122-11129	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
53-17	11129-11130	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Individuals were instructed to abstain from drugs and alcohol 24 hours prior to the laboratory assessments, which was verified via breath alcohol and urine screens.
54-1	11131-11142	Individuals	_
54-2	11143-11147	were	_
54-3	11148-11158	instructed	_
54-4	11159-11161	to	_
54-5	11162-11169	abstain	_
54-6	11170-11174	from	_
54-7	11175-11180	drugs	_
54-8	11181-11184	and	_
54-9	11185-11192	alcohol	_
54-10	11193-11195	24	_
54-11	11196-11201	hours	_
54-12	11202-11207	prior	_
54-13	11208-11210	to	_
54-14	11211-11214	the	_
54-15	11215-11225	laboratory	_
54-16	11226-11237	assessments	_
54-17	11237-11238	,	_
54-18	11239-11244	which	_
54-19	11245-11248	was	_
54-20	11249-11257	verified	_
54-21	11258-11261	via	_
54-22	11262-11268	breath	_
54-23	11269-11276	alcohol	_
54-24	11277-11280	and	_
54-25	11281-11286	urine	_
54-26	11287-11294	screens	_
54-27	11294-11295	.	_

#Text=Participants were monetarily compensated for their time.
55-1	11296-11308	Participants	_
55-2	11309-11313	were	_
55-3	11314-11324	monetarily	_
55-4	11325-11336	compensated	_
55-5	11337-11340	for	_
55-6	11341-11346	their	_
55-7	11347-11351	time	_
55-8	11351-11352	.	_

#Text=A total of 37 individuals with AUD and 24 controls enrolled in the study and completed all laboratory procedures (total n = 61).
56-1	11353-11354	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-2	11355-11360	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-3	11361-11363	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-4	11364-11366	37	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-5	11367-11378	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]
56-6	11379-11383	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]
56-7	11384-11387	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]
56-8	11388-11391	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-9	11392-11394	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-10	11395-11403	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]
56-11	11404-11412	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-12	11413-11415	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-13	11416-11419	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-14	11420-11425	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-15	11426-11429	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-16	11430-11439	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-17	11440-11443	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-18	11444-11454	laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-19	11455-11465	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-20	11466-11467	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-21	11467-11472	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-22	11473-11474	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-23	11475-11476	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-24	11477-11479	61	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-25	11479-11480	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
56-26	11480-11481	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=A total of 4 individuals had excessive motion during the fMRI scan (i.e., <2.5-mm displacement in any direction) and were excluded from analyses (3 AUD subjects and 1 control) for a final sample of 57 individuals.
57-1	11482-11483	A	_
57-2	11484-11489	total	_
57-3	11490-11492	of	_
57-4	11493-11494	4	_
57-5	11495-11506	individuals	_
57-6	11507-11510	had	_
57-7	11511-11520	excessive	_
57-8	11521-11527	motion	_
57-9	11528-11534	during	_
57-10	11535-11538	the	_
57-11	11539-11543	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]
57-12	11544-11548	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]
57-13	11549-11550	(	_
57-14	11550-11553	i.e	_
57-15	11553-11554	.	_
57-16	11554-11555	,	_
57-17	11556-11557	<	_
57-18	11557-11560	2.5	_
57-19	11560-11561	-	_
57-20	11561-11563	mm	_
57-21	11564-11576	displacement	_
57-22	11577-11579	in	_
57-23	11580-11583	any	_
57-24	11584-11593	direction	_
57-25	11593-11594	)	_
57-26	11595-11598	and	_
57-27	11599-11603	were	_
57-28	11604-11612	excluded	_
57-29	11613-11617	from	_
57-30	11618-11626	analyses	_
57-31	11627-11628	(	_
57-32	11628-11629	3	_
57-33	11630-11633	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[20]
57-34	11634-11642	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[20]
57-35	11643-11646	and	_
57-36	11647-11648	1	_
57-37	11649-11656	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
57-38	11656-11657	)	_
57-39	11658-11661	for	_
57-40	11662-11663	a	_
57-41	11664-11669	final	_
57-42	11670-11676	sample	_
57-43	11677-11679	of	_
57-44	11680-11682	57	_
57-45	11683-11694	individuals	_
57-46	11694-11695	.	_

#Text=Please see Table 1 for participants’ demographics and clinical characteristics.
58-1	11696-11702	Please	_
58-2	11703-11706	see	_
58-3	11707-11712	Table	_
58-4	11713-11714	1	_
58-5	11715-11718	for	_
58-6	11719-11731	participants	_
58-7	11731-11732	’	_
58-8	11733-11745	demographics	_
58-9	11746-11749	and	_
58-10	11750-11758	clinical	_
58-11	11759-11774	characteristics	_
58-12	11774-11775	.	_

#Text=Demographics and clinical characteristics
#Text=\tAUD (n = 33)\tControls (n = 24)\tCombined (n = 57)\t \tDemographics\t\t\t\t \tAge (years)\t23.6 (2.8)\t24.0 (2.6)\t23.8 (2.7)\t \tSex (female)\t39.4%\t54.2%\t45.6%\t \tEthnicity (Hispanic)\t30.3%\t8.3%\t21.1%\t \tRace\t\t\t\t \tWhite\t66.7%\t45.8%\t56.1%\t \tBlack\t3.0%\t16.7%\t8.8%\t \tAsian\t6.1%\t29.2%\t15.8%\t \tNative Hawaiian\t3.0%\t0.0%\t1.8%\t \tAmerican Indian or Alaskan Native\t3.0%\t0.0%\t1.8%\t \tOther\t18.2%\t8.3%\t15.7%\t \tClinical variables\t\t\t\t \tDrinks per week\t10.0 (7.2)\t4.0 (5.8)\t7.5 (7.2)\t \tNumber of binge episodes\t8.3 (6.1)\t2.4 (4.6)\t5.2 (6.0)\t \tAUD age of onset\t19.5 (2.8)\t–\t19.5 (2.8)\t \tDaily cigarette smoker\t0.0%\t0.0%\t0.0%\t \tNo. times used cannabis\t0.2 (0.6)\t0.2 (0.6)\t0.2 (0.6)\t \tNo. times used *other illicit drugs\t0.2 (1.3)\t0.04 (0.2)\t0.2 (0.9)\t \tBDNF variable\t\t\t\t \tPlasma BDNF (pg/μL)\t47.0 (11.2)\t40.4 (8.8)\t44.2 (10.7)\t \tDiagnostic variables\t\t\t\t \tCurrent major depressive disorder\t9.1%\t8.3%\t8.8%\t \tLifetime major depressive disorder\t24.2%\t16.7%\t21.1%\t \tCurrent anxiety disorder\t12.1%\t8.3%\t10.5%\t \tLifetime anxiety disorder\t27.3%\t16.7%\t22.8%\t \tCurrent posttraumatic stress disorder\t0.0%\t4.2%\t1.8%\t \tLifetime posttraumatic stress disorder\t0.0%\t4.2%\t1.8%\t \t
#Text=All values are means, standard deviations, unless otherwise notes.
59-1	11776-11788	Demographics	_
59-2	11789-11792	and	_
59-3	11793-11801	clinical	_
59-4	11802-11817	characteristics	_
59-5	11819-11822	AUD	_
59-6	11823-11824	(	_
59-7	11824-11825	n	_
59-8	11826-11827	=	_
59-9	11828-11830	33	_
59-10	11830-11831	)	_
59-11	11832-11840	Controls	_
59-12	11841-11842	(	_
59-13	11842-11843	n	_
59-14	11844-11845	=	_
59-15	11846-11848	24	_
59-16	11848-11849	)	_
59-17	11850-11858	Combined	_
59-18	11859-11860	(	_
59-19	11860-11861	n	_
59-20	11862-11863	=	_
59-21	11864-11866	57	_
59-22	11866-11867	)	_
59-23	11870-11882	Demographics	_
59-24	11888-11891	Age	_
59-25	11892-11893	(	_
59-26	11893-11898	years	_
59-27	11898-11899	)	_
59-28	11900-11904	23.6	_
59-29	11905-11906	(	_
59-30	11906-11909	2.8	_
59-31	11909-11910	)	_
59-32	11911-11915	24.0	_
59-33	11916-11917	(	_
59-34	11917-11920	2.6	_
59-35	11920-11921	)	_
59-36	11922-11926	23.8	_
59-37	11927-11928	(	_
59-38	11928-11931	2.7	_
59-39	11931-11932	)	_
59-40	11935-11938	Sex	_
59-41	11939-11940	(	_
59-42	11940-11946	female	_
59-43	11946-11947	)	_
59-44	11948-11953	39.4%	_
59-45	11954-11959	54.2%	_
59-46	11960-11965	45.6%	_
59-47	11968-11977	Ethnicity	_
59-48	11978-11979	(	_
59-49	11979-11987	Hispanic	_
59-50	11987-11988	)	_
59-51	11989-11994	30.3%	_
59-52	11995-11999	8.3%	_
59-53	12000-12005	21.1%	_
59-54	12008-12012	Race	_
59-55	12018-12023	White	_
59-56	12024-12029	66.7%	_
59-57	12030-12035	45.8%	_
59-58	12036-12041	56.1%	_
59-59	12044-12049	Black	_
59-60	12050-12054	3.0%	_
59-61	12055-12060	16.7%	_
59-62	12061-12065	8.8%	_
59-63	12068-12073	Asian	_
59-64	12074-12078	6.1%	_
59-65	12079-12084	29.2%	_
59-66	12085-12090	15.8%	_
59-67	12093-12099	Native	_
59-68	12100-12108	Hawaiian	_
59-69	12109-12113	3.0%	_
59-70	12114-12118	0.0%	_
59-71	12119-12123	1.8%	_
59-72	12126-12134	American	_
59-73	12135-12141	Indian	_
59-74	12142-12144	or	_
59-75	12145-12152	Alaskan	_
59-76	12153-12159	Native	_
59-77	12160-12164	3.0%	_
59-78	12165-12169	0.0%	_
59-79	12170-12174	1.8%	_
59-80	12177-12182	Other	_
59-81	12183-12188	18.2%	_
59-82	12189-12193	8.3%	_
59-83	12194-12199	15.7%	_
59-84	12202-12210	Clinical	_
59-85	12211-12220	variables	_
59-86	12226-12232	Drinks	_
59-87	12233-12236	per	_
59-88	12237-12241	week	_
59-89	12242-12246	10.0	_
59-90	12247-12248	(	_
59-91	12248-12251	7.2	_
59-92	12251-12252	)	_
59-93	12253-12256	4.0	_
59-94	12257-12258	(	_
59-95	12258-12261	5.8	_
59-96	12261-12262	)	_
59-97	12263-12266	7.5	_
59-98	12267-12268	(	_
59-99	12268-12271	7.2	_
59-100	12271-12272	)	_
59-101	12275-12281	Number	_
59-102	12282-12284	of	_
59-103	12285-12290	binge	_
59-104	12291-12299	episodes	_
59-105	12300-12303	8.3	_
59-106	12304-12305	(	_
59-107	12305-12308	6.1	_
59-108	12308-12309	)	_
59-109	12310-12313	2.4	_
59-110	12314-12315	(	_
59-111	12315-12318	4.6	_
59-112	12318-12319	)	_
59-113	12320-12323	5.2	_
59-114	12324-12325	(	_
59-115	12325-12328	6.0	_
59-116	12328-12329	)	_
59-117	12332-12335	AUD	_
59-118	12336-12339	age	_
59-119	12340-12342	of	_
59-120	12343-12348	onset	_
59-121	12349-12353	19.5	_
59-122	12354-12355	(	_
59-123	12355-12358	2.8	_
59-124	12358-12359	)	_
59-125	12360-12361	–	_
59-126	12362-12366	19.5	_
59-127	12367-12368	(	_
59-128	12368-12371	2.8	_
59-129	12371-12372	)	_
59-130	12375-12380	Daily	_
59-131	12381-12390	cigarette	_
59-132	12391-12397	smoker	_
59-133	12398-12402	0.0%	_
59-134	12403-12407	0.0%	_
59-135	12408-12412	0.0%	_
59-136	12415-12417	No	_
59-137	12417-12418	.	_
59-138	12419-12424	times	_
59-139	12425-12429	used	_
59-140	12430-12438	cannabis	_
59-141	12439-12442	0.2	_
59-142	12443-12444	(	_
59-143	12444-12447	0.6	_
59-144	12447-12448	)	_
59-145	12449-12452	0.2	_
59-146	12453-12454	(	_
59-147	12454-12457	0.6	_
59-148	12457-12458	)	_
59-149	12459-12462	0.2	_
59-150	12463-12464	(	_
59-151	12464-12467	0.6	_
59-152	12467-12468	)	_
59-153	12471-12473	No	_
59-154	12473-12474	.	_
59-155	12475-12480	times	_
59-156	12481-12485	used	_
59-157	12486-12487	*	_
59-158	12487-12492	other	_
59-159	12493-12500	illicit	_
59-160	12501-12506	drugs	_
59-161	12507-12510	0.2	_
59-162	12511-12512	(	_
59-163	12512-12515	1.3	_
59-164	12515-12516	)	_
59-165	12517-12521	0.04	_
59-166	12522-12523	(	_
59-167	12523-12526	0.2	_
59-168	12526-12527	)	_
59-169	12528-12531	0.2	_
59-170	12532-12533	(	_
59-171	12533-12536	0.9	_
59-172	12536-12537	)	_
59-173	12540-12544	BDNF	_
59-174	12545-12553	variable	_
59-175	12559-12565	Plasma	_
59-176	12566-12570	BDNF	_
59-177	12571-12572	(	_
59-178	12572-12574	pg	_
59-179	12574-12575	/	_
59-180	12575-12577	μL	_
59-181	12577-12578	)	_
59-182	12579-12583	47.0	_
59-183	12584-12585	(	_
59-184	12585-12589	11.2	_
59-185	12589-12590	)	_
59-186	12591-12595	40.4	_
59-187	12596-12597	(	_
59-188	12597-12600	8.8	_
59-189	12600-12601	)	_
59-190	12602-12606	44.2	_
59-191	12607-12608	(	_
59-192	12608-12612	10.7	_
59-193	12612-12613	)	_
59-194	12616-12626	Diagnostic	_
59-195	12627-12636	variables	_
59-196	12642-12649	Current	_
59-197	12650-12655	major	_
59-198	12656-12666	depressive	_
59-199	12667-12675	disorder	_
59-200	12676-12680	9.1%	_
59-201	12681-12685	8.3%	_
59-202	12686-12690	8.8%	_
59-203	12693-12701	Lifetime	_
59-204	12702-12707	major	_
59-205	12708-12718	depressive	_
59-206	12719-12727	disorder	_
59-207	12728-12733	24.2%	_
59-208	12734-12739	16.7%	_
59-209	12740-12745	21.1%	_
59-210	12748-12755	Current	_
59-211	12756-12763	anxiety	_
59-212	12764-12772	disorder	_
59-213	12773-12778	12.1%	_
59-214	12779-12783	8.3%	_
59-215	12784-12789	10.5%	_
59-216	12792-12800	Lifetime	_
59-217	12801-12808	anxiety	_
59-218	12809-12817	disorder	_
59-219	12818-12823	27.3%	_
59-220	12824-12829	16.7%	_
59-221	12830-12835	22.8%	_
59-222	12838-12845	Current	_
59-223	12846-12859	posttraumatic	_
59-224	12860-12866	stress	_
59-225	12867-12875	disorder	_
59-226	12876-12880	0.0%	_
59-227	12881-12885	4.2%	_
59-228	12886-12890	1.8%	_
59-229	12893-12901	Lifetime	_
59-230	12902-12915	posttraumatic	_
59-231	12916-12922	stress	_
59-232	12923-12931	disorder	_
59-233	12932-12936	0.0%	_
59-234	12937-12941	4.2%	_
59-235	12942-12946	1.8%	_
59-236	12950-12953	All	_
59-237	12954-12960	values	_
59-238	12961-12964	are	_
59-239	12965-12970	means	_
59-240	12970-12971	,	_
59-241	12972-12980	standard	_
59-242	12981-12991	deviations	_
59-243	12991-12992	,	_
59-244	12993-12999	unless	_
59-245	13000-13009	otherwise	_
59-246	13010-13015	notes	_
59-247	13015-13016	.	_

#Text=Abbreviation: BDNF, brain derived neurotrophic factor.
60-1	13017-13029	Abbreviation	_
60-2	13029-13030	:	_
60-3	13031-13035	BDNF	_
60-4	13035-13036	,	_
60-5	13037-13042	brain	_
60-6	13043-13050	derived	_
60-7	13051-13063	neurotrophic	_
60-8	13064-13070	factor	_
60-9	13070-13071	.	_

#Text=Clinical Assessments and Procedure
#Text=Participants completed 2 laboratory visits separated by 1–7 days.
61-1	13072-13080	Clinical	_
61-2	13081-13092	Assessments	_
61-3	13093-13096	and	_
61-4	13097-13106	Procedure	_
61-5	13107-13119	Participants	_
61-6	13120-13129	completed	_
61-7	13130-13131	2	_
61-8	13132-13142	laboratory	_
61-9	13143-13149	visits	_
61-10	13150-13159	separated	_
61-11	13160-13162	by	_
61-12	13163-13164	1	_
61-13	13164-13165	–	_
61-14	13165-13166	7	_
61-15	13167-13171	days	_
61-16	13171-13172	.	_

#Text=The first visit included a clinical interview, a battery of self-report questionnaires, a blood draw, and a set of psychophysiological tasks.
62-1	13173-13176	The	_
62-2	13177-13182	first	_
62-3	13183-13188	visit	_
62-4	13189-13197	included	_
62-5	13198-13199	a	_
62-6	13200-13208	clinical	_
62-7	13209-13218	interview	_
62-8	13218-13219	,	_
62-9	13220-13221	a	_
62-10	13222-13229	battery	_
62-11	13230-13232	of	_
62-12	13233-13244	self-report	_
62-13	13245-13259	questionnaires	_
62-14	13259-13260	,	_
62-15	13261-13262	a	_
62-16	13263-13268	blood	_
62-17	13269-13273	draw	_
62-18	13273-13274	,	_
62-19	13275-13278	and	_
62-20	13279-13280	a	_
62-21	13281-13284	set	_
62-22	13285-13287	of	_
62-23	13288-13307	psychophysiological	_
62-24	13308-13313	tasks	_
62-25	13313-13314	.	_

#Text=The second visit involved fMRI data collection.
63-1	13315-13318	The	_
63-2	13319-13325	second	_
63-3	13326-13331	visit	_
63-4	13332-13340	involved	_
63-5	13341-13345	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-6	13346-13350	data	_
63-7	13351-13361	collection	_
63-8	13361-13362	.	_

#Text=At the initial session, lifetime psychopathology was assessed via the Structured Clinical Interview for DSM-5 Disorders (American Psychiatric Association, 2015), in-person, by trained assessors and supervised by a clinical psychologist.
64-1	13363-13365	At	_
64-2	13366-13369	the	_
64-3	13370-13377	initial	_
64-4	13378-13385	session	_
64-5	13385-13386	,	_
64-6	13387-13395	lifetime	_
64-7	13396-13411	psychopathology	_
64-8	13412-13415	was	_
64-9	13416-13424	assessed	_
64-10	13425-13428	via	_
64-11	13429-13432	the	_
64-12	13433-13443	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-13	13444-13452	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-14	13453-13462	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-15	13463-13466	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-16	13467-13470	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-17	13470-13471	-	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-18	13471-13472	5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-19	13473-13482	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[21]
64-20	13483-13484	(	_
64-21	13484-13492	American	_
64-22	13493-13504	Psychiatric	_
64-23	13505-13516	Association	_
64-24	13516-13517	,	_
64-25	13518-13522	2015	_
64-26	13522-13523	)	_
64-27	13523-13524	,	_
64-28	13525-13534	in-person	_
64-29	13534-13535	,	_
64-30	13536-13538	by	_
64-31	13539-13546	trained	_
64-32	13547-13556	assessors	_
64-33	13557-13560	and	_
64-34	13561-13571	supervised	_
64-35	13572-13574	by	_
64-36	13575-13576	a	_
64-37	13577-13585	clinical	_
64-38	13586-13598	psychologist	_
64-39	13598-13599	.	_

#Text=Age of onset of AUD was recorded during the Structured Clinical Interview for DSM-5 Disorders interview and examined in the current study given that lower age of onset is associated with worse AUD prognosis, and BDNF expression in the amygdala is decreased in individuals with early, but not late, AUD onset.
65-1	13600-13603	Age	_
65-2	13604-13606	of	_
65-3	13607-13612	onset	_
65-4	13613-13615	of	_
65-5	13616-13619	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
65-6	13620-13623	was	_
65-7	13624-13632	recorded	_
65-8	13633-13639	during	_
65-9	13640-13643	the	_
65-10	13644-13654	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-11	13655-13663	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-12	13664-13673	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-13	13674-13677	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-14	13678-13681	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-15	13681-13682	-	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-16	13682-13683	5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-17	13684-13693	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[22]
65-18	13694-13703	interview	_
65-19	13704-13707	and	_
65-20	13708-13716	examined	_
65-21	13717-13719	in	_
65-22	13720-13723	the	_
65-23	13724-13731	current	_
65-24	13732-13737	study	_
65-25	13738-13743	given	_
65-26	13744-13748	that	_
65-27	13749-13754	lower	_
65-28	13755-13758	age	_
65-29	13759-13761	of	_
65-30	13762-13767	onset	_
65-31	13768-13770	is	_
65-32	13771-13781	associated	_
65-33	13782-13786	with	_
65-34	13787-13792	worse	_
65-35	13793-13796	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
65-36	13797-13806	prognosis	_
65-37	13806-13807	,	_
65-38	13808-13811	and	_
65-39	13812-13816	BDNF	_
65-40	13817-13827	expression	_
65-41	13828-13830	in	_
65-42	13831-13834	the	_
65-43	13835-13843	amygdala	_
65-44	13844-13846	is	_
65-45	13847-13856	decreased	_
65-46	13857-13859	in	_
65-47	13860-13871	individuals	_
65-48	13872-13876	with	_
65-49	13877-13882	early	_
65-50	13882-13883	,	_
65-51	13884-13887	but	_
65-52	13888-13891	not	_
65-53	13892-13896	late	_
65-54	13896-13897	,	_
65-55	13898-13901	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
65-56	13902-13907	onset	_
65-57	13907-13908	.	_

#Text=Participants also completed a detailed assessment of their recent alcohol use employing the Timeline Follow-Back technique (Sobell and).
66-1	13909-13921	Participants	_
66-2	13922-13926	also	_
66-3	13927-13936	completed	_
66-4	13937-13938	a	_
66-5	13939-13947	detailed	_
66-6	13948-13958	assessment	_
66-7	13959-13961	of	_
66-8	13962-13967	their	_
66-9	13968-13974	recent	_
66-10	13975-13982	alcohol	_
66-11	13983-13986	use	_
66-12	13987-13996	employing	_
66-13	13997-14000	the	_
66-14	14001-14009	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]
66-15	14010-14021	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]
66-16	14022-14031	technique	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]
66-17	14032-14033	(	_
66-18	14033-14039	Sobell	_
66-19	14040-14043	and	_
66-20	14043-14044	)	_
66-21	14044-14045	.	_

#Text=Participants were presented with a calendar of the past 60 days, marked with holidays and special events, and were asked to indicate on what days they drank and how many drinks they consumed on each occasion.
67-1	14046-14058	Participants	_
67-2	14059-14063	were	_
67-3	14064-14073	presented	_
67-4	14074-14078	with	_
67-5	14079-14080	a	_
67-6	14081-14089	calendar	_
67-7	14090-14092	of	_
67-8	14093-14096	the	_
67-9	14097-14101	past	_
67-10	14102-14104	60	_
67-11	14105-14109	days	_
67-12	14109-14110	,	_
67-13	14111-14117	marked	_
67-14	14118-14122	with	_
67-15	14123-14131	holidays	_
67-16	14132-14135	and	_
67-17	14136-14143	special	_
67-18	14144-14150	events	_
67-19	14150-14151	,	_
67-20	14152-14155	and	_
67-21	14156-14160	were	_
67-22	14161-14166	asked	_
67-23	14167-14169	to	_
67-24	14170-14178	indicate	_
67-25	14179-14181	on	_
67-26	14182-14186	what	_
67-27	14187-14191	days	_
67-28	14192-14196	they	_
67-29	14197-14202	drank	_
67-30	14203-14206	and	_
67-31	14207-14210	how	_
67-32	14211-14215	many	_
67-33	14216-14222	drinks	_
67-34	14223-14227	they	_
67-35	14228-14236	consumed	_
67-36	14237-14239	on	_
67-37	14240-14244	each	_
67-38	14245-14253	occasion	_
67-39	14253-14254	.	_

#Text=Using the Timeline Follow-Back technique, we calculated average number of drinks consumed per week and total number of binge episodes over the past 60 days.
68-1	14255-14260	Using	_
68-2	14261-14264	the	_
68-3	14265-14273	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[24]
68-4	14274-14285	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[24]
68-5	14286-14295	technique	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[24]
68-6	14295-14296	,	_
68-7	14297-14299	we	_
68-8	14300-14310	calculated	_
68-9	14311-14318	average	_
68-10	14319-14325	number	_
68-11	14326-14328	of	_
68-12	14329-14335	drinks	_
68-13	14336-14344	consumed	_
68-14	14345-14348	per	_
68-15	14349-14353	week	_
68-16	14354-14357	and	_
68-17	14358-14363	total	_
68-18	14364-14370	number	_
68-19	14371-14373	of	_
68-20	14374-14379	binge	_
68-21	14380-14388	episodes	_
68-22	14389-14393	over	_
68-23	14394-14397	the	_
68-24	14398-14402	past	_
68-25	14403-14405	60	_
68-26	14406-14410	days	_
68-27	14410-14411	.	_

#Text=Binge episodes were defined as consuming ≥5 standard drinks for men and ≥4 drinks for women in 1 sitting.
69-1	14412-14417	Binge	_
69-2	14418-14426	episodes	_
69-3	14427-14431	were	_
69-4	14432-14439	defined	_
69-5	14440-14442	as	_
69-6	14443-14452	consuming	_
69-7	14453-14454	≥	_
69-8	14454-14455	5	_
69-9	14456-14464	standard	_
69-10	14465-14471	drinks	_
69-11	14472-14475	for	_
69-12	14476-14479	men	_
69-13	14480-14483	and	_
69-14	14484-14485	≥	_
69-15	14485-14486	4	_
69-16	14487-14493	drinks	_
69-17	14494-14497	for	_
69-18	14498-14503	women	_
69-19	14504-14506	in	_
69-20	14507-14508	1	_
69-21	14509-14516	sitting	_
69-22	14516-14517	.	_

#Text=Blood Collection and BDNF Protein Measurement
#Text=Each participant provided 40 mL of whole blood, which was collected via a trained phlebotomist.
70-1	14518-14523	Blood	_
70-2	14524-14534	Collection	_
70-3	14535-14538	and	_
70-4	14539-14543	BDNF	_
70-5	14544-14551	Protein	_
70-6	14552-14563	Measurement	_
70-7	14564-14568	Each	_
70-8	14569-14580	participant	_
70-9	14581-14589	provided	_
70-10	14590-14592	40	_
70-11	14593-14595	mL	_
70-12	14596-14598	of	_
70-13	14599-14604	whole	_
70-14	14605-14610	blood	_
70-15	14610-14611	,	_
70-16	14612-14617	which	_
70-17	14618-14621	was	_
70-18	14622-14631	collected	_
70-19	14632-14635	via	_
70-20	14636-14637	a	_
70-21	14638-14645	trained	_
70-22	14646-14658	phlebotomist	_
70-23	14658-14659	.	_

#Text=All blood draws occurred between the hours of 10 am and 1 pm.
71-1	14660-14663	All	_
71-2	14664-14669	blood	_
71-3	14670-14675	draws	_
71-4	14676-14684	occurred	_
71-5	14685-14692	between	_
71-6	14693-14696	the	_
71-7	14697-14702	hours	_
71-8	14703-14705	of	_
71-9	14706-14708	10	_
71-10	14709-14711	am	_
71-11	14712-14715	and	_
71-12	14716-14717	1	_
71-13	14718-14720	pm	_
71-14	14720-14721	.	_

#Text=Blood samples were collected in K2EDTA-coated tubes and centrifuged 700 rpm for 10 minutes at 4°C.
72-1	14722-14727	Blood	_
72-2	14728-14735	samples	_
72-3	14736-14740	were	_
72-4	14741-14750	collected	_
72-5	14751-14753	in	_
72-6	14754-14767	K2EDTA-coated	_
72-7	14768-14773	tubes	_
72-8	14774-14777	and	_
72-9	14778-14789	centrifuged	_
72-10	14790-14793	700	_
72-11	14794-14797	rpm	_
72-12	14798-14801	for	_
72-13	14802-14804	10	_
72-14	14805-14812	minutes	_
72-15	14813-14815	at	_
72-16	14816-14817	4	_
72-17	14817-14818	°	_
72-18	14818-14819	C	_
72-19	14819-14820	.	_

#Text=Plasma supernatant was subsequently transferred to a clean tube and immediately frozen at −80°C until use.
73-1	14821-14827	Plasma	_
73-2	14828-14839	supernatant	_
73-3	14840-14843	was	_
73-4	14844-14856	subsequently	_
73-5	14857-14868	transferred	_
73-6	14869-14871	to	_
73-7	14872-14873	a	_
73-8	14874-14879	clean	_
73-9	14880-14884	tube	_
73-10	14885-14888	and	_
73-11	14889-14900	immediately	_
73-12	14901-14907	frozen	_
73-13	14908-14910	at	_
73-14	14911-14912	−	_
73-15	14912-14914	80	_
73-16	14914-14915	°	_
73-17	14915-14916	C	_
73-18	14917-14922	until	_
73-19	14923-14926	use	_
73-20	14926-14927	.	_

#Text=In preparation for protein measurement, plasma samples were thawed on ice, clarified via a 20-minute spin at 10 000 g at 4°C for complete platelet removal, and supernatant transferred to new tube.
74-1	14928-14930	In	_
74-2	14931-14942	preparation	_
74-3	14943-14946	for	_
74-4	14947-14954	protein	_
74-5	14955-14966	measurement	_
74-6	14966-14967	,	_
74-7	14968-14974	plasma	_
74-8	14975-14982	samples	_
74-9	14983-14987	were	_
74-10	14988-14994	thawed	_
74-11	14995-14997	on	_
74-12	14998-15001	ice	_
74-13	15001-15002	,	_
74-14	15003-15012	clarified	_
74-15	15013-15016	via	_
74-16	15017-15018	a	_
74-17	15019-15021	20	_
74-18	15021-15022	-	_
74-19	15022-15028	minute	_
74-20	15029-15033	spin	_
74-21	15034-15036	at	_
74-22	15037-15039	10	_
74-23	15040-15043	000	_
74-24	15044-15045	g	_
74-25	15046-15048	at	_
74-26	15049-15050	4	_
74-27	15050-15051	°	_
74-28	15051-15052	C	_
74-29	15053-15056	for	_
74-30	15057-15065	complete	_
74-31	15066-15074	platelet	_
74-32	15075-15082	removal	_
74-33	15082-15083	,	_
74-34	15084-15087	and	_
74-35	15088-15099	supernatant	_
74-36	15100-15111	transferred	_
74-37	15112-15114	to	_
74-38	15115-15118	new	_
74-39	15119-15123	tube	_
74-40	15123-15124	.	_

#Text=BDNF levels were ascertained using a quantitative in vitro enzyme-linked immunosorbent assay kit (BioVision, Milpitas, CA).
75-1	15125-15129	BDNF	_
75-2	15130-15136	levels	_
75-3	15137-15141	were	_
75-4	15142-15153	ascertained	_
75-5	15154-15159	using	_
75-6	15160-15161	a	_
75-7	15162-15174	quantitative	_
75-8	15175-15177	in	_
75-9	15178-15183	vitro	_
75-10	15184-15197	enzyme-linked	_
75-11	15198-15211	immunosorbent	_
75-12	15212-15217	assay	_
75-13	15218-15221	kit	_
75-14	15222-15223	(	_
75-15	15223-15232	BioVision	_
75-16	15232-15233	,	_
75-17	15234-15242	Milpitas	_
75-18	15242-15243	,	_
75-19	15244-15246	CA	_
75-20	15246-15247	)	_
75-21	15247-15248	.	_

#Text=Briefly, 100 µL of BDNF standards (0.066–16 pg/uL recombinant human BDNF) were applied in duplicate to 96-well plates precoated with an antibody specific for human BDNF.
76-1	15249-15256	Briefly	_
76-2	15256-15257	,	_
76-3	15258-15261	100	_
76-4	15262-15264	µL	_
76-5	15265-15267	of	_
76-6	15268-15272	BDNF	_
76-7	15273-15282	standards	_
76-8	15283-15284	(	_
76-9	15284-15289	0.066	_
76-10	15289-15290	–	_
76-11	15290-15292	16	_
76-12	15293-15295	pg	_
76-13	15295-15296	/	_
76-14	15296-15298	uL	_
76-15	15299-15310	recombinant	_
76-16	15311-15316	human	_
76-17	15317-15321	BDNF	_
76-18	15321-15322	)	_
76-19	15323-15327	were	_
76-20	15328-15335	applied	_
76-21	15336-15338	in	_
76-22	15339-15348	duplicate	_
76-23	15349-15351	to	_
76-24	15352-15354	96	_
76-25	15354-15355	-	_
76-26	15355-15359	well	_
76-27	15360-15366	plates	_
76-28	15367-15376	precoated	_
76-29	15377-15381	with	_
76-30	15382-15384	an	_
76-31	15385-15393	antibody	_
76-32	15394-15402	specific	_
76-33	15403-15406	for	_
76-34	15407-15412	human	_
76-35	15413-15417	BDNF	_
76-36	15417-15418	.	_

#Text=The samples were diluted (1:10) and 100 µL was added to the plate in duplicate.
77-1	15419-15422	The	_
77-2	15423-15430	samples	_
77-3	15431-15435	were	_
77-4	15436-15443	diluted	_
77-5	15444-15445	(	_
77-6	15445-15446	1	_
77-7	15446-15447	:	_
77-8	15447-15449	10	_
77-9	15449-15450	)	_
77-10	15451-15454	and	_
77-11	15455-15458	100	_
77-12	15459-15461	µL	_
77-13	15462-15465	was	_
77-14	15466-15471	added	_
77-15	15472-15474	to	_
77-16	15475-15478	the	_
77-17	15479-15484	plate	_
77-18	15485-15487	in	_
77-19	15488-15497	duplicate	_
77-20	15497-15498	.	_

#Text=The plate was sealed and incubated overnight at 4°C.
78-1	15499-15502	The	_
78-2	15503-15508	plate	_
78-3	15509-15512	was	_
78-4	15513-15519	sealed	_
78-5	15520-15523	and	_
78-6	15524-15533	incubated	_
78-7	15534-15543	overnight	_
78-8	15544-15546	at	_
78-9	15547-15548	4	_
78-10	15548-15549	°	_
78-11	15549-15550	C	_
78-12	15550-15551	.	_

#Text=The next morning, the plate was rinsed with wash-buffer 4 times and incubated with biotinylated primary antiserum at room temperature with gentle shaking for 1 hour.
79-1	15552-15555	The	_
79-2	15556-15560	next	_
79-3	15561-15568	morning	_
79-4	15568-15569	,	_
79-5	15570-15573	the	_
79-6	15574-15579	plate	_
79-7	15580-15583	was	_
79-8	15584-15590	rinsed	_
79-9	15591-15595	with	_
79-10	15596-15607	wash-buffer	_
79-11	15608-15609	4	_
79-12	15610-15615	times	_
79-13	15616-15619	and	_
79-14	15620-15629	incubated	_
79-15	15630-15634	with	_
79-16	15635-15647	biotinylated	_
79-17	15648-15655	primary	_
79-18	15656-15665	antiserum	_
79-19	15666-15668	at	_
79-20	15669-15673	room	_
79-21	15674-15685	temperature	_
79-22	15686-15690	with	_
79-23	15691-15697	gentle	_
79-24	15698-15705	shaking	_
79-25	15706-15709	for	_
79-26	15710-15711	1	_
79-27	15712-15716	hour	_
79-28	15716-15717	.	_

#Text=Wells were washed again, incubated with a streptavidin-HRP complex for 45 minutes and developed in a solution of tetramethylbenzidine for 20 minutes in the dark prior to stopping the reaction with a 2N sulfuric acid stop solution.
80-1	15718-15723	Wells	_
80-2	15724-15728	were	_
80-3	15729-15735	washed	_
80-4	15736-15741	again	_
80-5	15741-15742	,	_
80-6	15743-15752	incubated	_
80-7	15753-15757	with	_
80-8	15758-15759	a	_
80-9	15760-15776	streptavidin-HRP	_
80-10	15777-15784	complex	_
80-11	15785-15788	for	_
80-12	15789-15791	45	_
80-13	15792-15799	minutes	_
80-14	15800-15803	and	_
80-15	15804-15813	developed	_
80-16	15814-15816	in	_
80-17	15817-15818	a	_
80-18	15819-15827	solution	_
80-19	15828-15830	of	_
80-20	15831-15851	tetramethylbenzidine	_
80-21	15852-15855	for	_
80-22	15856-15858	20	_
80-23	15859-15866	minutes	_
80-24	15867-15869	in	_
80-25	15870-15873	the	_
80-26	15874-15878	dark	_
80-27	15879-15884	prior	_
80-28	15885-15887	to	_
80-29	15888-15896	stopping	_
80-30	15897-15900	the	_
80-31	15901-15909	reaction	_
80-32	15910-15914	with	_
80-33	15915-15916	a	_
80-34	15917-15919	2N	_
80-35	15920-15928	sulfuric	_
80-36	15929-15933	acid	_
80-37	15934-15938	stop	_
80-38	15939-15947	solution	_
80-39	15947-15948	.	_

#Text=Samples and standards were run in duplicate and replicated across a minimum of 2 enzyme-linked immunosorbent assays.
81-1	15949-15956	Samples	_
81-2	15957-15960	and	_
81-3	15961-15970	standards	_
81-4	15971-15975	were	_
81-5	15976-15979	run	_
81-6	15980-15982	in	_
81-7	15983-15992	duplicate	_
81-8	15993-15996	and	_
81-9	15997-16007	replicated	_
81-10	16008-16014	across	_
81-11	16015-16016	a	_
81-12	16017-16024	minimum	_
81-13	16025-16027	of	_
81-14	16028-16029	2	_
81-15	16030-16043	enzyme-linked	_
81-16	16044-16057	immunosorbent	_
81-17	16058-16064	assays	_
81-18	16064-16065	.	_

#Text=The optical density of each sample and standard was measured at 450 nm using the Spectra MR microplate reader (Dynex Technologies, Chantilly, VA), and the amount of BDNF in each sample was calculated against the BDNF standard curve and expressed as pg/uL of protein.
#Text=fMRI Threat Task
#Text=Prior to the task, electrodes were placed on participants’ left foot and a shock work-up was completed to identify the level of shock intensity each participant described as “highly annoying but not painful” (between 1 and 5 mA).
82-1	16066-16069	The	_
82-2	16070-16077	optical	_
82-3	16078-16085	density	_
82-4	16086-16088	of	_
82-5	16089-16093	each	_
82-6	16094-16100	sample	_
82-7	16101-16104	and	_
82-8	16105-16113	standard	_
82-9	16114-16117	was	_
82-10	16118-16126	measured	_
82-11	16127-16129	at	_
82-12	16130-16133	450	_
82-13	16134-16136	nm	_
82-14	16137-16142	using	_
82-15	16143-16146	the	_
82-16	16147-16154	Spectra	_
82-17	16155-16157	MR	_
82-18	16158-16168	microplate	_
82-19	16169-16175	reader	_
82-20	16176-16177	(	_
82-21	16177-16182	Dynex	_
82-22	16183-16195	Technologies	_
82-23	16195-16196	,	_
82-24	16197-16206	Chantilly	_
82-25	16206-16207	,	_
82-26	16208-16210	VA	_
82-27	16210-16211	)	_
82-28	16211-16212	,	_
82-29	16213-16216	and	_
82-30	16217-16220	the	_
82-31	16221-16227	amount	_
82-32	16228-16230	of	_
82-33	16231-16235	BDNF	_
82-34	16236-16238	in	_
82-35	16239-16243	each	_
82-36	16244-16250	sample	_
82-37	16251-16254	was	_
82-38	16255-16265	calculated	_
82-39	16266-16273	against	_
82-40	16274-16277	the	_
82-41	16278-16282	BDNF	_
82-42	16283-16291	standard	_
82-43	16292-16297	curve	_
82-44	16298-16301	and	_
82-45	16302-16311	expressed	_
82-46	16312-16314	as	_
82-47	16315-16317	pg	_
82-48	16317-16318	/	_
82-49	16318-16320	uL	_
82-50	16321-16323	of	_
82-51	16324-16331	protein	_
82-52	16331-16332	.	_
82-53	16333-16337	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
82-54	16338-16344	Threat	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
82-55	16345-16349	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
82-56	16350-16355	Prior	_
82-57	16356-16358	to	_
82-58	16359-16362	the	_
82-59	16363-16367	task	_
82-60	16367-16368	,	_
82-61	16369-16379	electrodes	_
82-62	16380-16384	were	_
82-63	16385-16391	placed	_
82-64	16392-16394	on	_
82-65	16395-16407	participants	_
82-66	16407-16408	’	_
82-67	16409-16413	left	_
82-68	16414-16418	foot	_
82-69	16419-16422	and	_
82-70	16423-16424	a	_
82-71	16425-16430	shock	_
82-72	16431-16438	work-up	_
82-73	16439-16442	was	_
82-74	16443-16452	completed	_
82-75	16453-16455	to	_
82-76	16456-16464	identify	_
82-77	16465-16468	the	_
82-78	16469-16474	level	_
82-79	16475-16477	of	_
82-80	16478-16483	shock	_
82-81	16484-16493	intensity	_
82-82	16494-16498	each	_
82-83	16499-16510	participant	_
82-84	16511-16520	described	_
82-85	16521-16523	as	_
82-86	16524-16525	“	_
82-87	16525-16531	highly	_
82-88	16532-16540	annoying	_
82-89	16541-16544	but	_
82-90	16545-16548	not	_
82-91	16549-16556	painful	_
82-92	16556-16557	”	_
82-93	16558-16559	(	_
82-94	16559-16566	between	_
82-95	16567-16568	1	_
82-96	16569-16572	and	_
82-97	16573-16574	5	_
82-98	16575-16577	mA	_
82-99	16577-16578	)	_
82-100	16578-16579	.	_

#Text=The task was designed to be analogous to the widely used NPU-threat task described by.
83-1	16580-16583	The	_
83-2	16584-16588	task	_
83-3	16589-16592	was	_
83-4	16593-16601	designed	_
83-5	16602-16604	to	_
83-6	16605-16607	be	_
83-7	16608-16617	analogous	_
83-8	16618-16620	to	_
83-9	16621-16624	the	_
83-10	16625-16631	widely	_
83-11	16632-16636	used	_
83-12	16637-16647	NPU-threat	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
83-13	16648-16652	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
83-14	16653-16662	described	_
83-15	16663-16665	by	_
83-16	16665-16666	.	_

#Text=There were 3 within-participant conditions: N, P shock, and U shock.
84-1	16667-16672	There	_
84-2	16673-16677	were	_
84-3	16678-16679	3	_
84-4	16680-16698	within-participant	_
84-5	16699-16709	conditions	_
84-6	16709-16710	:	_
84-7	16711-16712	N	_
84-8	16712-16713	,	_
84-9	16714-16715	P	_
84-10	16716-16721	shock	_
84-11	16721-16722	,	_
84-12	16723-16726	and	_
84-13	16727-16728	U	_
84-14	16729-16734	shock	_
84-15	16734-16735	.	_

#Text=During each condition, participants viewed a numeric countdown that ranged between 3 and 8 seconds (M = 5 seconds).
85-1	16736-16742	During	_
85-2	16743-16747	each	_
85-3	16748-16757	condition	_
85-4	16757-16758	,	_
85-5	16759-16771	participants	_
85-6	16772-16778	viewed	_
85-7	16779-16780	a	_
85-8	16781-16788	numeric	_
85-9	16789-16798	countdown	_
85-10	16799-16803	that	_
85-11	16804-16810	ranged	_
85-12	16811-16818	between	_
85-13	16819-16820	3	_
85-14	16821-16824	and	_
85-15	16825-16826	8	_
85-16	16827-16834	seconds	_
85-17	16835-16836	(	_
85-18	16836-16837	M	_
85-19	16838-16839	=	_
85-20	16840-16841	5	_
85-21	16842-16849	seconds	_
85-22	16849-16850	)	_
85-23	16850-16851	.	_

#Text=Text at the bottom of the computer monitor informed participants of the current condition.
86-1	16852-16856	Text	_
86-2	16857-16859	at	_
86-3	16860-16863	the	_
86-4	16864-16870	bottom	_
86-5	16871-16873	of	_
86-6	16874-16877	the	_
86-7	16878-16886	computer	_
86-8	16887-16894	monitor	_
86-9	16895-16903	informed	_
86-10	16904-16916	participants	_
86-11	16917-16919	of	_
86-12	16920-16923	the	_
86-13	16924-16931	current	_
86-14	16932-16941	condition	_
86-15	16941-16942	.	_

#Text=During N, no shocks were delivered and the text read “no shock.”
87-1	16943-16949	During	_
87-2	16950-16951	N	_
87-3	16951-16952	,	_
87-4	16953-16955	no	_
87-5	16956-16962	shocks	_
87-6	16963-16967	were	_
87-7	16968-16977	delivered	_
87-8	16978-16981	and	_
87-9	16982-16985	the	_
87-10	16986-16990	text	_
87-11	16991-16995	read	_
87-12	16996-16997	“	_
87-13	16997-16999	no	_
87-14	17000-17005	shock	_
87-15	17005-17006	.	_
87-16	17006-17007	”	_

#Text=During P, participants received a shock only when the countdown reached “1” and the text read “shock at 1”.
88-1	17008-17014	During	_
88-2	17015-17016	P	_
88-3	17016-17017	,	_
88-4	17018-17030	participants	_
88-5	17031-17039	received	_
88-6	17040-17041	a	_
88-7	17042-17047	shock	_
88-8	17048-17052	only	_
88-9	17053-17057	when	_
88-10	17058-17061	the	_
88-11	17062-17071	countdown	_
88-12	17072-17079	reached	_
88-13	17080-17081	“	_
88-14	17081-17082	1	_
88-15	17082-17083	”	_
88-16	17084-17087	and	_
88-17	17088-17091	the	_
88-18	17092-17096	text	_
88-19	17097-17101	read	_
88-20	17102-17103	“	_
88-21	17103-17108	shock	_
88-22	17109-17111	at	_
88-23	17112-17113	1	_
88-24	17113-17114	”	_
88-25	17114-17115	.	_

#Text=During U, participants received a shock at random, regardless of the number on the screen and the text read “shock at anytime.”
89-1	17116-17122	During	_
89-2	17123-17124	U	_
89-3	17124-17125	,	_
89-4	17126-17138	participants	_
89-5	17139-17147	received	_
89-6	17148-17149	a	_
89-7	17150-17155	shock	_
89-8	17156-17158	at	_
89-9	17159-17165	random	_
89-10	17165-17166	,	_
89-11	17167-17177	regardless	_
89-12	17178-17180	of	_
89-13	17181-17184	the	_
89-14	17185-17191	number	_
89-15	17192-17194	on	_
89-16	17195-17198	the	_
89-17	17199-17205	screen	_
89-18	17206-17209	and	_
89-19	17210-17213	the	_
89-20	17214-17218	text	_
89-21	17219-17223	read	_
89-22	17224-17225	“	_
89-23	17225-17230	shock	_
89-24	17231-17233	at	_
89-25	17234-17241	anytime	_
89-26	17241-17242	.	_
89-27	17242-17243	”	_

#Text=Following each countdown, individuals saw a fixation cross for 5 to 7 seconds (M = 6 seconds).
90-1	17244-17253	Following	_
90-2	17254-17258	each	_
90-3	17259-17268	countdown	_
90-4	17268-17269	,	_
90-5	17270-17281	individuals	_
90-6	17282-17285	saw	_
90-7	17286-17287	a	_
90-8	17288-17296	fixation	_
90-9	17297-17302	cross	_
90-10	17303-17306	for	_
90-11	17307-17308	5	_
90-12	17309-17311	to	_
90-13	17312-17313	7	_
90-14	17314-17321	seconds	_
90-15	17322-17323	(	_
90-16	17323-17324	M	_
90-17	17325-17326	=	_
90-18	17327-17328	6	_
90-19	17329-17336	seconds	_
90-20	17336-17337	)	_
90-21	17337-17338	.	_

#Text=N, P, and U countdowns were presented in blocks of 6, and each condition/block was administered in a randomized order (counterbalanced) 6 times over the course of 2 runs.
91-1	17339-17340	N	_
91-2	17340-17341	,	_
91-3	17342-17343	P	_
91-4	17343-17344	,	_
91-5	17345-17348	and	_
91-6	17349-17350	U	_
91-7	17351-17361	countdowns	_
91-8	17362-17366	were	_
91-9	17367-17376	presented	_
91-10	17377-17379	in	_
91-11	17380-17386	blocks	_
91-12	17387-17389	of	_
91-13	17390-17391	6	_
91-14	17391-17392	,	_
91-15	17393-17396	and	_
91-16	17397-17401	each	_
91-17	17402-17411	condition	_
91-18	17411-17412	/	_
91-19	17412-17417	block	_
91-20	17418-17421	was	_
91-21	17422-17434	administered	_
91-22	17435-17437	in	_
91-23	17438-17439	a	_
91-24	17440-17450	randomized	_
91-25	17451-17456	order	_
91-26	17457-17458	(	_
91-27	17458-17473	counterbalanced	_
91-28	17473-17474	)	_
91-29	17475-17476	6	_
91-30	17477-17482	times	_
91-31	17483-17487	over	_
91-32	17488-17491	the	_
91-33	17492-17498	course	_
91-34	17499-17501	of	_
91-35	17502-17503	2	_
91-36	17504-17508	runs	_
91-37	17508-17509	.	_

#Text=Notably, not all countdowns ran full-length or terminated with “1,” allowing us to match the 3 conditions on total number of data points (i.e., TRs/repetition times).
92-1	17510-17517	Notably	_
92-2	17517-17518	,	_
92-3	17519-17522	not	_
92-4	17523-17526	all	_
92-5	17527-17537	countdowns	_
92-6	17538-17541	ran	_
92-7	17542-17553	full-length	_
92-8	17554-17556	or	_
92-9	17557-17567	terminated	_
92-10	17568-17572	with	_
92-11	17573-17574	“	_
92-12	17574-17575	1	_
92-13	17575-17576	,	_
92-14	17576-17577	”	_
92-15	17578-17586	allowing	_
92-16	17587-17589	us	_
92-17	17590-17592	to	_
92-18	17593-17598	match	_
92-19	17599-17602	the	_
92-20	17603-17604	3	_
92-21	17605-17615	conditions	_
92-22	17616-17618	on	_
92-23	17619-17624	total	_
92-24	17625-17631	number	_
92-25	17632-17634	of	_
92-26	17635-17639	data	_
92-27	17640-17646	points	_
92-28	17647-17648	(	_
92-29	17648-17651	i.e	_
92-30	17651-17652	.	_
92-31	17652-17653	,	_
92-32	17654-17657	TRs	_
92-33	17657-17658	/	_
92-34	17658-17668	repetition	_
92-35	17669-17674	times	_
92-36	17674-17675	)	_
92-37	17675-17676	.	_

#Text=Participants received 10 electric shocks during P and 10 electric shocks during U during each run.
93-1	17677-17689	Participants	_
93-2	17690-17698	received	_
93-3	17699-17701	10	_
93-4	17702-17710	electric	_
93-5	17711-17717	shocks	_
93-6	17718-17724	during	_
93-7	17725-17726	P	_
93-8	17727-17730	and	_
93-9	17731-17733	10	_
93-10	17734-17742	electric	_
93-11	17743-17749	shocks	_
93-12	17750-17756	during	_
93-13	17757-17758	U	_
93-14	17759-17765	during	_
93-15	17766-17770	each	_
93-16	17771-17774	run	_
93-17	17774-17775	.	_

#Text=The rate of “shock at 1” during the P condition was 60%, consistent with the NPU version used by Grillon and colleagues.
#Text=fMRI Data Collection and Processing
#Text=fMRI was performed on a 3.0 Tesla GE MR 750 scanner (General Electric Healthcare, Waukesha, WI) using an 8-channel phased-array radio frequency head coil.
94-1	17776-17779	The	_
94-2	17780-17784	rate	_
94-3	17785-17787	of	_
94-4	17788-17789	“	_
94-5	17789-17794	shock	_
94-6	17795-17797	at	_
94-7	17798-17799	1	_
94-8	17799-17800	”	_
94-9	17801-17807	during	_
94-10	17808-17811	the	_
94-11	17812-17813	P	_
94-12	17814-17823	condition	_
94-13	17824-17827	was	_
94-14	17828-17831	60%	_
94-15	17831-17832	,	_
94-16	17833-17843	consistent	_
94-17	17844-17848	with	_
94-18	17849-17852	the	_
94-19	17853-17856	NPU	_
94-20	17857-17864	version	_
94-21	17865-17869	used	_
94-22	17870-17872	by	_
94-23	17873-17880	Grillon	_
94-24	17881-17884	and	_
94-25	17885-17895	colleagues	_
94-26	17895-17896	.	_
94-27	17897-17901	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
94-28	17902-17906	Data	_
94-29	17907-17917	Collection	_
94-30	17918-17921	and	_
94-31	17922-17932	Processing	_
94-32	17933-17937	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
94-33	17938-17941	was	_
94-34	17942-17951	performed	_
94-35	17952-17954	on	_
94-36	17955-17956	a	_
94-37	17957-17960	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-38	17961-17966	Tesla	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-39	17967-17969	GE	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-40	17970-17972	MR	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-41	17973-17976	750	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-42	17977-17984	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]
94-43	17985-17986	(	_
94-44	17986-17993	General	_
94-45	17994-18002	Electric	_
94-46	18003-18013	Healthcare	_
94-47	18013-18014	,	_
94-48	18015-18023	Waukesha	_
94-49	18023-18024	,	_
94-50	18025-18027	WI	_
94-51	18027-18028	)	_
94-52	18029-18034	using	_
94-53	18035-18037	an	_
94-54	18038-18039	8	_
94-55	18039-18040	-	_
94-56	18040-18047	channel	_
94-57	18048-18060	phased-array	_
94-58	18061-18066	radio	_
94-59	18067-18076	frequency	_
94-60	18077-18081	head	_
94-61	18082-18086	coil	_
94-62	18086-18087	.	_

#Text=A standard T2-sensitive gradient-echo echoplanar imaging sequence was used (2 seconds TR; 22.2 milliseconds TE; 90° flip; 64 × 64 matrix; 22 cm FOV; 44 axial slices; 3.44 × 3.44 × 3.0 mm voxels; 336 volumes).
95-1	18088-18089	A	_
95-2	18090-18098	standard	_
95-3	18099-18101	T2	_
95-4	18101-18102	-	_
95-5	18102-18111	sensitive	_
95-6	18112-18125	gradient-echo	_
95-7	18126-18136	echoplanar	_
95-8	18137-18144	imaging	_
95-9	18145-18153	sequence	_
95-10	18154-18157	was	_
95-11	18158-18162	used	_
95-12	18163-18164	(	_
95-13	18164-18165	2	_
95-14	18166-18173	seconds	_
95-15	18174-18176	TR	_
95-16	18176-18177	;	_
95-17	18178-18182	22.2	_
95-18	18183-18195	milliseconds	_
95-19	18196-18198	TE	_
95-20	18198-18199	;	_
95-21	18200-18202	90	_
95-22	18202-18203	°	_
95-23	18204-18208	flip	_
95-24	18208-18209	;	_
95-25	18210-18212	64	_
95-26	18213-18214	×	_
95-27	18215-18217	64	_
95-28	18218-18224	matrix	_
95-29	18224-18225	;	_
95-30	18226-18228	22	_
95-31	18229-18231	cm	_
95-32	18232-18235	FOV	_
95-33	18235-18236	;	_
95-34	18237-18239	44	_
95-35	18240-18245	axial	_
95-36	18246-18252	slices	_
95-37	18252-18253	;	_
95-38	18254-18258	3.44	_
95-39	18259-18260	×	_
95-40	18261-18265	3.44	_
95-41	18266-18267	×	_
95-42	18268-18271	3.0	_
95-43	18272-18274	mm	_
95-44	18275-18281	voxels	_
95-45	18281-18282	;	_
95-46	18283-18286	336	_
95-47	18287-18294	volumes	_
95-48	18294-18295	)	_
95-49	18295-18296	.	_

#Text=All fMRI data met criteria for high quality and scan stability with minimum motion correction (i.e., <2 mm displacement in any direction).
96-1	18297-18300	All	_
96-2	18301-18305	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
96-3	18306-18310	data	_
96-4	18311-18314	met	_
96-5	18315-18323	criteria	_
96-6	18324-18327	for	_
96-7	18328-18332	high	_
96-8	18333-18340	quality	_
96-9	18341-18344	and	_
96-10	18345-18349	scan	_
96-11	18350-18359	stability	_
96-12	18360-18364	with	_
96-13	18365-18372	minimum	_
96-14	18373-18379	motion	_
96-15	18380-18390	correction	_
96-16	18391-18392	(	_
96-17	18392-18395	i.e	_
96-18	18395-18396	.	_
96-19	18396-18397	,	_
96-20	18398-18399	<	_
96-21	18399-18400	2	_
96-22	18401-18403	mm	_
96-23	18404-18416	displacement	_
96-24	18417-18419	in	_
96-25	18420-18423	any	_
96-26	18424-18433	direction	_
96-27	18433-18434	)	_
96-28	18434-18435	.	_

#Text=Preprocessing of fMRI data was conducted using Statistical Parametric Mapping software (SPM12, Wellcome Department of Imaging Neuro-Science, London, UK), and, accordingly, we followed the standard preprocessing routines suggested by SPM.
97-1	18436-18449	Preprocessing	_
97-2	18450-18452	of	_
97-3	18453-18457	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
97-4	18458-18462	data	_
97-5	18463-18466	was	_
97-6	18467-18476	conducted	_
97-7	18477-18482	using	_
97-8	18483-18494	Statistical	_
97-9	18495-18505	Parametric	_
97-10	18506-18513	Mapping	_
97-11	18514-18522	software	_
97-12	18523-18524	(	_
97-13	18524-18529	SPM12	_
97-14	18529-18530	,	_
97-15	18531-18539	Wellcome	_
97-16	18540-18550	Department	_
97-17	18551-18553	of	_
97-18	18554-18561	Imaging	_
97-19	18562-18575	Neuro-Science	_
97-20	18575-18576	,	_
97-21	18577-18583	London	_
97-22	18583-18584	,	_
97-23	18585-18587	UK	_
97-24	18587-18588	)	_
97-25	18588-18589	,	_
97-26	18590-18593	and	_
97-27	18593-18594	,	_
97-28	18595-18606	accordingly	_
97-29	18606-18607	,	_
97-30	18608-18610	we	_
97-31	18611-18619	followed	_
97-32	18620-18623	the	_
97-33	18624-18632	standard	_
97-34	18633-18646	preprocessing	_
97-35	18647-18655	routines	_
97-36	18656-18665	suggested	_
97-37	18666-18668	by	_
97-38	18669-18672	SPM	_
97-39	18672-18673	.	_

#Text=The first 4 volumes were discarded to allow for T1 equilibration effects.
98-1	18674-18677	The	_
98-2	18678-18683	first	_
98-3	18684-18685	4	_
98-4	18686-18693	volumes	_
98-5	18694-18698	were	_
98-6	18699-18708	discarded	_
98-7	18709-18711	to	_
98-8	18712-18717	allow	_
98-9	18718-18721	for	_
98-10	18722-18724	T1	_
98-11	18725-18738	equilibration	_
98-12	18739-18746	effects	_
98-13	18746-18747	.	_

#Text=Images were slice time corrected with the reference slice based on the middle of each TR, realigned with the first volume to correct for head motion, co-registered to the participants’ T1-weighted image in Montreal Neurological Institute (MNI) space, re-sampled to 2-mm3 voxels, and smoothed using a 8-mm isotropic Gaussian kernel.
99-1	18748-18754	Images	_
99-2	18755-18759	were	_
99-3	18760-18765	slice	_
99-4	18766-18770	time	_
99-5	18771-18780	corrected	_
99-6	18781-18785	with	_
99-7	18786-18789	the	_
99-8	18790-18799	reference	_
99-9	18800-18805	slice	_
99-10	18806-18811	based	_
99-11	18812-18814	on	_
99-12	18815-18818	the	_
99-13	18819-18825	middle	_
99-14	18826-18828	of	_
99-15	18829-18833	each	_
99-16	18834-18836	TR	_
99-17	18836-18837	,	_
99-18	18838-18847	realigned	_
99-19	18848-18852	with	_
99-20	18853-18856	the	_
99-21	18857-18862	first	_
99-22	18863-18869	volume	_
99-23	18870-18872	to	_
99-24	18873-18880	correct	_
99-25	18881-18884	for	_
99-26	18885-18889	head	_
99-27	18890-18896	motion	_
99-28	18896-18897	,	_
99-29	18898-18911	co-registered	_
99-30	18912-18914	to	_
99-31	18915-18918	the	_
99-32	18919-18931	participants	_
99-33	18931-18932	’	_
99-34	18933-18935	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]
99-35	18935-18936	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]
99-36	18936-18944	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]
99-37	18945-18950	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]
99-38	18951-18953	in	_
99-39	18954-18962	Montreal	_
99-40	18963-18975	Neurological	_
99-41	18976-18985	Institute	_
99-42	18986-18987	(	_
99-43	18987-18990	MNI	_
99-44	18990-18991	)	_
99-45	18992-18997	space	_
99-46	18997-18998	,	_
99-47	18999-19009	re-sampled	_
99-48	19010-19012	to	_
99-49	19013-19014	2	_
99-50	19014-19015	-	_
99-51	19015-19018	mm3	_
99-52	19019-19025	voxels	_
99-53	19025-19026	,	_
99-54	19027-19030	and	_
99-55	19031-19039	smoothed	_
99-56	19040-19045	using	_
99-57	19046-19047	a	_
99-58	19048-19049	8	_
99-59	19049-19050	-	_
99-60	19050-19052	mm	_
99-61	19053-19062	isotropic	_
99-62	19063-19071	Gaussian	_
99-63	19072-19078	kernel	_
99-64	19078-19079	.	_

#Text=The general linear model was applied to the time series, convolved with the canonical hemodynamic response function and with a 128-second high-pass filter.
100-1	19080-19083	The	_
100-2	19084-19091	general	_
100-3	19092-19098	linear	_
100-4	19099-19104	model	_
100-5	19105-19108	was	_
100-6	19109-19116	applied	_
100-7	19117-19119	to	_
100-8	19120-19123	the	_
100-9	19124-19128	time	_
100-10	19129-19135	series	_
100-11	19135-19136	,	_
100-12	19137-19146	convolved	_
100-13	19147-19151	with	_
100-14	19152-19155	the	_
100-15	19156-19165	canonical	_
100-16	19166-19177	hemodynamic	_
100-17	19178-19186	response	_
100-18	19187-19195	function	_
100-19	19196-19199	and	_
100-20	19200-19204	with	_
100-21	19205-19206	a	_
100-22	19207-19210	128	_
100-23	19210-19211	-	_
100-24	19211-19217	second	_
100-25	19218-19227	high-pass	_
100-26	19228-19234	filter	_
100-27	19234-19235	.	_

#Text=Condition effects for U, P, and N anticipation were separately estimated at each voxel for each participant.
101-1	19236-19245	Condition	_
101-2	19246-19253	effects	_
101-3	19254-19257	for	_
101-4	19258-19259	U	_
101-5	19259-19260	,	_
101-6	19261-19262	P	_
101-7	19262-19263	,	_
101-8	19264-19267	and	_
101-9	19268-19269	N	_
101-10	19270-19282	anticipation	_
101-11	19283-19287	were	_
101-12	19288-19298	separately	_
101-13	19299-19308	estimated	_
101-14	19309-19311	at	_
101-15	19312-19316	each	_
101-16	19317-19322	voxel	_
101-17	19323-19326	for	_
101-18	19327-19331	each	_
101-19	19332-19343	participant	_
101-20	19343-19344	.	_

#Text=For each condition, the countdowns prior to the shock, or prior to trial termination in instances where there was no shock, were modeled.
102-1	19345-19348	For	_
102-2	19349-19353	each	_
102-3	19354-19363	condition	_
102-4	19363-19364	,	_
102-5	19365-19368	the	_
102-6	19369-19379	countdowns	_
102-7	19380-19385	prior	_
102-8	19386-19388	to	_
102-9	19389-19392	the	_
102-10	19393-19398	shock	_
102-11	19398-19399	,	_
102-12	19400-19402	or	_
102-13	19403-19408	prior	_
102-14	19409-19411	to	_
102-15	19412-19417	trial	_
102-16	19418-19429	termination	_
102-17	19430-19432	in	_
102-18	19433-19442	instances	_
102-19	19443-19448	where	_
102-20	19449-19454	there	_
102-21	19455-19458	was	_
102-22	19459-19461	no	_
102-23	19462-19467	shock	_
102-24	19467-19468	,	_
102-25	19469-19473	were	_
102-26	19474-19481	modeled	_
102-27	19481-19482	.	_

#Text=Of note, we conducted an additional set of analyses where the U- and P-shocks were included as regressors in the first level model.
103-1	19483-19485	Of	_
103-2	19486-19490	note	_
103-3	19490-19491	,	_
103-4	19492-19494	we	_
103-5	19495-19504	conducted	_
103-6	19505-19507	an	_
103-7	19508-19518	additional	_
103-8	19519-19522	set	_
103-9	19523-19525	of	_
103-10	19526-19534	analyses	_
103-11	19535-19540	where	_
103-12	19541-19544	the	_
103-13	19545-19546	U	_
103-14	19546-19547	-	_
103-15	19548-19551	and	_
103-16	19552-19560	P-shocks	_
103-17	19561-19565	were	_
103-18	19566-19574	included	_
103-19	19575-19577	as	_
103-20	19578-19588	regressors	_
103-21	19589-19591	in	_
103-22	19592-19595	the	_
103-23	19596-19601	first	_
103-24	19602-19607	level	_
103-25	19608-19613	model	_
103-26	19613-19614	.	_

#Text=The results of the paper were consistent whether shocks were included or excluded from the model.
104-1	19615-19618	The	_
104-2	19619-19626	results	_
104-3	19627-19629	of	_
104-4	19630-19633	the	_
104-5	19634-19639	paper	_
104-6	19640-19644	were	_
104-7	19645-19655	consistent	_
104-8	19656-19663	whether	_
104-9	19664-19670	shocks	_
104-10	19671-19675	were	_
104-11	19676-19684	included	_
104-12	19685-19687	or	_
104-13	19688-19696	excluded	_
104-14	19697-19701	from	_
104-15	19702-19705	the	_
104-16	19706-19711	model	_
104-17	19711-19712	.	_

#Text=Movement parameters obtained during realignment were included in the model as regressors of no interest to account for motion-related effects on BOLD.
105-1	19713-19721	Movement	_
105-2	19722-19732	parameters	_
105-3	19733-19741	obtained	_
105-4	19742-19748	during	_
105-5	19749-19760	realignment	_
105-6	19761-19765	were	_
105-7	19766-19774	included	_
105-8	19775-19777	in	_
105-9	19778-19781	the	_
105-10	19782-19787	model	_
105-11	19788-19790	as	_
105-12	19791-19801	regressors	_
105-13	19802-19804	of	_
105-14	19805-19807	no	_
105-15	19808-19816	interest	_
105-16	19817-19819	to	_
105-17	19820-19827	account	_
105-18	19828-19831	for	_
105-19	19832-19846	motion-related	_
105-20	19847-19854	effects	_
105-21	19855-19857	on	_
105-22	19858-19862	BOLD	_
105-23	19862-19863	.	_

#Text=Individual contrast maps for U-threat > no-threat (i.e., anticipatory anxiety) and P-threat > no-threat (i.e., fear) were created for each participant.
106-1	19864-19874	Individual	_
106-2	19875-19883	contrast	_
106-3	19884-19888	maps	_
106-4	19889-19892	for	_
106-5	19893-19901	U-threat	_
106-6	19902-19903	>	_
106-7	19904-19913	no-threat	_
106-8	19914-19915	(	_
106-9	19915-19918	i.e	_
106-10	19918-19919	.	_
106-11	19919-19920	,	_
106-12	19921-19933	anticipatory	_
106-13	19934-19941	anxiety	_
106-14	19941-19942	)	_
106-15	19943-19946	and	_
106-16	19947-19955	P-threat	_
106-17	19956-19957	>	_
106-18	19958-19967	no-threat	_
106-19	19968-19969	(	_
106-20	19969-19972	i.e	_
106-21	19972-19973	.	_
106-22	19973-19974	,	_
106-23	19975-19979	fear	_
106-24	19979-19980	)	_
106-25	19981-19985	were	_
106-26	19986-19993	created	_
106-27	19994-19997	for	_
106-28	19998-20002	each	_
106-29	20003-20014	participant	_
106-30	20014-20015	.	_

#Text=For functional connectivity, we used a seed-based, generalized form of context-dependent psychophysiological interaction (PPI) analyses (http://brainmap.wisc.edu/PPI,), with left and right anatomical amygdala masks (created using AAL atlas) as the seeds of interest.
107-1	20016-20019	For	_
107-2	20020-20030	functional	_
107-3	20031-20043	connectivity	_
107-4	20043-20044	,	_
107-5	20045-20047	we	_
107-6	20048-20052	used	_
107-7	20053-20054	a	_
107-8	20055-20065	seed-based	_
107-9	20065-20066	,	_
107-10	20067-20078	generalized	_
107-11	20079-20083	form	_
107-12	20084-20086	of	_
107-13	20087-20104	context-dependent	_
107-14	20105-20124	psychophysiological	_
107-15	20125-20136	interaction	_
107-16	20137-20138	(	_
107-17	20138-20141	PPI	_
107-18	20141-20142	)	_
107-19	20143-20151	analyses	_
107-20	20152-20153	(	_
107-21	20153-20157	http	_
107-22	20157-20158	:	_
107-23	20158-20159	/	_
107-24	20159-20160	/	_
107-25	20160-20177	brainmap.wisc.edu	_
107-26	20177-20178	/	_
107-27	20178-20181	PPI	_
107-28	20181-20182	,	_
107-29	20182-20183	)	_
107-30	20183-20184	,	_
107-31	20185-20189	with	_
107-32	20190-20194	left	_
107-33	20195-20198	and	_
107-34	20199-20204	right	_
107-35	20205-20215	anatomical	_
107-36	20216-20224	amygdala	_
107-37	20225-20230	masks	_
107-38	20231-20232	(	_
107-39	20232-20239	created	_
107-40	20240-20245	using	_
107-41	20246-20249	AAL	_
107-42	20250-20255	atlas	_
107-43	20255-20256	)	_
107-44	20257-20259	as	_
107-45	20260-20263	the	_
107-46	20264-20269	seeds	_
107-47	20270-20272	of	_
107-48	20273-20281	interest	_
107-49	20281-20282	.	_

#Text=The de-convolved time series from the amygdala masks were extracted for each participant to create the physiological variables.
108-1	20283-20286	The	_
108-2	20287-20299	de-convolved	_
108-3	20300-20304	time	_
108-4	20305-20311	series	_
108-5	20312-20316	from	_
108-6	20317-20320	the	_
108-7	20321-20329	amygdala	_
108-8	20330-20335	masks	_
108-9	20336-20340	were	_
108-10	20341-20350	extracted	_
108-11	20351-20354	for	_
108-12	20355-20359	each	_
108-13	20360-20371	participant	_
108-14	20372-20374	to	_
108-15	20375-20381	create	_
108-16	20382-20385	the	_
108-17	20386-20399	physiological	_
108-18	20400-20409	variables	_
108-19	20409-20410	.	_

#Text=The condition onset times for U-threat, P-threat, and no-threat were separately convolved with the canonical hemodynamic response function (HRF) for each condition, creating the psychological regressors.
109-1	20411-20414	The	_
109-2	20415-20424	condition	_
109-3	20425-20430	onset	_
109-4	20431-20436	times	_
109-5	20437-20440	for	_
109-6	20441-20449	U-threat	_
109-7	20449-20450	,	_
109-8	20451-20459	P-threat	_
109-9	20459-20460	,	_
109-10	20461-20464	and	_
109-11	20465-20474	no-threat	_
109-12	20475-20479	were	_
109-13	20480-20490	separately	_
109-14	20491-20500	convolved	_
109-15	20501-20505	with	_
109-16	20506-20509	the	_
109-17	20510-20519	canonical	_
109-18	20520-20531	hemodynamic	_
109-19	20532-20540	response	_
109-20	20541-20549	function	_
109-21	20550-20551	(	_
109-22	20551-20554	HRF	_
109-23	20554-20555	)	_
109-24	20556-20559	for	_
109-25	20560-20564	each	_
109-26	20565-20574	condition	_
109-27	20574-20575	,	_
109-28	20576-20584	creating	_
109-29	20585-20588	the	_
109-30	20589-20602	psychological	_
109-31	20603-20613	regressors	_
109-32	20613-20614	.	_

#Text=The interaction terms (PPIs) were computed by multiplying the time series from the psychological regressors with the physiological variable.
110-1	20615-20618	The	_
110-2	20619-20630	interaction	_
110-3	20631-20636	terms	_
110-4	20637-20638	(	_
110-5	20638-20642	PPIs	_
110-6	20642-20643	)	_
110-7	20644-20648	were	_
110-8	20649-20657	computed	_
110-9	20658-20660	by	_
110-10	20661-20672	multiplying	_
110-11	20673-20676	the	_
110-12	20677-20681	time	_
110-13	20682-20688	series	_
110-14	20689-20693	from	_
110-15	20694-20697	the	_
110-16	20698-20711	psychological	_
110-17	20712-20722	regressors	_
110-18	20723-20727	with	_
110-19	20728-20731	the	_
110-20	20732-20745	physiological	_
110-21	20746-20754	variable	_
110-22	20754-20755	.	_

#Text=Activity within the amygdala was then regressed on a voxel-wise basis against the interaction, with the physiological and psychological variables serving as regressors of interest.
111-1	20756-20764	Activity	_
111-2	20765-20771	within	_
111-3	20772-20775	the	_
111-4	20776-20784	amygdala	_
111-5	20785-20788	was	_
111-6	20789-20793	then	_
111-7	20794-20803	regressed	_
111-8	20804-20806	on	_
111-9	20807-20808	a	_
111-10	20809-20819	voxel-wise	_
111-11	20820-20825	basis	_
111-12	20826-20833	against	_
111-13	20834-20837	the	_
111-14	20838-20849	interaction	_
111-15	20849-20850	,	_
111-16	20851-20855	with	_
111-17	20856-20859	the	_
111-18	20860-20873	physiological	_
111-19	20874-20877	and	_
111-20	20878-20891	psychological	_
111-21	20892-20901	variables	_
111-22	20902-20909	serving	_
111-23	20910-20912	as	_
111-24	20913-20923	regressors	_
111-25	20924-20926	of	_
111-26	20927-20935	interest	_
111-27	20935-20936	.	_

#Text=Individual U-threat > no-threat and P-threat > no-threat PPI images were created for every participant.
112-1	20937-20947	Individual	_
112-2	20948-20956	U-threat	_
112-3	20957-20958	>	_
112-4	20959-20968	no-threat	_
112-5	20969-20972	and	_
112-6	20973-20981	P-threat	_
112-7	20982-20983	>	_
112-8	20984-20993	no-threat	_
112-9	20994-20997	PPI	_
112-10	20998-21004	images	_
112-11	21005-21009	were	_
112-12	21010-21017	created	_
112-13	21018-21021	for	_
112-14	21022-21027	every	_
112-15	21028-21039	participant	_
112-16	21039-21040	.	_

#Text=Data Analysis Plan
#Text=To examine whether BDNF was associated with amygdala reactivity, we used a focused, region-of-interest analysis approach.
113-1	21041-21045	Data	_
113-2	21046-21054	Analysis	_
113-3	21055-21059	Plan	_
113-4	21060-21062	To	_
113-5	21063-21070	examine	_
113-6	21071-21078	whether	_
113-7	21079-21083	BDNF	_
113-8	21084-21087	was	_
113-9	21088-21098	associated	_
113-10	21099-21103	with	_
113-11	21104-21112	amygdala	_
113-12	21113-21123	reactivity	_
113-13	21123-21124	,	_
113-14	21125-21127	we	_
113-15	21128-21132	used	_
113-16	21133-21134	a	_
113-17	21135-21142	focused	_
113-18	21142-21143	,	_
113-19	21144-21162	region-of-interest	_
113-20	21163-21171	analysis	_
113-21	21172-21180	approach	_
113-22	21180-21181	.	_

#Text=We entered the U-threat > no-threat and P-threat > no-threat images into separate 1-sample t tests.
114-1	21182-21184	We	_
114-2	21185-21192	entered	_
114-3	21193-21196	the	_
114-4	21197-21205	U-threat	_
114-5	21206-21207	>	_
114-6	21208-21217	no-threat	_
114-7	21218-21221	and	_
114-8	21222-21230	P-threat	_
114-9	21231-21232	>	_
114-10	21233-21242	no-threat	_
114-11	21243-21249	images	_
114-12	21250-21254	into	_
114-13	21255-21263	separate	_
114-14	21264-21265	1	_
114-15	21265-21266	-	_
114-16	21266-21272	sample	_
114-17	21273-21274	t	_
114-18	21275-21280	tests	_
114-19	21280-21281	.	_

#Text=Then we extracted mean task activation parameter estimates (β-weights; arbitrary unit) from separate left and right whole anatomical amygdala masks (created using AAL atlas) from each model (U-threat and P-threat).
115-1	21282-21286	Then	_
115-2	21287-21289	we	_
115-3	21290-21299	extracted	_
115-4	21300-21304	mean	_
115-5	21305-21309	task	_
115-6	21310-21320	activation	_
115-7	21321-21330	parameter	_
115-8	21331-21340	estimates	_
115-9	21341-21342	(	_
115-10	21342-21351	β-weights	_
115-11	21351-21352	;	_
115-12	21353-21362	arbitrary	_
115-13	21363-21367	unit	_
115-14	21367-21368	)	_
115-15	21369-21373	from	_
115-16	21374-21382	separate	_
115-17	21383-21387	left	_
115-18	21388-21391	and	_
115-19	21392-21397	right	_
115-20	21398-21403	whole	_
115-21	21404-21414	anatomical	_
115-22	21415-21423	amygdala	_
115-23	21424-21429	masks	_
115-24	21430-21431	(	_
115-25	21431-21438	created	_
115-26	21439-21444	using	_
115-27	21445-21448	AAL	_
115-28	21449-21454	atlas	_
115-29	21454-21455	)	_
115-30	21456-21460	from	_
115-31	21461-21465	each	_
115-32	21466-21471	model	_
115-33	21472-21473	(	_
115-34	21473-21481	U-threat	_
115-35	21482-21485	and	_
115-36	21486-21494	P-threat	_
115-37	21494-21495	)	_
115-38	21495-21496	.	_

#Text=Using Pearson’s correlations, we assessed whether plasma BDNF levels were associated with focal left and right amygdala reactivity during U-threat and P-threat.
116-1	21497-21502	Using	_
116-2	21503-21510	Pearson	_
116-3	21510-21511	’	_
116-4	21511-21512	s	_
116-5	21513-21525	correlations	_
116-6	21525-21526	,	_
116-7	21527-21529	we	_
116-8	21530-21538	assessed	_
116-9	21539-21546	whether	_
116-10	21547-21553	plasma	_
116-11	21554-21558	BDNF	_
116-12	21559-21565	levels	_
116-13	21566-21570	were	_
116-14	21571-21581	associated	_
116-15	21582-21586	with	_
116-16	21587-21592	focal	_
116-17	21593-21597	left	_
116-18	21598-21601	and	_
116-19	21602-21607	right	_
116-20	21608-21616	amygdala	_
116-21	21617-21627	reactivity	_
116-22	21628-21634	during	_
116-23	21635-21643	U-threat	_
116-24	21644-21647	and	_
116-25	21648-21656	P-threat	_
116-26	21656-21657	.	_

#Text=To examine the impact of BDNF on amygdala-PFC functional connectivity, the U-threat > no-threat and P-threat > no-threat images were entered into 2 separate 2nd-level 1-sample t tests with individual BDNF values as a regressor.
117-1	21658-21660	To	_
117-2	21661-21668	examine	_
117-3	21669-21672	the	_
117-4	21673-21679	impact	_
117-5	21680-21682	of	_
117-6	21683-21687	BDNF	_
117-7	21688-21690	on	_
117-8	21691-21703	amygdala-PFC	_
117-9	21704-21714	functional	_
117-10	21715-21727	connectivity	_
117-11	21727-21728	,	_
117-12	21729-21732	the	_
117-13	21733-21741	U-threat	_
117-14	21742-21743	>	_
117-15	21744-21753	no-threat	_
117-16	21754-21757	and	_
117-17	21758-21766	P-threat	_
117-18	21767-21768	>	_
117-19	21769-21778	no-threat	_
117-20	21779-21785	images	_
117-21	21786-21790	were	_
117-22	21791-21798	entered	_
117-23	21799-21803	into	_
117-24	21804-21805	2	_
117-25	21806-21814	separate	_
117-26	21815-21824	2nd-level	_
117-27	21825-21826	1	_
117-28	21826-21827	-	_
117-29	21827-21833	sample	_
117-30	21834-21835	t	_
117-31	21836-21841	tests	_
117-32	21842-21846	with	_
117-33	21847-21857	individual	_
117-34	21858-21862	BDNF	_
117-35	21863-21869	values	_
117-36	21870-21872	as	_
117-37	21873-21874	a	_
117-38	21875-21884	regressor	_
117-39	21884-21885	.	_

#Text=To determine our fMRI significance threshold, we applied an anatomically derived (AAL atlas) partial brain mask of the entire PFC to our data (search volume = 451 840 mm3, encompassing 56 480 voxels).
118-1	21886-21888	To	_
118-2	21889-21898	determine	_
118-3	21899-21902	our	_
118-4	21903-21907	fMRI	_
118-5	21908-21920	significance	_
118-6	21921-21930	threshold	_
118-7	21930-21931	,	_
118-8	21932-21934	we	_
118-9	21935-21942	applied	_
118-10	21943-21945	an	_
118-11	21946-21958	anatomically	_
118-12	21959-21966	derived	_
118-13	21967-21968	(	_
118-14	21968-21971	AAL	_
118-15	21972-21977	atlas	_
118-16	21977-21978	)	_
118-17	21979-21986	partial	_
118-18	21987-21992	brain	_
118-19	21993-21997	mask	_
118-20	21998-22000	of	_
118-21	22001-22004	the	_
118-22	22005-22011	entire	_
118-23	22012-22015	PFC	_
118-24	22016-22018	to	_
118-25	22019-22022	our	_
118-26	22023-22027	data	_
118-27	22028-22029	(	_
118-28	22029-22035	search	_
118-29	22036-22042	volume	_
118-30	22043-22044	=	_
118-31	22045-22048	451	_
118-32	22049-22052	840	_
118-33	22053-22056	mm3	_
118-34	22056-22057	,	_
118-35	22058-22070	encompassing	_
118-36	22071-22073	56	_
118-37	22074-22077	480	_
118-38	22078-22084	voxels	_
118-39	22084-22085	)	_
118-40	22085-22086	.	_

#Text=The search for significant results was restricted to the PFC given our strong a priori hypotheses regarding frontolimibic connectivity.
119-1	22087-22090	The	_
119-2	22091-22097	search	_
119-3	22098-22101	for	_
119-4	22102-22113	significant	_
119-5	22114-22121	results	_
119-6	22122-22125	was	_
119-7	22126-22136	restricted	_
119-8	22137-22139	to	_
119-9	22140-22143	the	_
119-10	22144-22147	PFC	_
119-11	22148-22153	given	_
119-12	22154-22157	our	_
119-13	22158-22164	strong	_
119-14	22165-22166	a	_
119-15	22167-22173	priori	_
119-16	22174-22184	hypotheses	_
119-17	22185-22194	regarding	_
119-18	22195-22208	frontolimibic	_
119-19	22209-22221	connectivity	_
119-20	22221-22222	.	_

#Text=Cluster-based significance thresholding was used to adjust for multiple comparisons within the search volume using Monte Carlo simulations (10 000 iterations) performed with the most up-to-date version of 3dClustSim, an adaptation of AlphaSim (https://afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html) in AFNI (19.2.06).
120-1	22223-22236	Cluster-based	_
120-2	22237-22249	significance	_
120-3	22250-22262	thresholding	_
120-4	22263-22266	was	_
120-5	22267-22271	used	_
120-6	22272-22274	to	_
120-7	22275-22281	adjust	_
120-8	22282-22285	for	_
120-9	22286-22294	multiple	_
120-10	22295-22306	comparisons	_
120-11	22307-22313	within	_
120-12	22314-22317	the	_
120-13	22318-22324	search	_
120-14	22325-22331	volume	_
120-15	22332-22337	using	_
120-16	22338-22343	Monte	_
120-17	22344-22349	Carlo	_
120-18	22350-22361	simulations	_
120-19	22362-22363	(	_
120-20	22363-22365	10	_
120-21	22366-22369	000	_
120-22	22370-22380	iterations	_
120-23	22380-22381	)	_
120-24	22382-22391	performed	_
120-25	22392-22396	with	_
120-26	22397-22400	the	_
120-27	22401-22405	most	_
120-28	22406-22416	up-to-date	_
120-29	22417-22424	version	_
120-30	22425-22427	of	_
120-31	22428-22438	3dClustSim	_
120-32	22438-22439	,	_
120-33	22440-22442	an	_
120-34	22443-22453	adaptation	_
120-35	22454-22456	of	_
120-36	22457-22465	AlphaSim	_
120-37	22466-22467	(	_
120-38	22467-22472	https	_
120-39	22472-22473	:	_
120-40	22473-22474	/	_
120-41	22474-22475	/	_
120-42	22475-22492	afni.nimh.nih.gov	_
120-43	22492-22493	/	_
120-44	22493-22496	pub	_
120-45	22496-22497	/	_
120-46	22497-22501	dist	_
120-47	22501-22502	/	_
120-48	22502-22505	doc	_
120-49	22505-22506	/	_
120-50	22506-22518	program_help	_
120-51	22518-22519	/	_
120-52	22519-22534	3dClustSim.html	_
120-53	22534-22535	)	_
120-54	22536-22538	in	_
120-55	22539-22543	AFNI	_
120-56	22544-22545	(	_
120-57	22545-22552	19.2.06	_
120-58	22552-22553	)	_
120-59	22553-22554	.	_

#Text=The mixed autocorrelation function was utilized to give an accurate estimation of non-Gaussian noise structure.
121-1	22555-22558	The	_
121-2	22559-22564	mixed	_
121-3	22565-22580	autocorrelation	_
121-4	22581-22589	function	_
121-5	22590-22593	was	_
121-6	22594-22602	utilized	_
121-7	22603-22605	to	_
121-8	22606-22610	give	_
121-9	22611-22613	an	_
121-10	22614-22622	accurate	_
121-11	22623-22633	estimation	_
121-12	22634-22636	of	_
121-13	22637-22649	non-Gaussian	_
121-14	22650-22655	noise	_
121-15	22656-22665	structure	_
121-16	22665-22666	.	_

#Text=A family wise error correction at α < 0.05 was achieved for voxel threshold of P < .005 with minimum cluster size of 233 contiguous voxels.
122-1	22667-22668	A	_
122-2	22669-22675	family	_
122-3	22676-22680	wise	_
122-4	22681-22686	error	_
122-5	22687-22697	correction	_
122-6	22698-22700	at	_
122-7	22701-22702	α	_
122-8	22703-22704	<	_
122-9	22705-22709	0.05	_
122-10	22710-22713	was	_
122-11	22714-22722	achieved	_
122-12	22723-22726	for	_
122-13	22727-22732	voxel	_
122-14	22733-22742	threshold	_
122-15	22743-22745	of	_
122-16	22746-22747	P	_
122-17	22748-22749	<	_
122-18	22750-22754	.005	_
122-19	22755-22759	with	_
122-20	22760-22767	minimum	_
122-21	22768-22775	cluster	_
122-22	22776-22780	size	_
122-23	22781-22783	of	_
122-24	22784-22787	233	_
122-25	22788-22798	contiguous	_
122-26	22799-22805	voxels	_
122-27	22805-22806	.	_

#Text=Connectivity parameter estimates from 8-mm-radius spheres surrounding peak activations within the PFC associated with BDNF levels were then extracted for further analysis.
123-1	22807-22819	Connectivity	_
123-2	22820-22829	parameter	_
123-3	22830-22839	estimates	_
123-4	22840-22844	from	_
123-5	22845-22846	8	_
123-6	22846-22847	-	_
123-7	22847-22856	mm-radius	_
123-8	22857-22864	spheres	_
123-9	22865-22876	surrounding	_
123-10	22877-22881	peak	_
123-11	22882-22893	activations	_
123-12	22894-22900	within	_
123-13	22901-22904	the	_
123-14	22905-22908	PFC	_
123-15	22909-22919	associated	_
123-16	22920-22924	with	_
123-17	22925-22929	BDNF	_
123-18	22930-22936	levels	_
123-19	22937-22941	were	_
123-20	22942-22946	then	_
123-21	22947-22956	extracted	_
123-22	22957-22960	for	_
123-23	22961-22968	further	_
123-24	22969-22977	analysis	_
123-25	22977-22978	.	_

#Text=We next examined whether BDNF levels and the significant neural findings (reactivity and/or connectivity) identified above correlated with real-world drinking behaviors, particularly average number of drinks per week and total number of binge episodes in the past 60 days.
124-1	22979-22981	We	_
124-2	22982-22986	next	_
124-3	22987-22995	examined	_
124-4	22996-23003	whether	_
124-5	23004-23008	BDNF	_
124-6	23009-23015	levels	_
124-7	23016-23019	and	_
124-8	23020-23023	the	_
124-9	23024-23035	significant	_
124-10	23036-23042	neural	_
124-11	23043-23051	findings	_
124-12	23052-23053	(	_
124-13	23053-23063	reactivity	_
124-14	23064-23067	and	_
124-15	23067-23068	/	_
124-16	23068-23070	or	_
124-17	23071-23083	connectivity	_
124-18	23083-23084	)	_
124-19	23085-23095	identified	_
124-20	23096-23101	above	_
124-21	23102-23112	correlated	_
124-22	23113-23117	with	_
124-23	23118-23128	real-world	_
124-24	23129-23137	drinking	_
124-25	23138-23147	behaviors	_
124-26	23147-23148	,	_
124-27	23149-23161	particularly	_
124-28	23162-23169	average	_
124-29	23170-23176	number	_
124-30	23177-23179	of	_
124-31	23180-23186	drinks	_
124-32	23187-23190	per	_
124-33	23191-23195	week	_
124-34	23196-23199	and	_
124-35	23200-23205	total	_
124-36	23206-23212	number	_
124-37	23213-23215	of	_
124-38	23216-23221	binge	_
124-39	23222-23230	episodes	_
124-40	23231-23233	in	_
124-41	23234-23237	the	_
124-42	23238-23242	past	_
124-43	23243-23245	60	_
124-44	23246-23250	days	_
124-45	23250-23251	.	_

#Text=We also examined associations with age of AUD onset within individuals with an AUD diagnosis.
125-1	23252-23254	We	_
125-2	23255-23259	also	_
125-3	23260-23268	examined	_
125-4	23269-23281	associations	_
125-5	23282-23286	with	_
125-6	23287-23290	age	_
125-7	23291-23293	of	_
125-8	23294-23297	AUD	_
125-9	23298-23303	onset	_
125-10	23304-23310	within	_
125-11	23311-23322	individuals	_
125-12	23323-23327	with	_
125-13	23328-23330	an	_
125-14	23331-23334	AUD	_
125-15	23335-23344	diagnosis	_
125-16	23344-23345	.	_

#Text=We conducted a series of Pearson’s correlations between plasma BDNF and peak significant parameter estimates and drinking behaviors.
126-1	23346-23348	We	_
126-2	23349-23358	conducted	_
126-3	23359-23360	a	_
126-4	23361-23367	series	_
126-5	23368-23370	of	_
126-6	23371-23378	Pearson	_
126-7	23378-23379	’	_
126-8	23379-23380	s	_
126-9	23381-23393	correlations	_
126-10	23394-23401	between	_
126-11	23402-23408	plasma	_
126-12	23409-23413	BDNF	_
126-13	23414-23417	and	_
126-14	23418-23422	peak	_
126-15	23423-23434	significant	_
126-16	23435-23444	parameter	_
126-17	23445-23454	estimates	_
126-18	23455-23458	and	_
126-19	23459-23467	drinking	_
126-20	23468-23477	behaviors	_
126-21	23477-23478	.	_

#Text=A total of 9 correlations were run.
127-1	23479-23480	A	_
127-2	23481-23486	total	_
127-3	23487-23489	of	_
127-4	23490-23491	9	_
127-5	23492-23504	correlations	_
127-6	23505-23509	were	_
127-7	23510-23513	run	_
127-8	23513-23514	.	_

#Text=A P value correction for multiple comparisons was not applied in order to comprehensively test relationships with several drinking variables (i.e., drinks per week, binge episodes, and AUD age of onset).
128-1	23515-23516	A	_
128-2	23517-23518	P	_
128-3	23519-23524	value	_
128-4	23525-23535	correction	_
128-5	23536-23539	for	_
128-6	23540-23548	multiple	_
128-7	23549-23560	comparisons	_
128-8	23561-23564	was	_
128-9	23565-23568	not	_
128-10	23569-23576	applied	_
128-11	23577-23579	in	_
128-12	23580-23585	order	_
128-13	23586-23588	to	_
128-14	23589-23604	comprehensively	_
128-15	23605-23609	test	_
128-16	23610-23623	relationships	_
128-17	23624-23628	with	_
128-18	23629-23636	several	_
128-19	23637-23645	drinking	_
128-20	23646-23655	variables	_
128-21	23656-23657	(	_
128-22	23657-23660	i.e	_
128-23	23660-23661	.	_
128-24	23661-23662	,	_
128-25	23663-23669	drinks	_
128-26	23670-23673	per	_
128-27	23674-23678	week	_
128-28	23678-23679	,	_
128-29	23680-23685	binge	_
128-30	23686-23694	episodes	_
128-31	23694-23695	,	_
128-32	23696-23699	and	_
128-33	23700-23703	AUD	_
128-34	23704-23707	age	_
128-35	23708-23710	of	_
128-36	23711-23716	onset	_
128-37	23716-23717	)	_
128-38	23717-23718	.	_

#Text=Although the aims of the current study were dimensional, participants were recruited into 2 groups: individuals with AUD and controls.
129-1	23719-23727	Although	_
129-2	23728-23731	the	_
129-3	23732-23736	aims	_
129-4	23737-23739	of	_
129-5	23740-23743	the	_
129-6	23744-23751	current	_
129-7	23752-23757	study	_
129-8	23758-23762	were	_
129-9	23763-23774	dimensional	_
129-10	23774-23775	,	_
129-11	23776-23788	participants	_
129-12	23789-23793	were	_
129-13	23794-23803	recruited	_
129-14	23804-23808	into	_
129-15	23809-23810	2	_
129-16	23811-23817	groups	_
129-17	23817-23818	:	_
129-18	23819-23830	individuals	_
129-19	23831-23835	with	_
129-20	23836-23839	AUD	_
129-21	23840-23843	and	_
129-22	23844-23852	controls	_
129-23	23852-23853	.	_

#Text=Therefore, post-hoc we tested whether group (AUD vs control) moderated any of the above associations.
130-1	23854-23863	Therefore	_
130-2	23863-23864	,	_
130-3	23865-23873	post-hoc	_
130-4	23874-23876	we	_
130-5	23877-23883	tested	_
130-6	23884-23891	whether	_
130-7	23892-23897	group	_
130-8	23898-23899	(	_
130-9	23899-23902	AUD	_
130-10	23903-23905	vs	_
130-11	23906-23913	control	_
130-12	23913-23914	)	_
130-13	23915-23924	moderated	_
130-14	23925-23928	any	_
130-15	23929-23931	of	_
130-16	23932-23935	the	_
130-17	23936-23941	above	_
130-18	23942-23954	associations	_
130-19	23954-23955	.	_

#Text=Similarly, the study included males and females and we therefore examined the moderating impact of biological sex.
131-1	23956-23965	Similarly	_
131-2	23965-23966	,	_
131-3	23967-23970	the	_
131-4	23971-23976	study	_
131-5	23977-23985	included	_
131-6	23986-23991	males	_
131-7	23992-23995	and	_
131-8	23996-24003	females	_
131-9	24004-24007	and	_
131-10	24008-24010	we	_
131-11	24011-24020	therefore	_
131-12	24021-24029	examined	_
131-13	24030-24033	the	_
131-14	24034-24044	moderating	_
131-15	24045-24051	impact	_
131-16	24052-24054	of	_
131-17	24055-24065	biological	_
131-18	24066-24069	sex	_
131-19	24069-24070	.	_

#Text=For each set of analyses (1: BDNF and amygdala reactivity; 2: BDNF and amygdala-PFC connectivity; and 3: correlations with drinking behaviors), we tested the impact of group and sex using hierarchical linear regression where group, sex, and the independent variable were entered in Step 1, and the 2-way interactions between group and the independent variable, and sex and the independent variable, were entered in Step 2.
132-1	24071-24074	For	_
132-2	24075-24079	each	_
132-3	24080-24083	set	_
132-4	24084-24086	of	_
132-5	24087-24095	analyses	_
132-6	24096-24097	(	_
132-7	24097-24098	1	_
132-8	24098-24099	:	_
132-9	24100-24104	BDNF	_
132-10	24105-24108	and	_
132-11	24109-24117	amygdala	_
132-12	24118-24128	reactivity	_
132-13	24128-24129	;	_
132-14	24130-24131	2	_
132-15	24131-24132	:	_
132-16	24133-24137	BDNF	_
132-17	24138-24141	and	_
132-18	24142-24154	amygdala-PFC	_
132-19	24155-24167	connectivity	_
132-20	24167-24168	;	_
132-21	24169-24172	and	_
132-22	24173-24174	3	_
132-23	24174-24175	:	_
132-24	24176-24188	correlations	_
132-25	24189-24193	with	_
132-26	24194-24202	drinking	_
132-27	24203-24212	behaviors	_
132-28	24212-24213	)	_
132-29	24213-24214	,	_
132-30	24215-24217	we	_
132-31	24218-24224	tested	_
132-32	24225-24228	the	_
132-33	24229-24235	impact	_
132-34	24236-24238	of	_
132-35	24239-24244	group	_
132-36	24245-24248	and	_
132-37	24249-24252	sex	_
132-38	24253-24258	using	_
132-39	24259-24271	hierarchical	_
132-40	24272-24278	linear	_
132-41	24279-24289	regression	_
132-42	24290-24295	where	_
132-43	24296-24301	group	_
132-44	24301-24302	,	_
132-45	24303-24306	sex	_
132-46	24306-24307	,	_
132-47	24308-24311	and	_
132-48	24312-24315	the	_
132-49	24316-24327	independent	_
132-50	24328-24336	variable	_
132-51	24337-24341	were	_
132-52	24342-24349	entered	_
132-53	24350-24352	in	_
132-54	24353-24357	Step	_
132-55	24358-24359	1	_
132-56	24359-24360	,	_
132-57	24361-24364	and	_
132-58	24365-24368	the	_
132-59	24369-24370	2	_
132-60	24370-24371	-	_
132-61	24371-24374	way	_
132-62	24375-24387	interactions	_
132-63	24388-24395	between	_
132-64	24396-24401	group	_
132-65	24402-24405	and	_
132-66	24406-24409	the	_
132-67	24410-24421	independent	_
132-68	24422-24430	variable	_
132-69	24430-24431	,	_
132-70	24432-24435	and	_
132-71	24436-24439	sex	_
132-72	24440-24443	and	_
132-73	24444-24447	the	_
132-74	24448-24459	independent	_
132-75	24460-24468	variable	_
132-76	24468-24469	,	_
132-77	24470-24474	were	_
132-78	24475-24482	entered	_
132-79	24483-24485	in	_
132-80	24486-24490	Step	_
132-81	24491-24492	2	_
132-82	24492-24493	.	_

#Text=Significant interactions were followed-up using standard simple slopes approach.
133-1	24494-24505	Significant	_
133-2	24506-24518	interactions	_
133-3	24519-24523	were	_
133-4	24524-24535	followed-up	_
133-5	24536-24541	using	_
133-6	24542-24550	standard	_
133-7	24551-24557	simple	_
133-8	24558-24564	slopes	_
133-9	24565-24573	approach	_
133-10	24573-24574	.	_

#Text=Lastly, we explored whether significant results were affected by 2 key variables/covariates: time (in days) between BDNF data collection and the fMRI session (for BDNF models only) and lifetime diagnosis of any major internalizing disorder (yes/no) defined as major depressive disorder, social anxiety disorder, panic disorder, specific phobia, agoraphobia, generalized anxiety disorder, and/or post-traumatic stress disorder.
134-1	24575-24581	Lastly	_
134-2	24581-24582	,	_
134-3	24583-24585	we	_
134-4	24586-24594	explored	_
134-5	24595-24602	whether	_
134-6	24603-24614	significant	_
134-7	24615-24622	results	_
134-8	24623-24627	were	_
134-9	24628-24636	affected	_
134-10	24637-24639	by	_
134-11	24640-24641	2	_
134-12	24642-24645	key	_
134-13	24646-24655	variables	_
134-14	24655-24656	/	_
134-15	24656-24666	covariates	_
134-16	24666-24667	:	_
134-17	24668-24672	time	_
134-18	24673-24674	(	_
134-19	24674-24676	in	_
134-20	24677-24681	days	_
134-21	24681-24682	)	_
134-22	24683-24690	between	_
134-23	24691-24695	BDNF	_
134-24	24696-24700	data	_
134-25	24701-24711	collection	_
134-26	24712-24715	and	_
134-27	24716-24719	the	_
134-28	24720-24724	fMRI	_
134-29	24725-24732	session	_
134-30	24733-24734	(	_
134-31	24734-24737	for	_
134-32	24738-24742	BDNF	_
134-33	24743-24749	models	_
134-34	24750-24754	only	_
134-35	24754-24755	)	_
134-36	24756-24759	and	_
134-37	24760-24768	lifetime	_
134-38	24769-24778	diagnosis	_
134-39	24779-24781	of	_
134-40	24782-24785	any	_
134-41	24786-24791	major	_
134-42	24792-24805	internalizing	_
134-43	24806-24814	disorder	_
134-44	24815-24816	(	_
134-45	24816-24819	yes	_
134-46	24819-24820	/	_
134-47	24820-24822	no	_
134-48	24822-24823	)	_
134-49	24824-24831	defined	_
134-50	24832-24834	as	_
134-51	24835-24840	major	_
134-52	24841-24851	depressive	_
134-53	24852-24860	disorder	_
134-54	24860-24861	,	_
134-55	24862-24868	social	_
134-56	24869-24876	anxiety	_
134-57	24877-24885	disorder	_
134-58	24885-24886	,	_
134-59	24887-24892	panic	_
134-60	24893-24901	disorder	_
134-61	24901-24902	,	_
134-62	24903-24911	specific	_
134-63	24912-24918	phobia	_
134-64	24918-24919	,	_
134-65	24920-24931	agoraphobia	_
134-66	24931-24932	,	_
134-67	24933-24944	generalized	_
134-68	24945-24952	anxiety	_
134-69	24953-24961	disorder	_
134-70	24961-24962	,	_
134-71	24963-24966	and	_
134-72	24966-24967	/	_
134-73	24967-24969	or	_
134-74	24970-24984	post-traumatic	_
134-75	24985-24991	stress	_
134-76	24992-25000	disorder	_
134-77	25000-25001	.	_

#Text=Correlations were run as partial correlations controlling for time and diagnosis.
135-1	25002-25014	Correlations	_
135-2	25015-25019	were	_
135-3	25020-25023	run	_
135-4	25024-25026	as	_
135-5	25027-25034	partial	_
135-6	25035-25047	correlations	_
135-7	25048-25059	controlling	_
135-8	25060-25063	for	_
135-9	25064-25068	time	_
135-10	25069-25072	and	_
135-11	25073-25082	diagnosis	_
135-12	25082-25083	.	_

#Text=For linear regression analyses, covariates were entered in Step 1 of the model.
136-1	25084-25087	For	_
136-2	25088-25094	linear	_
136-3	25095-25105	regression	_
136-4	25106-25114	analyses	_
136-5	25114-25115	,	_
136-6	25116-25126	covariates	_
136-7	25127-25131	were	_
136-8	25132-25139	entered	_
136-9	25140-25142	in	_
136-10	25143-25147	Step	_
136-11	25148-25149	1	_
136-12	25150-25152	of	_
136-13	25153-25156	the	_
136-14	25157-25162	model	_
136-15	25162-25163	.	_

#Text=RESULTS
#Text=BDNF and Amygdala Reactivity
#Text=Whole-brain task activation patterns for individuals with and without AUD are reported in.
137-1	25164-25171	RESULTS	_
137-2	25172-25176	BDNF	_
137-3	25177-25180	and	_
137-4	25181-25189	Amygdala	_
137-5	25190-25200	Reactivity	_
137-6	25201-25212	Whole-brain	_
137-7	25213-25217	task	_
137-8	25218-25228	activation	_
137-9	25229-25237	patterns	_
137-10	25238-25241	for	_
137-11	25242-25253	individuals	_
137-12	25254-25258	with	_
137-13	25259-25262	and	_
137-14	25263-25270	without	_
137-15	25271-25274	AUD	_
137-16	25275-25278	are	_
137-17	25279-25287	reported	_
137-18	25288-25290	in	_
137-19	25290-25291	.	_

#Text=In the current study, there were no significant associations between BDNF levels and amygdala reactivity to U-threat or P-threat (rs: −.07 to .07, P > .61).
138-1	25292-25294	In	_
138-2	25295-25298	the	_
138-3	25299-25306	current	_
138-4	25307-25312	study	_
138-5	25312-25313	,	_
138-6	25314-25319	there	_
138-7	25320-25324	were	_
138-8	25325-25327	no	_
138-9	25328-25339	significant	_
138-10	25340-25352	associations	_
138-11	25353-25360	between	_
138-12	25361-25365	BDNF	_
138-13	25366-25372	levels	_
138-14	25373-25376	and	_
138-15	25377-25385	amygdala	_
138-16	25386-25396	reactivity	_
138-17	25397-25399	to	_
138-18	25400-25408	U-threat	_
138-19	25409-25411	or	_
138-20	25412-25420	P-threat	_
138-21	25421-25422	(	_
138-22	25422-25424	rs	_
138-23	25424-25425	:	_
138-24	25426-25427	−	_
138-25	25427-25430	.07	_
138-26	25431-25433	to	_
138-27	25434-25437	.07	_
138-28	25437-25438	,	_
138-29	25439-25440	P	_
138-30	25441-25442	>	_
138-31	25443-25446	.61	_
138-32	25446-25447	)	_
138-33	25447-25448	.	_

#Text=Group (AUD vs no AUD) and sex did not moderate any of the null associations between BDNF levels and amygdala reactivity (P > .26).
139-1	25449-25454	Group	_
139-2	25455-25456	(	_
139-3	25456-25459	AUD	_
139-4	25460-25462	vs	_
139-5	25463-25465	no	_
139-6	25466-25469	AUD	_
139-7	25469-25470	)	_
139-8	25471-25474	and	_
139-9	25475-25478	sex	_
139-10	25479-25482	did	_
139-11	25483-25486	not	_
139-12	25487-25495	moderate	_
139-13	25496-25499	any	_
139-14	25500-25502	of	_
139-15	25503-25506	the	_
139-16	25507-25511	null	_
139-17	25512-25524	associations	_
139-18	25525-25532	between	_
139-19	25533-25537	BDNF	_
139-20	25538-25544	levels	_
139-21	25545-25548	and	_
139-22	25549-25557	amygdala	_
139-23	25558-25568	reactivity	_
139-24	25569-25570	(	_
139-25	25570-25571	P	_
139-26	25572-25573	>	_
139-27	25574-25577	.26	_
139-28	25577-25578	)	_
139-29	25578-25579	.	_

#Text=BDNF and Amygdala Functional Connectivity
#Text=During U-threat, lower levels of plasma BDNF were associated with less functional connectivity between the left amygdala and the medial PFC (mPFC) (MNI peak [10, 62, 10], Z = 3.14, k = 2480 mm3, P = .001; Figure 1A) and the left amygdala and the left inferior frontal gyrus (IFG) (MNI peak [−42, 32, 0], Z = 3.47, k = 5104 mm3, P = .0001; Figure 1B).
140-1	25580-25584	BDNF	_
140-2	25585-25588	and	_
140-3	25589-25597	Amygdala	_
140-4	25598-25608	Functional	_
140-5	25609-25621	Connectivity	_
140-6	25622-25628	During	_
140-7	25629-25637	U-threat	_
140-8	25637-25638	,	_
140-9	25639-25644	lower	_
140-10	25645-25651	levels	_
140-11	25652-25654	of	_
140-12	25655-25661	plasma	_
140-13	25662-25666	BDNF	_
140-14	25667-25671	were	_
140-15	25672-25682	associated	_
140-16	25683-25687	with	_
140-17	25688-25692	less	_
140-18	25693-25703	functional	_
140-19	25704-25716	connectivity	_
140-20	25717-25724	between	_
140-21	25725-25728	the	_
140-22	25729-25733	left	_
140-23	25734-25742	amygdala	_
140-24	25743-25746	and	_
140-25	25747-25750	the	_
140-26	25751-25757	medial	_
140-27	25758-25761	PFC	_
140-28	25762-25763	(	_
140-29	25763-25767	mPFC	_
140-30	25767-25768	)	_
140-31	25769-25770	(	_
140-32	25770-25773	MNI	_
140-33	25774-25778	peak	_
140-34	25779-25780	[	_
140-35	25780-25782	10	_
140-36	25782-25783	,	_
140-37	25784-25786	62	_
140-38	25786-25787	,	_
140-39	25788-25790	10	_
140-40	25790-25791	]	_
140-41	25791-25792	,	_
140-42	25793-25794	Z	_
140-43	25795-25796	=	_
140-44	25797-25801	3.14	_
140-45	25801-25802	,	_
140-46	25803-25804	k	_
140-47	25805-25806	=	_
140-48	25807-25811	2480	_
140-49	25812-25815	mm3	_
140-50	25815-25816	,	_
140-51	25817-25818	P	_
140-52	25819-25820	=	_
140-53	25821-25825	.001	_
140-54	25825-25826	;	_
140-55	25827-25833	Figure	_
140-56	25834-25836	1A	_
140-57	25836-25837	)	_
140-58	25838-25841	and	_
140-59	25842-25845	the	_
140-60	25846-25850	left	_
140-61	25851-25859	amygdala	_
140-62	25860-25863	and	_
140-63	25864-25867	the	_
140-64	25868-25872	left	_
140-65	25873-25881	inferior	_
140-66	25882-25889	frontal	_
140-67	25890-25895	gyrus	_
140-68	25896-25897	(	_
140-69	25897-25900	IFG	_
140-70	25900-25901	)	_
140-71	25902-25903	(	_
140-72	25903-25906	MNI	_
140-73	25907-25911	peak	_
140-74	25912-25913	[	_
140-75	25913-25914	−	_
140-76	25914-25916	42	_
140-77	25916-25917	,	_
140-78	25918-25920	32	_
140-79	25920-25921	,	_
140-80	25922-25923	0	_
140-81	25923-25924	]	_
140-82	25924-25925	,	_
140-83	25926-25927	Z	_
140-84	25928-25929	=	_
140-85	25930-25934	3.47	_
140-86	25934-25935	,	_
140-87	25936-25937	k	_
140-88	25938-25939	=	_
140-89	25940-25944	5104	_
140-90	25945-25948	mm3	_
140-91	25948-25949	,	_
140-92	25950-25951	P	_
140-93	25952-25953	=	_
140-94	25954-25959	.0001	_
140-95	25959-25960	;	_
140-96	25961-25967	Figure	_
140-97	25968-25970	1B	_
140-98	25970-25971	)	_
140-99	25971-25972	.	_

#Text=There were no other significant associations during U-threat or any significant BDNF and functional connectivity associations during P-threat.
141-1	25973-25978	There	_
141-2	25979-25983	were	_
141-3	25984-25986	no	_
141-4	25987-25992	other	_
141-5	25993-26004	significant	_
141-6	26005-26017	associations	_
141-7	26018-26024	during	_
141-8	26025-26033	U-threat	_
141-9	26034-26036	or	_
141-10	26037-26040	any	_
141-11	26041-26052	significant	_
141-12	26053-26057	BDNF	_
141-13	26058-26061	and	_
141-14	26062-26072	functional	_
141-15	26073-26085	connectivity	_
141-16	26086-26098	associations	_
141-17	26099-26105	during	_
141-18	26106-26114	P-threat	_
141-19	26114-26115	.	_

#Text=Group and sex did not moderate the association between BDNF and amygdala-mPFC connectivity (group: β = 0.23, t = 0.81, P = .42; sex: β = 0.06, t = 0.09, P = .93) or amygdala-IFG connectivity (group: β = −0.12, t = −0.44, P = .66; sex: β = 0.15, t = 0.23, P = .82) during U-threat.
142-1	26116-26121	Group	_
142-2	26122-26125	and	_
142-3	26126-26129	sex	_
142-4	26130-26133	did	_
142-5	26134-26137	not	_
142-6	26138-26146	moderate	_
142-7	26147-26150	the	_
142-8	26151-26162	association	_
142-9	26163-26170	between	_
142-10	26171-26175	BDNF	_
142-11	26176-26179	and	_
142-12	26180-26193	amygdala-mPFC	_
142-13	26194-26206	connectivity	_
142-14	26207-26208	(	_
142-15	26208-26213	group	_
142-16	26213-26214	:	_
142-17	26215-26216	β	_
142-18	26217-26218	=	_
142-19	26219-26223	0.23	_
142-20	26223-26224	,	_
142-21	26225-26226	t	_
142-22	26227-26228	=	_
142-23	26229-26233	0.81	_
142-24	26233-26234	,	_
142-25	26235-26236	P	_
142-26	26237-26238	=	_
142-27	26239-26242	.42	_
142-28	26242-26243	;	_
142-29	26244-26247	sex	_
142-30	26247-26248	:	_
142-31	26249-26250	β	_
142-32	26251-26252	=	_
142-33	26253-26257	0.06	_
142-34	26257-26258	,	_
142-35	26259-26260	t	_
142-36	26261-26262	=	_
142-37	26263-26267	0.09	_
142-38	26267-26268	,	_
142-39	26269-26270	P	_
142-40	26271-26272	=	_
142-41	26273-26276	.93	_
142-42	26276-26277	)	_
142-43	26278-26280	or	_
142-44	26281-26293	amygdala-IFG	_
142-45	26294-26306	connectivity	_
142-46	26307-26308	(	_
142-47	26308-26313	group	_
142-48	26313-26314	:	_
142-49	26315-26316	β	_
142-50	26317-26318	=	_
142-51	26319-26320	−	_
142-52	26320-26324	0.12	_
142-53	26324-26325	,	_
142-54	26326-26327	t	_
142-55	26328-26329	=	_
142-56	26330-26331	−	_
142-57	26331-26335	0.44	_
142-58	26335-26336	,	_
142-59	26337-26338	P	_
142-60	26339-26340	=	_
142-61	26341-26344	.66	_
142-62	26344-26345	;	_
142-63	26346-26349	sex	_
142-64	26349-26350	:	_
142-65	26351-26352	β	_
142-66	26353-26354	=	_
142-67	26355-26359	0.15	_
142-68	26359-26360	,	_
142-69	26361-26362	t	_
142-70	26363-26364	=	_
142-71	26365-26369	0.23	_
142-72	26369-26370	,	_
142-73	26371-26372	P	_
142-74	26373-26374	=	_
142-75	26375-26378	.82	_
142-76	26378-26379	)	_
142-77	26380-26386	during	_
142-78	26387-26395	U-threat	_
142-79	26395-26396	.	_

#Text=Top of the figure displays the left and right anatomical amygdala seed-regions-of-interest (SOIs).
143-1	26397-26400	Top	_
143-2	26401-26403	of	_
143-3	26404-26407	the	_
143-4	26408-26414	figure	_
143-5	26415-26423	displays	_
143-6	26424-26427	the	_
143-7	26428-26432	left	_
143-8	26433-26436	and	_
143-9	26437-26442	right	_
143-10	26443-26453	anatomical	_
143-11	26454-26462	amygdala	_
143-12	26463-26487	seed-regions-of-interest	_
143-13	26488-26489	(	_
143-14	26489-26493	SOIs	_
143-15	26493-26494	)	_
143-16	26494-26495	.	_

#Text=Top of panel (A) shows a statistical t-map on a canonical brain illustrating the significant correlation between plasma brain-derived neurotrophic factor (BDNF) levels and left amygdala and medial prefrontal cortex (mPFC) connectivity during unpredictable threat (U-threat).
144-1	26496-26499	Top	_
144-2	26500-26502	of	_
144-3	26503-26508	panel	_
144-4	26509-26510	(	_
144-5	26510-26511	A	_
144-6	26511-26512	)	_
144-7	26513-26518	shows	_
144-8	26519-26520	a	_
144-9	26521-26532	statistical	_
144-10	26533-26538	t-map	_
144-11	26539-26541	on	_
144-12	26542-26543	a	_
144-13	26544-26553	canonical	_
144-14	26554-26559	brain	_
144-15	26560-26572	illustrating	_
144-16	26573-26576	the	_
144-17	26577-26588	significant	_
144-18	26589-26600	correlation	_
144-19	26601-26608	between	_
144-20	26609-26615	plasma	_
144-21	26616-26629	brain-derived	_
144-22	26630-26642	neurotrophic	_
144-23	26643-26649	factor	_
144-24	26650-26651	(	_
144-25	26651-26655	BDNF	_
144-26	26655-26656	)	_
144-27	26657-26663	levels	_
144-28	26664-26667	and	_
144-29	26668-26672	left	_
144-30	26673-26681	amygdala	_
144-31	26682-26685	and	_
144-32	26686-26692	medial	_
144-33	26693-26703	prefrontal	_
144-34	26704-26710	cortex	_
144-35	26711-26712	(	_
144-36	26712-26716	mPFC	_
144-37	26716-26717	)	_
144-38	26718-26730	connectivity	_
144-39	26731-26737	during	_
144-40	26738-26751	unpredictable	_
144-41	26752-26758	threat	_
144-42	26759-26760	(	_
144-43	26760-26768	U-threat	_
144-44	26768-26769	)	_
144-45	26769-26770	.	_

#Text=Bottom of panel (A) displays a scatter plot of the correlation (P < .05) between plasma BDNF levels and extracted parameter estimates of amygdala-mPFC functional connectivity.
145-1	26771-26777	Bottom	_
145-2	26778-26780	of	_
145-3	26781-26786	panel	_
145-4	26787-26788	(	_
145-5	26788-26789	A	_
145-6	26789-26790	)	_
145-7	26791-26799	displays	_
145-8	26800-26801	a	_
145-9	26802-26809	scatter	_
145-10	26810-26814	plot	_
145-11	26815-26817	of	_
145-12	26818-26821	the	_
145-13	26822-26833	correlation	_
145-14	26834-26835	(	_
145-15	26835-26836	P	_
145-16	26837-26838	<	_
145-17	26839-26842	.05	_
145-18	26842-26843	)	_
145-19	26844-26851	between	_
145-20	26852-26858	plasma	_
145-21	26859-26863	BDNF	_
145-22	26864-26870	levels	_
145-23	26871-26874	and	_
145-24	26875-26884	extracted	_
145-25	26885-26894	parameter	_
145-26	26895-26904	estimates	_
145-27	26905-26907	of	_
145-28	26908-26921	amygdala-mPFC	_
145-29	26922-26932	functional	_
145-30	26933-26945	connectivity	_
145-31	26945-26946	.	_

#Text=Top of panel (B) shows a statistical t-map on a canonical brain illustrating the significant correlation between plasma BDNF levels and left amygdala and left inferior frontal gyrus (IFG) connectivity during unpredictable threat (U-threat).
146-1	26947-26950	Top	_
146-2	26951-26953	of	_
146-3	26954-26959	panel	_
146-4	26960-26961	(	_
146-5	26961-26962	B	_
146-6	26962-26963	)	_
146-7	26964-26969	shows	_
146-8	26970-26971	a	_
146-9	26972-26983	statistical	_
146-10	26984-26989	t-map	_
146-11	26990-26992	on	_
146-12	26993-26994	a	_
146-13	26995-27004	canonical	_
146-14	27005-27010	brain	_
146-15	27011-27023	illustrating	_
146-16	27024-27027	the	_
146-17	27028-27039	significant	_
146-18	27040-27051	correlation	_
146-19	27052-27059	between	_
146-20	27060-27066	plasma	_
146-21	27067-27071	BDNF	_
146-22	27072-27078	levels	_
146-23	27079-27082	and	_
146-24	27083-27087	left	_
146-25	27088-27096	amygdala	_
146-26	27097-27100	and	_
146-27	27101-27105	left	_
146-28	27106-27114	inferior	_
146-29	27115-27122	frontal	_
146-30	27123-27128	gyrus	_
146-31	27129-27130	(	_
146-32	27130-27133	IFG	_
146-33	27133-27134	)	_
146-34	27135-27147	connectivity	_
146-35	27148-27154	during	_
146-36	27155-27168	unpredictable	_
146-37	27169-27175	threat	_
146-38	27176-27177	(	_
146-39	27177-27185	U-threat	_
146-40	27185-27186	)	_
146-41	27186-27187	.	_

#Text=Bottom of panel (B) displays a scatter plot of the correlation (P < .05) between plasma BDNF levels and extracted parameter estimates of amygdala-IFG functional connectivity.
147-1	27188-27194	Bottom	_
147-2	27195-27197	of	_
147-3	27198-27203	panel	_
147-4	27204-27205	(	_
147-5	27205-27206	B	_
147-6	27206-27207	)	_
147-7	27208-27216	displays	_
147-8	27217-27218	a	_
147-9	27219-27226	scatter	_
147-10	27227-27231	plot	_
147-11	27232-27234	of	_
147-12	27235-27238	the	_
147-13	27239-27250	correlation	_
147-14	27251-27252	(	_
147-15	27252-27253	P	_
147-16	27254-27255	<	_
147-17	27256-27259	.05	_
147-18	27259-27260	)	_
147-19	27261-27268	between	_
147-20	27269-27275	plasma	_
147-21	27276-27280	BDNF	_
147-22	27281-27287	levels	_
147-23	27288-27291	and	_
147-24	27292-27301	extracted	_
147-25	27302-27311	parameter	_
147-26	27312-27321	estimates	_
147-27	27322-27324	of	_
147-28	27325-27337	amygdala-IFG	_
147-29	27338-27348	functional	_
147-30	27349-27361	connectivity	_
147-31	27361-27362	.	_

#Text=(n = 24 controls; 33 alcohol use disorder [AUD] participants).
148-1	27363-27364	(	_
148-2	27364-27365	n	_
148-3	27366-27367	=	_
148-4	27368-27370	24	_
148-5	27371-27379	controls	_
148-6	27379-27380	;	_
148-7	27381-27383	33	_
148-8	27384-27391	alcohol	_
148-9	27392-27395	use	_
148-10	27396-27404	disorder	_
148-11	27405-27406	[	_
148-12	27406-27409	AUD	_
148-13	27409-27410	]	_
148-14	27411-27423	participants	_
148-15	27423-27424	)	_
148-16	27424-27425	.	_

#Text=Associations With Drinking Behaviors
#Text=As a group, individuals with AUD had higher levels of plasma BDNF compared with controls (F[1, 56] = 5.60, P = .02).
149-1	27426-27438	Associations	_
149-2	27439-27443	With	_
149-3	27444-27452	Drinking	_
149-4	27453-27462	Behaviors	_
149-5	27463-27465	As	_
149-6	27466-27467	a	_
149-7	27468-27473	group	_
149-8	27473-27474	,	_
149-9	27475-27486	individuals	_
149-10	27487-27491	with	_
149-11	27492-27495	AUD	_
149-12	27496-27499	had	_
149-13	27500-27506	higher	_
149-14	27507-27513	levels	_
149-15	27514-27516	of	_
149-16	27517-27523	plasma	_
149-17	27524-27528	BDNF	_
149-18	27529-27537	compared	_
149-19	27538-27542	with	_
149-20	27543-27551	controls	_
149-21	27552-27553	(	_
149-22	27553-27554	F	_
149-23	27554-27555	[	_
149-24	27555-27556	1	_
149-25	27556-27557	,	_
149-26	27558-27560	56	_
149-27	27560-27561	]	_
149-28	27562-27563	=	_
149-29	27564-27568	5.60	_
149-30	27568-27569	,	_
149-31	27570-27571	P	_
149-32	27572-27573	=	_
149-33	27574-27577	.02	_
149-34	27577-27578	)	_
149-35	27578-27579	.	_

#Text=Across the entire sample, there were no associations between plasma BDNF levels and average number of drinks per week (r < 0.01, P = .98) or number binge episodes in the past 60 days (r = −0.08, P = .57).
150-1	27580-27586	Across	_
150-2	27587-27590	the	_
150-3	27591-27597	entire	_
150-4	27598-27604	sample	_
150-5	27604-27605	,	_
150-6	27606-27611	there	_
150-7	27612-27616	were	_
150-8	27617-27619	no	_
150-9	27620-27632	associations	_
150-10	27633-27640	between	_
150-11	27641-27647	plasma	_
150-12	27648-27652	BDNF	_
150-13	27653-27659	levels	_
150-14	27660-27663	and	_
150-15	27664-27671	average	_
150-16	27672-27678	number	_
150-17	27679-27681	of	_
150-18	27682-27688	drinks	_
150-19	27689-27692	per	_
150-20	27693-27697	week	_
150-21	27698-27699	(	_
150-22	27699-27700	r	_
150-23	27701-27702	<	_
150-24	27703-27707	0.01	_
150-25	27707-27708	,	_
150-26	27709-27710	P	_
150-27	27711-27712	=	_
150-28	27713-27716	.98	_
150-29	27716-27717	)	_
150-30	27718-27720	or	_
150-31	27721-27727	number	_
150-32	27728-27733	binge	_
150-33	27734-27742	episodes	_
150-34	27743-27745	in	_
150-35	27746-27749	the	_
150-36	27750-27754	past	_
150-37	27755-27757	60	_
150-38	27758-27762	days	_
150-39	27763-27764	(	_
150-40	27764-27765	r	_
150-41	27766-27767	=	_
150-42	27768-27769	−	_
150-43	27769-27773	0.08	_
150-44	27773-27774	,	_
150-45	27775-27776	P	_
150-46	27777-27778	=	_
150-47	27779-27782	.57	_
150-48	27782-27783	)	_
150-49	27783-27784	.	_

#Text=However, group (AUD vs controls) moderated the association between plasma BDNF levels and number of binge episodes (β = 0.68, t = 2.93, P = .01) such that within individuals with AUD, lower BDNF was associated with more binge episodes (β = −.51, t = −3.09, P = .02; Figure 2A), but within individuals without AUD there was no association between BDNF levels and binge episodes (β = .44, t = 1.33, P = .18).
151-1	27785-27792	However	_
151-2	27792-27793	,	_
151-3	27794-27799	group	_
151-4	27800-27801	(	_
151-5	27801-27804	AUD	_
151-6	27805-27807	vs	_
151-7	27808-27816	controls	_
151-8	27816-27817	)	_
151-9	27818-27827	moderated	_
151-10	27828-27831	the	_
151-11	27832-27843	association	_
151-12	27844-27851	between	_
151-13	27852-27858	plasma	_
151-14	27859-27863	BDNF	_
151-15	27864-27870	levels	_
151-16	27871-27874	and	_
151-17	27875-27881	number	_
151-18	27882-27884	of	_
151-19	27885-27890	binge	_
151-20	27891-27899	episodes	_
151-21	27900-27901	(	_
151-22	27901-27902	β	_
151-23	27903-27904	=	_
151-24	27905-27909	0.68	_
151-25	27909-27910	,	_
151-26	27911-27912	t	_
151-27	27913-27914	=	_
151-28	27915-27919	2.93	_
151-29	27919-27920	,	_
151-30	27921-27922	P	_
151-31	27923-27924	=	_
151-32	27925-27928	.01	_
151-33	27928-27929	)	_
151-34	27930-27934	such	_
151-35	27935-27939	that	_
151-36	27940-27946	within	_
151-37	27947-27958	individuals	_
151-38	27959-27963	with	_
151-39	27964-27967	AUD	_
151-40	27967-27968	,	_
151-41	27969-27974	lower	_
151-42	27975-27979	BDNF	_
151-43	27980-27983	was	_
151-44	27984-27994	associated	_
151-45	27995-27999	with	_
151-46	28000-28004	more	_
151-47	28005-28010	binge	_
151-48	28011-28019	episodes	_
151-49	28020-28021	(	_
151-50	28021-28022	β	_
151-51	28023-28024	=	_
151-52	28025-28026	−	_
151-53	28026-28029	.51	_
151-54	28029-28030	,	_
151-55	28031-28032	t	_
151-56	28033-28034	=	_
151-57	28035-28036	−	_
151-58	28036-28040	3.09	_
151-59	28040-28041	,	_
151-60	28042-28043	P	_
151-61	28044-28045	=	_
151-62	28046-28049	.02	_
151-63	28049-28050	;	_
151-64	28051-28057	Figure	_
151-65	28058-28060	2A	_
151-66	28060-28061	)	_
151-67	28061-28062	,	_
151-68	28063-28066	but	_
151-69	28067-28073	within	_
151-70	28074-28085	individuals	_
151-71	28086-28093	without	_
151-72	28094-28097	AUD	_
151-73	28098-28103	there	_
151-74	28104-28107	was	_
151-75	28108-28110	no	_
151-76	28111-28122	association	_
151-77	28123-28130	between	_
151-78	28131-28135	BDNF	_
151-79	28136-28142	levels	_
151-80	28143-28146	and	_
151-81	28147-28152	binge	_
151-82	28153-28161	episodes	_
151-83	28162-28163	(	_
151-84	28163-28164	β	_
151-85	28165-28166	=	_
151-86	28167-28170	.44	_
151-87	28170-28171	,	_
151-88	28172-28173	t	_
151-89	28174-28175	=	_
151-90	28176-28180	1.33	_
151-91	28180-28181	,	_
151-92	28182-28183	P	_
151-93	28184-28185	=	_
151-94	28186-28189	.18	_
151-95	28189-28190	)	_
151-96	28190-28191	.	_

#Text=Group did not moderate the association between BDNF and drinks per week (β = −1.07, t = −1.66, P = .10).
152-1	28192-28197	Group	_
152-2	28198-28201	did	_
152-3	28202-28205	not	_
152-4	28206-28214	moderate	_
152-5	28215-28218	the	_
152-6	28219-28230	association	_
152-7	28231-28238	between	_
152-8	28239-28243	BDNF	_
152-9	28244-28247	and	_
152-10	28248-28254	drinks	_
152-11	28255-28258	per	_
152-12	28259-28263	week	_
152-13	28264-28265	(	_
152-14	28265-28266	β	_
152-15	28267-28268	=	_
152-16	28269-28270	−	_
152-17	28270-28274	1.07	_
152-18	28274-28275	,	_
152-19	28276-28277	t	_
152-20	28278-28279	=	_
152-21	28280-28281	−	_
152-22	28281-28285	1.66	_
152-23	28285-28286	,	_
152-24	28287-28288	P	_
152-25	28289-28290	=	_
152-26	28291-28294	.10	_
152-27	28294-28295	)	_
152-28	28295-28296	.	_

#Text=Sex did not moderate the association between BDNF and drinks per week (β = 0.12, t = 0.20, P = .84) or number of binge episodes (β = −0.07, t = −0.12, P = .91).
153-1	28297-28300	Sex	_
153-2	28301-28304	did	_
153-3	28305-28308	not	_
153-4	28309-28317	moderate	_
153-5	28318-28321	the	_
153-6	28322-28333	association	_
153-7	28334-28341	between	_
153-8	28342-28346	BDNF	_
153-9	28347-28350	and	_
153-10	28351-28357	drinks	_
153-11	28358-28361	per	_
153-12	28362-28366	week	_
153-13	28367-28368	(	_
153-14	28368-28369	β	_
153-15	28370-28371	=	_
153-16	28372-28376	0.12	_
153-17	28376-28377	,	_
153-18	28378-28379	t	_
153-19	28380-28381	=	_
153-20	28382-28386	0.20	_
153-21	28386-28387	,	_
153-22	28388-28389	P	_
153-23	28390-28391	=	_
153-24	28392-28395	.84	_
153-25	28395-28396	)	_
153-26	28397-28399	or	_
153-27	28400-28406	number	_
153-28	28407-28409	of	_
153-29	28410-28415	binge	_
153-30	28416-28424	episodes	_
153-31	28425-28426	(	_
153-32	28426-28427	β	_
153-33	28428-28429	=	_
153-34	28430-28431	−	_
153-35	28431-28435	0.07	_
153-36	28435-28436	,	_
153-37	28437-28438	t	_
153-38	28439-28440	=	_
153-39	28441-28442	−	_
153-40	28442-28446	0.12	_
153-41	28446-28447	,	_
153-42	28448-28449	P	_
153-43	28450-28451	=	_
153-44	28452-28455	.91	_
153-45	28455-28456	)	_
153-46	28456-28457	.	_

#Text=Results within the AUD group only also revealed that lower BDNF was associated with lower age of AUD onset (r = .40, P = .02; Figure 2C).
154-1	28458-28465	Results	_
154-2	28466-28472	within	_
154-3	28473-28476	the	_
154-4	28477-28480	AUD	_
154-5	28481-28486	group	_
154-6	28487-28491	only	_
154-7	28492-28496	also	_
154-8	28497-28505	revealed	_
154-9	28506-28510	that	_
154-10	28511-28516	lower	_
154-11	28517-28521	BDNF	_
154-12	28522-28525	was	_
154-13	28526-28536	associated	_
154-14	28537-28541	with	_
154-15	28542-28547	lower	_
154-16	28548-28551	age	_
154-17	28552-28554	of	_
154-18	28555-28558	AUD	_
154-19	28559-28564	onset	_
154-20	28565-28566	(	_
154-21	28566-28567	r	_
154-22	28568-28569	=	_
154-23	28570-28573	.40	_
154-24	28573-28574	,	_
154-25	28575-28576	P	_
154-26	28577-28578	=	_
154-27	28579-28582	.02	_
154-28	28582-28583	;	_
154-29	28584-28590	Figure	_
154-30	28591-28593	2C	_
154-31	28593-28594	)	_
154-32	28594-28595	.	_

#Text=Scatter plots of the significant correlations.
155-1	28596-28603	Scatter	_
155-2	28604-28609	plots	_
155-3	28610-28612	of	_
155-4	28613-28616	the	_
155-5	28617-28628	significant	_
155-6	28629-28641	correlations	_
155-7	28641-28642	.	_

#Text=Top panel shows the association between number of binges in the past 60 days and plasma brain-derived neurotrophic factor (BDNF) levels (P = .01) (A) and amygdala-medial prefrontal cortex (mPFC) functional connectivity during unpredictable threat (U-threat) (P = .02) (B).
156-1	28643-28646	Top	_
156-2	28647-28652	panel	_
156-3	28653-28658	shows	_
156-4	28659-28662	the	_
156-5	28663-28674	association	_
156-6	28675-28682	between	_
156-7	28683-28689	number	_
156-8	28690-28692	of	_
156-9	28693-28699	binges	_
156-10	28700-28702	in	_
156-11	28703-28706	the	_
156-12	28707-28711	past	_
156-13	28712-28714	60	_
156-14	28715-28719	days	_
156-15	28720-28723	and	_
156-16	28724-28730	plasma	_
156-17	28731-28744	brain-derived	_
156-18	28745-28757	neurotrophic	_
156-19	28758-28764	factor	_
156-20	28765-28766	(	_
156-21	28766-28770	BDNF	_
156-22	28770-28771	)	_
156-23	28772-28778	levels	_
156-24	28779-28780	(	_
156-25	28780-28781	P	_
156-26	28782-28783	=	_
156-27	28784-28787	.01	_
156-28	28787-28788	)	_
156-29	28789-28790	(	_
156-30	28790-28791	A	_
156-31	28791-28792	)	_
156-32	28793-28796	and	_
156-33	28797-28812	amygdala-medial	_
156-34	28813-28823	prefrontal	_
156-35	28824-28830	cortex	_
156-36	28831-28832	(	_
156-37	28832-28836	mPFC	_
156-38	28836-28837	)	_
156-39	28838-28848	functional	_
156-40	28849-28861	connectivity	_
156-41	28862-28868	during	_
156-42	28869-28882	unpredictable	_
156-43	28883-28889	threat	_
156-44	28890-28891	(	_
156-45	28891-28899	U-threat	_
156-46	28899-28900	)	_
156-47	28901-28902	(	_
156-48	28902-28903	P	_
156-49	28904-28905	=	_
156-50	28906-28909	.02	_
156-51	28909-28910	)	_
156-52	28911-28912	(	_
156-53	28912-28913	B	_
156-54	28913-28914	)	_
156-55	28914-28915	.	_

#Text=Bottom panel shows the association between alcohol use disorder (AUD) age of onset and plasma BDNF levels (P = .02) (C) and amygdala-mPFC functional connectivity during U-threat (P = .03) (D). n = 33 AUD subjects.
157-1	28916-28922	Bottom	_
157-2	28923-28928	panel	_
157-3	28929-28934	shows	_
157-4	28935-28938	the	_
157-5	28939-28950	association	_
157-6	28951-28958	between	_
157-7	28959-28966	alcohol	_
157-8	28967-28970	use	_
157-9	28971-28979	disorder	_
157-10	28980-28981	(	_
157-11	28981-28984	AUD	_
157-12	28984-28985	)	_
157-13	28986-28989	age	_
157-14	28990-28992	of	_
157-15	28993-28998	onset	_
157-16	28999-29002	and	_
157-17	29003-29009	plasma	_
157-18	29010-29014	BDNF	_
157-19	29015-29021	levels	_
157-20	29022-29023	(	_
157-21	29023-29024	P	_
157-22	29025-29026	=	_
157-23	29027-29030	.02	_
157-24	29030-29031	)	_
157-25	29032-29033	(	_
157-26	29033-29034	C	_
157-27	29034-29035	)	_
157-28	29036-29039	and	_
157-29	29040-29053	amygdala-mPFC	_
157-30	29054-29064	functional	_
157-31	29065-29077	connectivity	_
157-32	29078-29084	during	_
157-33	29085-29093	U-threat	_
157-34	29094-29095	(	_
157-35	29095-29096	P	_
157-36	29097-29098	=	_
157-37	29099-29102	.03	_
157-38	29102-29103	)	_
157-39	29104-29105	(	_
157-40	29105-29106	D	_
157-41	29106-29107	)	_
157-42	29107-29108	.	_
157-43	29109-29110	n	_
157-44	29111-29112	=	_
157-45	29113-29115	33	_
157-46	29116-29119	AUD	_
157-47	29120-29128	subjects	_
157-48	29128-29129	.	_

#Text=Given the null amygdala reactivity findings, we only explored links between drinking behaviors and significant peak functional connectivity parameter estimates associated with BDNF levels (i.e., mPFC and IFG).
158-1	29130-29135	Given	_
158-2	29136-29139	the	_
158-3	29140-29144	null	_
158-4	29145-29153	amygdala	_
158-5	29154-29164	reactivity	_
158-6	29165-29173	findings	_
158-7	29173-29174	,	_
158-8	29175-29177	we	_
158-9	29178-29182	only	_
158-10	29183-29191	explored	_
158-11	29192-29197	links	_
158-12	29198-29205	between	_
158-13	29206-29214	drinking	_
158-14	29215-29224	behaviors	_
158-15	29225-29228	and	_
158-16	29229-29240	significant	_
158-17	29241-29245	peak	_
158-18	29246-29256	functional	_
158-19	29257-29269	connectivity	_
158-20	29270-29279	parameter	_
158-21	29280-29289	estimates	_
158-22	29290-29300	associated	_
158-23	29301-29305	with	_
158-24	29306-29310	BDNF	_
158-25	29311-29317	levels	_
158-26	29318-29319	(	_
158-27	29319-29322	i.e	_
158-28	29322-29323	.	_
158-29	29323-29324	,	_
158-30	29325-29329	mPFC	_
158-31	29330-29333	and	_
158-32	29334-29337	IFG	_
158-33	29337-29338	)	_
158-34	29338-29339	.	_

#Text=Results revealed no associations across the entire sample between amygdala-mPFC connectivity and average number of drinks per week (r < 0.01, P = .98) or number of binge episodes (r = −0.05, P = .73).
159-1	29340-29347	Results	_
159-2	29348-29356	revealed	_
159-3	29357-29359	no	_
159-4	29360-29372	associations	_
159-5	29373-29379	across	_
159-6	29380-29383	the	_
159-7	29384-29390	entire	_
159-8	29391-29397	sample	_
159-9	29398-29405	between	_
159-10	29406-29419	amygdala-mPFC	_
159-11	29420-29432	connectivity	_
159-12	29433-29436	and	_
159-13	29437-29444	average	_
159-14	29445-29451	number	_
159-15	29452-29454	of	_
159-16	29455-29461	drinks	_
159-17	29462-29465	per	_
159-18	29466-29470	week	_
159-19	29471-29472	(	_
159-20	29472-29473	r	_
159-21	29474-29475	<	_
159-22	29476-29480	0.01	_
159-23	29480-29481	,	_
159-24	29482-29483	P	_
159-25	29484-29485	=	_
159-26	29486-29489	.98	_
159-27	29489-29490	)	_
159-28	29491-29493	or	_
159-29	29494-29500	number	_
159-30	29501-29503	of	_
159-31	29504-29509	binge	_
159-32	29510-29518	episodes	_
159-33	29519-29520	(	_
159-34	29520-29521	r	_
159-35	29522-29523	=	_
159-36	29524-29525	−	_
159-37	29525-29529	0.05	_
159-38	29529-29530	,	_
159-39	29531-29532	P	_
159-40	29533-29534	=	_
159-41	29535-29538	.73	_
159-42	29538-29539	)	_
159-43	29539-29540	.	_

#Text=There were also no associations between amygdala-IFG connectivity and drinks per week (r = −0.02, P = .87) or number of binge episodes (r = −0.09, P = .50).
160-1	29541-29546	There	_
160-2	29547-29551	were	_
160-3	29552-29556	also	_
160-4	29557-29559	no	_
160-5	29560-29572	associations	_
160-6	29573-29580	between	_
160-7	29581-29593	amygdala-IFG	_
160-8	29594-29606	connectivity	_
160-9	29607-29610	and	_
160-10	29611-29617	drinks	_
160-11	29618-29621	per	_
160-12	29622-29626	week	_
160-13	29627-29628	(	_
160-14	29628-29629	r	_
160-15	29630-29631	=	_
160-16	29632-29633	−	_
160-17	29633-29637	0.02	_
160-18	29637-29638	,	_
160-19	29639-29640	P	_
160-20	29641-29642	=	_
160-21	29643-29646	.87	_
160-22	29646-29647	)	_
160-23	29648-29650	or	_
160-24	29651-29657	number	_
160-25	29658-29660	of	_
160-26	29661-29666	binge	_
160-27	29667-29675	episodes	_
160-28	29676-29677	(	_
160-29	29677-29678	r	_
160-30	29679-29680	=	_
160-31	29681-29682	−	_
160-32	29682-29686	0.09	_
160-33	29686-29687	,	_
160-34	29688-29689	P	_
160-35	29690-29691	=	_
160-36	29692-29695	.50	_
160-37	29695-29696	)	_
160-38	29696-29697	.	_

#Text=However, group moderated the association between amygdala-mPFC connectivity and number of binge episodes (β = −0.40, t = −2.52, P = .02).
161-1	29698-29705	However	_
161-2	29705-29706	,	_
161-3	29707-29712	group	_
161-4	29713-29722	moderated	_
161-5	29723-29726	the	_
161-6	29727-29738	association	_
161-7	29739-29746	between	_
161-8	29747-29760	amygdala-mPFC	_
161-9	29761-29773	connectivity	_
161-10	29774-29777	and	_
161-11	29778-29784	number	_
161-12	29785-29787	of	_
161-13	29788-29793	binge	_
161-14	29794-29802	episodes	_
161-15	29803-29804	(	_
161-16	29804-29805	β	_
161-17	29806-29807	=	_
161-18	29808-29809	−	_
161-19	29809-29813	0.40	_
161-20	29813-29814	,	_
161-21	29815-29816	t	_
161-22	29817-29818	=	_
161-23	29819-29820	−	_
161-24	29820-29824	2.52	_
161-25	29824-29825	,	_
161-26	29826-29827	P	_
161-27	29828-29829	=	_
161-28	29830-29833	.02	_
161-29	29833-29834	)	_
161-30	29834-29835	.	_

#Text=Within individuals with AUD, less amygdala-mPFC connectivity was associated with more binges (β = −0.48, t = −2.55, P = .01; Figure 2B) and within controls, there was no association between amygdala-mPFC connectivity and binge episodes (β = 0.15, t = 1.25, P = .22).
162-1	29836-29842	Within	_
162-2	29843-29854	individuals	_
162-3	29855-29859	with	_
162-4	29860-29863	AUD	_
162-5	29863-29864	,	_
162-6	29865-29869	less	_
162-7	29870-29883	amygdala-mPFC	_
162-8	29884-29896	connectivity	_
162-9	29897-29900	was	_
162-10	29901-29911	associated	_
162-11	29912-29916	with	_
162-12	29917-29921	more	_
162-13	29922-29928	binges	_
162-14	29929-29930	(	_
162-15	29930-29931	β	_
162-16	29932-29933	=	_
162-17	29934-29935	−	_
162-18	29935-29939	0.48	_
162-19	29939-29940	,	_
162-20	29941-29942	t	_
162-21	29943-29944	=	_
162-22	29945-29946	−	_
162-23	29946-29950	2.55	_
162-24	29950-29951	,	_
162-25	29952-29953	P	_
162-26	29954-29955	=	_
162-27	29956-29959	.01	_
162-28	29959-29960	;	_
162-29	29961-29967	Figure	_
162-30	29968-29970	2B	_
162-31	29970-29971	)	_
162-32	29972-29975	and	_
162-33	29976-29982	within	_
162-34	29983-29991	controls	_
162-35	29991-29992	,	_
162-36	29993-29998	there	_
162-37	29999-30002	was	_
162-38	30003-30005	no	_
162-39	30006-30017	association	_
162-40	30018-30025	between	_
162-41	30026-30039	amygdala-mPFC	_
162-42	30040-30052	connectivity	_
162-43	30053-30056	and	_
162-44	30057-30062	binge	_
162-45	30063-30071	episodes	_
162-46	30072-30073	(	_
162-47	30073-30074	β	_
162-48	30075-30076	=	_
162-49	30077-30081	0.15	_
162-50	30081-30082	,	_
162-51	30083-30084	t	_
162-52	30085-30086	=	_
162-53	30087-30091	1.25	_
162-54	30091-30092	,	_
162-55	30093-30094	P	_
162-56	30095-30096	=	_
162-57	30097-30100	.22	_
162-58	30100-30101	)	_
162-59	30101-30102	.	_

#Text=Group did not moderate the association between amygdala-mPFC connectivity and drinks per week or the association between amygdala-IFG connectivity and either drinking variable (P > .15).
163-1	30103-30108	Group	_
163-2	30109-30112	did	_
163-3	30113-30116	not	_
163-4	30117-30125	moderate	_
163-5	30126-30129	the	_
163-6	30130-30141	association	_
163-7	30142-30149	between	_
163-8	30150-30163	amygdala-mPFC	_
163-9	30164-30176	connectivity	_
163-10	30177-30180	and	_
163-11	30181-30187	drinks	_
163-12	30188-30191	per	_
163-13	30192-30196	week	_
163-14	30197-30199	or	_
163-15	30200-30203	the	_
163-16	30204-30215	association	_
163-17	30216-30223	between	_
163-18	30224-30236	amygdala-IFG	_
163-19	30237-30249	connectivity	_
163-20	30250-30253	and	_
163-21	30254-30260	either	_
163-22	30261-30269	drinking	_
163-23	30270-30278	variable	_
163-24	30279-30280	(	_
163-25	30280-30281	P	_
163-26	30282-30283	>	_
163-27	30284-30287	.15	_
163-28	30287-30288	)	_
163-29	30288-30289	.	_

#Text=Sex also did not moderate any of the tested associations (P > .38).
164-1	30290-30293	Sex	_
164-2	30294-30298	also	_
164-3	30299-30302	did	_
164-4	30303-30306	not	_
164-5	30307-30315	moderate	_
164-6	30316-30319	any	_
164-7	30320-30322	of	_
164-8	30323-30326	the	_
164-9	30327-30333	tested	_
164-10	30334-30346	associations	_
164-11	30347-30348	(	_
164-12	30348-30349	P	_
164-13	30350-30351	>	_
164-14	30352-30355	.38	_
164-15	30355-30356	)	_
164-16	30356-30357	.	_

#Text=Results within the AUD group indicated that lower amygdala-mPFC connectivity was associated with younger age of AUD onset (r = .39, P = .03; Figure 2D).
165-1	30358-30365	Results	_
165-2	30366-30372	within	_
165-3	30373-30376	the	_
165-4	30377-30380	AUD	_
165-5	30381-30386	group	_
165-6	30387-30396	indicated	_
165-7	30397-30401	that	_
165-8	30402-30407	lower	_
165-9	30408-30421	amygdala-mPFC	_
165-10	30422-30434	connectivity	_
165-11	30435-30438	was	_
165-12	30439-30449	associated	_
165-13	30450-30454	with	_
165-14	30455-30462	younger	_
165-15	30463-30466	age	_
165-16	30467-30469	of	_
165-17	30470-30473	AUD	_
165-18	30474-30479	onset	_
165-19	30480-30481	(	_
165-20	30481-30482	r	_
165-21	30483-30484	=	_
165-22	30485-30488	.39	_
165-23	30488-30489	,	_
165-24	30490-30491	P	_
165-25	30492-30493	=	_
165-26	30494-30497	.03	_
165-27	30497-30498	;	_
165-28	30499-30505	Figure	_
165-29	30506-30508	2D	_
165-30	30508-30509	)	_
165-31	30509-30510	.	_

#Text=Impact of Potential Covariates
#Text=All significant analyses were re-run controlling for time (in days) between BDNF data collection and the fMRI session and lifetime diagnosis of any major internalizing disorder (yes/no).
166-1	30511-30517	Impact	_
166-2	30518-30520	of	_
166-3	30521-30530	Potential	_
166-4	30531-30541	Covariates	_
166-5	30542-30545	All	_
166-6	30546-30557	significant	_
166-7	30558-30566	analyses	_
166-8	30567-30571	were	_
166-9	30572-30578	re-run	_
166-10	30579-30590	controlling	_
166-11	30591-30594	for	_
166-12	30595-30599	time	_
166-13	30600-30601	(	_
166-14	30601-30603	in	_
166-15	30604-30608	days	_
166-16	30608-30609	)	_
166-17	30610-30617	between	_
166-18	30618-30622	BDNF	_
166-19	30623-30627	data	_
166-20	30628-30638	collection	_
166-21	30639-30642	and	_
166-22	30643-30646	the	_
166-23	30647-30651	fMRI	_
166-24	30652-30659	session	_
166-25	30660-30663	and	_
166-26	30664-30672	lifetime	_
166-27	30673-30682	diagnosis	_
166-28	30683-30685	of	_
166-29	30686-30689	any	_
166-30	30690-30695	major	_
166-31	30696-30709	internalizing	_
166-32	30710-30718	disorder	_
166-33	30719-30720	(	_
166-34	30720-30723	yes	_
166-35	30723-30724	/	_
166-36	30724-30726	no	_
166-37	30726-30727	)	_
166-38	30727-30728	.	_

#Text=The results indicated that neither covariate had a significant impact on the pattern of results, and the findings were identical in each covariate model.
167-1	30729-30732	The	_
167-2	30733-30740	results	_
167-3	30741-30750	indicated	_
167-4	30751-30755	that	_
167-5	30756-30763	neither	_
167-6	30764-30773	covariate	_
167-7	30774-30777	had	_
167-8	30778-30779	a	_
167-9	30780-30791	significant	_
167-10	30792-30798	impact	_
167-11	30799-30801	on	_
167-12	30802-30805	the	_
167-13	30806-30813	pattern	_
167-14	30814-30816	of	_
167-15	30817-30824	results	_
167-16	30824-30825	,	_
167-17	30826-30829	and	_
167-18	30830-30833	the	_
167-19	30834-30842	findings	_
167-20	30843-30847	were	_
167-21	30848-30857	identical	_
167-22	30858-30860	in	_
167-23	30861-30865	each	_
167-24	30866-30875	covariate	_
167-25	30876-30881	model	_
167-26	30881-30882	.	_

#Text=Discussion
#Text=The primary aim of the study was to test whether plasma BDNF levels were associated with individual differences in amygdala reactivity and amygdala-PFC functional connectivity during 2 forms of aversive responding: anticipatory anxiety elicited by U-threat and fear elicited by P-threat.
168-1	30883-30893	Discussion	_
168-2	30894-30897	The	_
168-3	30898-30905	primary	_
168-4	30906-30909	aim	_
168-5	30910-30912	of	_
168-6	30913-30916	the	_
168-7	30917-30922	study	_
168-8	30923-30926	was	_
168-9	30927-30929	to	_
168-10	30930-30934	test	_
168-11	30935-30942	whether	_
168-12	30943-30949	plasma	_
168-13	30950-30954	BDNF	_
168-14	30955-30961	levels	_
168-15	30962-30966	were	_
168-16	30967-30977	associated	_
168-17	30978-30982	with	_
168-18	30983-30993	individual	_
168-19	30994-31005	differences	_
168-20	31006-31008	in	_
168-21	31009-31017	amygdala	_
168-22	31018-31028	reactivity	_
168-23	31029-31032	and	_
168-24	31033-31045	amygdala-PFC	_
168-25	31046-31056	functional	_
168-26	31057-31069	connectivity	_
168-27	31070-31076	during	_
168-28	31077-31078	2	_
168-29	31079-31084	forms	_
168-30	31085-31087	of	_
168-31	31088-31096	aversive	_
168-32	31097-31107	responding	_
168-33	31107-31108	:	_
168-34	31109-31121	anticipatory	_
168-35	31122-31129	anxiety	_
168-36	31130-31138	elicited	_
168-37	31139-31141	by	_
168-38	31142-31150	U-threat	_
168-39	31151-31154	and	_
168-40	31155-31159	fear	_
168-41	31160-31168	elicited	_
168-42	31169-31171	by	_
168-43	31172-31180	P-threat	_
168-44	31180-31181	.	_

#Text=We also examined whether BDNF levels and our neural findings were associated with real-world drinking behaviors.
169-1	31182-31184	We	_
169-2	31185-31189	also	_
169-3	31190-31198	examined	_
169-4	31199-31206	whether	_
169-5	31207-31211	BDNF	_
169-6	31212-31218	levels	_
169-7	31219-31222	and	_
169-8	31223-31226	our	_
169-9	31227-31233	neural	_
169-10	31234-31242	findings	_
169-11	31243-31247	were	_
169-12	31248-31258	associated	_
169-13	31259-31263	with	_
169-14	31264-31274	real-world	_
169-15	31275-31283	drinking	_
169-16	31284-31293	behaviors	_
169-17	31293-31294	.	_

#Text=Results obtained revealed that during U-threat, but not P-threat, lower levels of BDNF were associated with less functional connectivity between the left amygdala and both the mPFC and IFG.
170-1	31295-31302	Results	_
170-2	31303-31311	obtained	_
170-3	31312-31320	revealed	_
170-4	31321-31325	that	_
170-5	31326-31332	during	_
170-6	31333-31341	U-threat	_
170-7	31341-31342	,	_
170-8	31343-31346	but	_
170-9	31347-31350	not	_
170-10	31351-31359	P-threat	_
170-11	31359-31360	,	_
170-12	31361-31366	lower	_
170-13	31367-31373	levels	_
170-14	31374-31376	of	_
170-15	31377-31381	BDNF	_
170-16	31382-31386	were	_
170-17	31387-31397	associated	_
170-18	31398-31402	with	_
170-19	31403-31407	less	_
170-20	31408-31418	functional	_
170-21	31419-31431	connectivity	_
170-22	31432-31439	between	_
170-23	31440-31443	the	_
170-24	31444-31448	left	_
170-25	31449-31457	amygdala	_
170-26	31458-31461	and	_
170-27	31462-31466	both	_
170-28	31467-31470	the	_
170-29	31471-31475	mPFC	_
170-30	31476-31479	and	_
170-31	31480-31483	IFG	_
170-32	31483-31484	.	_

#Text=In addition, within individuals with AUD (only), lower levels of BDNF and amygdala-mPFC functional connectivity during U-threat were associated with more binge episodes within the past 60 days and a younger age of AUD onset.
171-1	31485-31487	In	_
171-2	31488-31496	addition	_
171-3	31496-31497	,	_
171-4	31498-31504	within	_
171-5	31505-31516	individuals	_
171-6	31517-31521	with	_
171-7	31522-31525	AUD	_
171-8	31526-31527	(	_
171-9	31527-31531	only	_
171-10	31531-31532	)	_
171-11	31532-31533	,	_
171-12	31534-31539	lower	_
171-13	31540-31546	levels	_
171-14	31547-31549	of	_
171-15	31550-31554	BDNF	_
171-16	31555-31558	and	_
171-17	31559-31572	amygdala-mPFC	_
171-18	31573-31583	functional	_
171-19	31584-31596	connectivity	_
171-20	31597-31603	during	_
171-21	31604-31612	U-threat	_
171-22	31613-31617	were	_
171-23	31618-31628	associated	_
171-24	31629-31633	with	_
171-25	31634-31638	more	_
171-26	31639-31644	binge	_
171-27	31645-31653	episodes	_
171-28	31654-31660	within	_
171-29	31661-31664	the	_
171-30	31665-31669	past	_
171-31	31670-31672	60	_
171-32	31673-31677	days	_
171-33	31678-31681	and	_
171-34	31682-31683	a	_
171-35	31684-31691	younger	_
171-36	31692-31695	age	_
171-37	31696-31698	of	_
171-38	31699-31702	AUD	_
171-39	31703-31708	onset	_
171-40	31708-31709	.	_

#Text=There were no associations with drinking behaviors in individuals without AUD.
172-1	31710-31715	There	_
172-2	31716-31720	were	_
172-3	31721-31723	no	_
172-4	31724-31736	associations	_
172-5	31737-31741	with	_
172-6	31742-31750	drinking	_
172-7	31751-31760	behaviors	_
172-8	31761-31763	in	_
172-9	31764-31775	individuals	_
172-10	31776-31783	without	_
172-11	31784-31787	AUD	_
172-12	31787-31788	.	_

#Text=In addition, there were no associations between BDNF levels and amygdala task-based reactivity.
173-1	31789-31791	In	_
173-2	31792-31800	addition	_
173-3	31800-31801	,	_
173-4	31802-31807	there	_
173-5	31808-31812	were	_
173-6	31813-31815	no	_
173-7	31816-31828	associations	_
173-8	31829-31836	between	_
173-9	31837-31841	BDNF	_
173-10	31842-31848	levels	_
173-11	31849-31852	and	_
173-12	31853-31861	amygdala	_
173-13	31862-31872	task-based	_
173-14	31873-31883	reactivity	_
173-15	31883-31884	.	_

#Text=Together, the results indicate that plasma BDNF levels are related to amygdala-PFC circuit functioning in humans, particularly during anticipatory anxiety, and these individual differences may contribute to drinking behaviors.
174-1	31885-31893	Together	_
174-2	31893-31894	,	_
174-3	31895-31898	the	_
174-4	31899-31906	results	_
174-5	31907-31915	indicate	_
174-6	31916-31920	that	_
174-7	31921-31927	plasma	_
174-8	31928-31932	BDNF	_
174-9	31933-31939	levels	_
174-10	31940-31943	are	_
174-11	31944-31951	related	_
174-12	31952-31954	to	_
174-13	31955-31967	amygdala-PFC	_
174-14	31968-31975	circuit	_
174-15	31976-31987	functioning	_
174-16	31988-31990	in	_
174-17	31991-31997	humans	_
174-18	31997-31998	,	_
174-19	31999-32011	particularly	_
174-20	32012-32018	during	_
174-21	32019-32031	anticipatory	_
174-22	32032-32039	anxiety	_
174-23	32039-32040	,	_
174-24	32041-32044	and	_
174-25	32045-32050	these	_
174-26	32051-32061	individual	_
174-27	32062-32073	differences	_
174-28	32074-32077	may	_
174-29	32078-32088	contribute	_
174-30	32089-32091	to	_
174-31	32092-32100	drinking	_
174-32	32101-32110	behaviors	_
174-33	32110-32111	.	_

#Text=Across all participants, lower levels of BDNF were associated with decreased amygdala-mPFC and amygdala-IFG functional connectivity during anticipatory anxiety.
175-1	32112-32118	Across	_
175-2	32119-32122	all	_
175-3	32123-32135	participants	_
175-4	32135-32136	,	_
175-5	32137-32142	lower	_
175-6	32143-32149	levels	_
175-7	32150-32152	of	_
175-8	32153-32157	BDNF	_
175-9	32158-32162	were	_
175-10	32163-32173	associated	_
175-11	32174-32178	with	_
175-12	32179-32188	decreased	_
175-13	32189-32202	amygdala-mPFC	_
175-14	32203-32206	and	_
175-15	32207-32219	amygdala-IFG	_
175-16	32220-32230	functional	_
175-17	32231-32243	connectivity	_
175-18	32244-32250	during	_
175-19	32251-32263	anticipatory	_
175-20	32264-32271	anxiety	_
175-21	32271-32272	.	_

#Text=These findings were observed in the absence of any direct associations between BDNF levels and amygdala reactivity, which is noteworthy in light of studies highlighting that measures of neural networks are more predictive than single regions of interest (e.g.,).
176-1	32273-32278	These	_
176-2	32279-32287	findings	_
176-3	32288-32292	were	_
176-4	32293-32301	observed	_
176-5	32302-32304	in	_
176-6	32305-32308	the	_
176-7	32309-32316	absence	_
176-8	32317-32319	of	_
176-9	32320-32323	any	_
176-10	32324-32330	direct	_
176-11	32331-32343	associations	_
176-12	32344-32351	between	_
176-13	32352-32356	BDNF	_
176-14	32357-32363	levels	_
176-15	32364-32367	and	_
176-16	32368-32376	amygdala	_
176-17	32377-32387	reactivity	_
176-18	32387-32388	,	_
176-19	32389-32394	which	_
176-20	32395-32397	is	_
176-21	32398-32408	noteworthy	_
176-22	32409-32411	in	_
176-23	32412-32417	light	_
176-24	32418-32420	of	_
176-25	32421-32428	studies	_
176-26	32429-32441	highlighting	_
176-27	32442-32446	that	_
176-28	32447-32455	measures	_
176-29	32456-32458	of	_
176-30	32459-32465	neural	_
176-31	32466-32474	networks	_
176-32	32475-32478	are	_
176-33	32479-32483	more	_
176-34	32484-32494	predictive	_
176-35	32495-32499	than	_
176-36	32500-32506	single	_
176-37	32507-32514	regions	_
176-38	32515-32517	of	_
176-39	32518-32526	interest	_
176-40	32527-32528	(	_
176-41	32528-32531	e.g	_
176-42	32531-32532	.	_
176-43	32532-32533	,	_
176-44	32533-32534	)	_
176-45	32534-32535	.	_

#Text=The amygdala networks identified in the current study include the mPFC and IFG, which are 2 key regions involved in emotion regulation and have been shown to exhibit regulatory influences on the amygdala during the inhibition of anxiety and negative affect.
177-1	32536-32539	The	_
177-2	32540-32548	amygdala	_
177-3	32549-32557	networks	_
177-4	32558-32568	identified	_
177-5	32569-32571	in	_
177-6	32572-32575	the	_
177-7	32576-32583	current	_
177-8	32584-32589	study	_
177-9	32590-32597	include	_
177-10	32598-32601	the	_
177-11	32602-32606	mPFC	_
177-12	32607-32610	and	_
177-13	32611-32614	IFG	_
177-14	32614-32615	,	_
177-15	32616-32621	which	_
177-16	32622-32625	are	_
177-17	32626-32627	2	_
177-18	32628-32631	key	_
177-19	32632-32639	regions	_
177-20	32640-32648	involved	_
177-21	32649-32651	in	_
177-22	32652-32659	emotion	_
177-23	32660-32670	regulation	_
177-24	32671-32674	and	_
177-25	32675-32679	have	_
177-26	32680-32684	been	_
177-27	32685-32690	shown	_
177-28	32691-32693	to	_
177-29	32694-32701	exhibit	_
177-30	32702-32712	regulatory	_
177-31	32713-32723	influences	_
177-32	32724-32726	on	_
177-33	32727-32730	the	_
177-34	32731-32739	amygdala	_
177-35	32740-32746	during	_
177-36	32747-32750	the	_
177-37	32751-32761	inhibition	_
177-38	32762-32764	of	_
177-39	32765-32772	anxiety	_
177-40	32773-32776	and	_
177-41	32777-32785	negative	_
177-42	32786-32792	affect	_
177-43	32792-32793	.	_

#Text=More specifically, prior studies have shown that healthy individuals exhibit greater functional coupling between the amygdala and the mPFC and IFG during threat and that greater connectivity is associated with greater affect regulation efficiency.
178-1	32794-32798	More	_
178-2	32799-32811	specifically	_
178-3	32811-32812	,	_
178-4	32813-32818	prior	_
178-5	32819-32826	studies	_
178-6	32827-32831	have	_
178-7	32832-32837	shown	_
178-8	32838-32842	that	_
178-9	32843-32850	healthy	_
178-10	32851-32862	individuals	_
178-11	32863-32870	exhibit	_
178-12	32871-32878	greater	_
178-13	32879-32889	functional	_
178-14	32890-32898	coupling	_
178-15	32899-32906	between	_
178-16	32907-32910	the	_
178-17	32911-32919	amygdala	_
178-18	32920-32923	and	_
178-19	32924-32927	the	_
178-20	32928-32932	mPFC	_
178-21	32933-32936	and	_
178-22	32937-32940	IFG	_
178-23	32941-32947	during	_
178-24	32948-32954	threat	_
178-25	32955-32958	and	_
178-26	32959-32963	that	_
178-27	32964-32971	greater	_
178-28	32972-32984	connectivity	_
178-29	32985-32987	is	_
178-30	32988-32998	associated	_
178-31	32999-33003	with	_
178-32	33004-33011	greater	_
178-33	33012-33018	affect	_
178-34	33019-33029	regulation	_
178-35	33030-33040	efficiency	_
178-36	33040-33041	.	_

#Text=Meanwhile, individuals characterized by high levels of chronic anxiety (e.g., posttraumatic stress disorder, generalized anxiety disorder) evidence decreased functional connectivity between the amygdala and the mPFC/IFG.
179-1	33042-33051	Meanwhile	_
179-2	33051-33052	,	_
179-3	33053-33064	individuals	_
179-4	33065-33078	characterized	_
179-5	33079-33081	by	_
179-6	33082-33086	high	_
179-7	33087-33093	levels	_
179-8	33094-33096	of	_
179-9	33097-33104	chronic	_
179-10	33105-33112	anxiety	_
179-11	33113-33114	(	_
179-12	33114-33117	e.g	_
179-13	33117-33118	.	_
179-14	33118-33119	,	_
179-15	33120-33133	posttraumatic	_
179-16	33134-33140	stress	_
179-17	33141-33149	disorder	_
179-18	33149-33150	,	_
179-19	33151-33162	generalized	_
179-20	33163-33170	anxiety	_
179-21	33171-33179	disorder	_
179-22	33179-33180	)	_
179-23	33181-33189	evidence	_
179-24	33190-33199	decreased	_
179-25	33200-33210	functional	_
179-26	33211-33223	connectivity	_
179-27	33224-33231	between	_
179-28	33232-33235	the	_
179-29	33236-33244	amygdala	_
179-30	33245-33248	and	_
179-31	33249-33252	the	_
179-32	33253-33257	mPFC	_
179-33	33257-33258	/	_
179-34	33258-33261	IFG	_
179-35	33261-33262	.	_

#Text=Together, these studies suggest that decreased amygdala-PFC connectivity reflects deficiencies in downregulating negative affect.
180-1	33263-33271	Together	_
180-2	33271-33272	,	_
180-3	33273-33278	these	_
180-4	33279-33286	studies	_
180-5	33287-33294	suggest	_
180-6	33295-33299	that	_
180-7	33300-33309	decreased	_
180-8	33310-33322	amygdala-PFC	_
180-9	33323-33335	connectivity	_
180-10	33336-33344	reflects	_
180-11	33345-33357	deficiencies	_
180-12	33358-33360	in	_
180-13	33361-33375	downregulating	_
180-14	33376-33384	negative	_
180-15	33385-33391	affect	_
180-16	33391-33392	.	_

#Text=Individuals with lower levels of BDNF may therefore have difficulty modulating anticipatory anxiety, particularly in the context of a U-threat.
181-1	33393-33404	Individuals	_
181-2	33405-33409	with	_
181-3	33410-33415	lower	_
181-4	33416-33422	levels	_
181-5	33423-33425	of	_
181-6	33426-33430	BDNF	_
181-7	33431-33434	may	_
181-8	33435-33444	therefore	_
181-9	33445-33449	have	_
181-10	33450-33460	difficulty	_
181-11	33461-33471	modulating	_
181-12	33472-33484	anticipatory	_
181-13	33485-33492	anxiety	_
181-14	33492-33493	,	_
181-15	33494-33506	particularly	_
181-16	33507-33509	in	_
181-17	33510-33513	the	_
181-18	33514-33521	context	_
181-19	33522-33524	of	_
181-20	33525-33526	a	_
181-21	33527-33535	U-threat	_
181-22	33535-33536	.	_

#Text=This emotion regulation deficit could be 1 potential mechanism that contributes to the link between BDNF levels and multiple forms of psychopathology.
182-1	33537-33541	This	_
182-2	33542-33549	emotion	_
182-3	33550-33560	regulation	_
182-4	33561-33568	deficit	_
182-5	33569-33574	could	_
182-6	33575-33577	be	_
182-7	33578-33579	1	_
182-8	33580-33589	potential	_
182-9	33590-33599	mechanism	_
182-10	33600-33604	that	_
182-11	33605-33616	contributes	_
182-12	33617-33619	to	_
182-13	33620-33623	the	_
182-14	33624-33628	link	_
182-15	33629-33636	between	_
182-16	33637-33641	BDNF	_
182-17	33642-33648	levels	_
182-18	33649-33652	and	_
182-19	33653-33661	multiple	_
182-20	33662-33667	forms	_
182-21	33668-33670	of	_
182-22	33671-33686	psychopathology	_
182-23	33686-33687	.	_

#Text=The mPFC also plays an essential role in assessing risk and determining the subjective value of uncertain outcomes and has repeatedly been shown to be engaged during times of uncertainty.
183-1	33688-33691	The	_
183-2	33692-33696	mPFC	_
183-3	33697-33701	also	_
183-4	33702-33707	plays	_
183-5	33708-33710	an	_
183-6	33711-33720	essential	_
183-7	33721-33725	role	_
183-8	33726-33728	in	_
183-9	33729-33738	assessing	_
183-10	33739-33743	risk	_
183-11	33744-33747	and	_
183-12	33748-33759	determining	_
183-13	33760-33763	the	_
183-14	33764-33774	subjective	_
183-15	33775-33780	value	_
183-16	33781-33783	of	_
183-17	33784-33793	uncertain	_
183-18	33794-33802	outcomes	_
183-19	33803-33806	and	_
183-20	33807-33810	has	_
183-21	33811-33821	repeatedly	_
183-22	33822-33826	been	_
183-23	33827-33832	shown	_
183-24	33833-33835	to	_
183-25	33836-33838	be	_
183-26	33839-33846	engaged	_
183-27	33847-33853	during	_
183-28	33854-33859	times	_
183-29	33860-33862	of	_
183-30	33863-33874	uncertainty	_
183-31	33874-33875	.	_

#Text=Cross-talk between the amygdala and mPFC is necessary for effectively coding subjective value, and decreased functional connectivity between these regions could reflect abnormal salience processing of unpredictable threat cues.
184-1	33876-33886	Cross-talk	_
184-2	33887-33894	between	_
184-3	33895-33898	the	_
184-4	33899-33907	amygdala	_
184-5	33908-33911	and	_
184-6	33912-33916	mPFC	_
184-7	33917-33919	is	_
184-8	33920-33929	necessary	_
184-9	33930-33933	for	_
184-10	33934-33945	effectively	_
184-11	33946-33952	coding	_
184-12	33953-33963	subjective	_
184-13	33964-33969	value	_
184-14	33969-33970	,	_
184-15	33971-33974	and	_
184-16	33975-33984	decreased	_
184-17	33985-33995	functional	_
184-18	33996-34008	connectivity	_
184-19	34009-34016	between	_
184-20	34017-34022	these	_
184-21	34023-34030	regions	_
184-22	34031-34036	could	_
184-23	34037-34044	reflect	_
184-24	34045-34053	abnormal	_
184-25	34054-34062	salience	_
184-26	34063-34073	processing	_
184-27	34074-34076	of	_
184-28	34077-34090	unpredictable	_
184-29	34091-34097	threat	_
184-30	34098-34102	cues	_
184-31	34102-34103	.	_

#Text=Thus, a complementary or potentially alternative hypothesis is that individuals with lower levels of BDNF exhibit impairments in appraising the relative danger vs safety of the U-threat conditions and determining threat salience.
185-1	34104-34108	Thus	_
185-2	34108-34109	,	_
185-3	34110-34111	a	_
185-4	34112-34125	complementary	_
185-5	34126-34128	or	_
185-6	34129-34140	potentially	_
185-7	34141-34152	alternative	_
185-8	34153-34163	hypothesis	_
185-9	34164-34166	is	_
185-10	34167-34171	that	_
185-11	34172-34183	individuals	_
185-12	34184-34188	with	_
185-13	34189-34194	lower	_
185-14	34195-34201	levels	_
185-15	34202-34204	of	_
185-16	34205-34209	BDNF	_
185-17	34210-34217	exhibit	_
185-18	34218-34229	impairments	_
185-19	34230-34232	in	_
185-20	34233-34243	appraising	_
185-21	34244-34247	the	_
185-22	34248-34256	relative	_
185-23	34257-34263	danger	_
185-24	34264-34266	vs	_
185-25	34267-34273	safety	_
185-26	34274-34276	of	_
185-27	34277-34280	the	_
185-28	34281-34289	U-threat	_
185-29	34290-34300	conditions	_
185-30	34301-34304	and	_
185-31	34305-34316	determining	_
185-32	34317-34323	threat	_
185-33	34324-34332	salience	_
185-34	34332-34333	.	_

#Text=This is the first study, to our knowledge, to examine associations between plasma BDNF levels and amygdala circuit function during fear and anxiety states in humans, although prior studies have examined whether differences in BDNF polymorphisms are associated with patterns of functional connectivity, especially during resting state.
186-1	34334-34338	This	_
186-2	34339-34341	is	_
186-3	34342-34345	the	_
186-4	34346-34351	first	_
186-5	34352-34357	study	_
186-6	34357-34358	,	_
186-7	34359-34361	to	_
186-8	34362-34365	our	_
186-9	34366-34375	knowledge	_
186-10	34375-34376	,	_
186-11	34377-34379	to	_
186-12	34380-34387	examine	_
186-13	34388-34400	associations	_
186-14	34401-34408	between	_
186-15	34409-34415	plasma	_
186-16	34416-34420	BDNF	_
186-17	34421-34427	levels	_
186-18	34428-34431	and	_
186-19	34432-34440	amygdala	_
186-20	34441-34448	circuit	_
186-21	34449-34457	function	_
186-22	34458-34464	during	_
186-23	34465-34469	fear	_
186-24	34470-34473	and	_
186-25	34474-34481	anxiety	_
186-26	34482-34488	states	_
186-27	34489-34491	in	_
186-28	34492-34498	humans	_
186-29	34498-34499	,	_
186-30	34500-34508	although	_
186-31	34509-34514	prior	_
186-32	34515-34522	studies	_
186-33	34523-34527	have	_
186-34	34528-34536	examined	_
186-35	34537-34544	whether	_
186-36	34545-34556	differences	_
186-37	34557-34559	in	_
186-38	34560-34564	BDNF	_
186-39	34565-34578	polymorphisms	_
186-40	34579-34582	are	_
186-41	34583-34593	associated	_
186-42	34594-34598	with	_
186-43	34599-34607	patterns	_
186-44	34608-34610	of	_
186-45	34611-34621	functional	_
186-46	34622-34634	connectivity	_
186-47	34634-34635	,	_
186-48	34636-34646	especially	_
186-49	34647-34653	during	_
186-50	34654-34661	resting	_
186-51	34662-34667	state	_
186-52	34667-34668	.	_

#Text=At rest, Val66Met carriers (who may be deficient in BDNF) show abnormalities across several large-scale circuits, including the default-mode network, executive control network, and salience network.
187-1	34669-34671	At	_
187-2	34672-34676	rest	_
187-3	34676-34677	,	_
187-4	34678-34686	Val66Met	_
187-5	34687-34695	carriers	_
187-6	34696-34697	(	_
187-7	34697-34700	who	_
187-8	34701-34704	may	_
187-9	34705-34707	be	_
187-10	34708-34717	deficient	_
187-11	34718-34720	in	_
187-12	34721-34725	BDNF	_
187-13	34725-34726	)	_
187-14	34727-34731	show	_
187-15	34732-34745	abnormalities	_
187-16	34746-34752	across	_
187-17	34753-34760	several	_
187-18	34761-34772	large-scale	_
187-19	34773-34781	circuits	_
187-20	34781-34782	,	_
187-21	34783-34792	including	_
187-22	34793-34796	the	_
187-23	34797-34809	default-mode	_
187-24	34810-34817	network	_
187-25	34817-34818	,	_
187-26	34819-34828	executive	_
187-27	34829-34836	control	_
187-28	34837-34844	network	_
187-29	34844-34845	,	_
187-30	34846-34849	and	_
187-31	34850-34858	salience	_
187-32	34859-34866	network	_
187-33	34866-34867	.	_

#Text=A few studies have also reported amygdala abnormalities including increased connectivity between the amygdala and insula.
188-1	34868-34869	A	_
188-2	34870-34873	few	_
188-3	34874-34881	studies	_
188-4	34882-34886	have	_
188-5	34887-34891	also	_
188-6	34892-34900	reported	_
188-7	34901-34909	amygdala	_
188-8	34910-34923	abnormalities	_
188-9	34924-34933	including	_
188-10	34934-34943	increased	_
188-11	34944-34956	connectivity	_
188-12	34957-34964	between	_
188-13	34965-34968	the	_
188-14	34969-34977	amygdala	_
188-15	34978-34981	and	_
188-16	34982-34988	insula	_
188-17	34988-34989	.	_

#Text=It is therefore possible that individual differences in BDNF expression have more widespread impact on brain function, and the nature of this impact depends on environmental and emotional context (e.g., resting-state vs U-threat).
189-1	34990-34992	It	_
189-2	34993-34995	is	_
189-3	34996-35005	therefore	_
189-4	35006-35014	possible	_
189-5	35015-35019	that	_
189-6	35020-35030	individual	_
189-7	35031-35042	differences	_
189-8	35043-35045	in	_
189-9	35046-35050	BDNF	_
189-10	35051-35061	expression	_
189-11	35062-35066	have	_
189-12	35067-35071	more	_
189-13	35072-35082	widespread	_
189-14	35083-35089	impact	_
189-15	35090-35092	on	_
189-16	35093-35098	brain	_
189-17	35099-35107	function	_
189-18	35107-35108	,	_
189-19	35109-35112	and	_
189-20	35113-35116	the	_
189-21	35117-35123	nature	_
189-22	35124-35126	of	_
189-23	35127-35131	this	_
189-24	35132-35138	impact	_
189-25	35139-35146	depends	_
189-26	35147-35149	on	_
189-27	35150-35163	environmental	_
189-28	35164-35167	and	_
189-29	35168-35177	emotional	_
189-30	35178-35185	context	_
189-31	35186-35187	(	_
189-32	35187-35190	e.g	_
189-33	35190-35191	.	_
189-34	35191-35192	,	_
189-35	35193-35206	resting-state	_
189-36	35207-35209	vs	_
189-37	35210-35218	U-threat	_
189-38	35218-35219	)	_
189-39	35219-35220	.	_

#Text=We originally hypothesized that lower levels of BDNF and decreased amygdala-PFC functional connectivity would be associated with real-world problem drinking behaviors across all participants.
190-1	35221-35223	We	_
190-2	35224-35234	originally	_
190-3	35235-35247	hypothesized	_
190-4	35248-35252	that	_
190-5	35253-35258	lower	_
190-6	35259-35265	levels	_
190-7	35266-35268	of	_
190-8	35269-35273	BDNF	_
190-9	35274-35277	and	_
190-10	35278-35287	decreased	_
190-11	35288-35300	amygdala-PFC	_
190-12	35301-35311	functional	_
190-13	35312-35324	connectivity	_
190-14	35325-35330	would	_
190-15	35331-35333	be	_
190-16	35334-35344	associated	_
190-17	35345-35349	with	_
190-18	35350-35360	real-world	_
190-19	35361-35368	problem	_
190-20	35369-35377	drinking	_
190-21	35378-35387	behaviors	_
190-22	35388-35394	across	_
190-23	35395-35398	all	_
190-24	35399-35411	participants	_
190-25	35411-35412	.	_

#Text=However, within the AUD group, lower levels of BDNF and decreased amygdala-mPFC functional connectivity during U-threat were associated with more binge episodes in the past 60 days and a lower age of AUD onset, whereas there were no associations with drinking behaviors in controls.
191-1	35413-35420	However	_
191-2	35420-35421	,	_
191-3	35422-35428	within	_
191-4	35429-35432	the	_
191-5	35433-35436	AUD	_
191-6	35437-35442	group	_
191-7	35442-35443	,	_
191-8	35444-35449	lower	_
191-9	35450-35456	levels	_
191-10	35457-35459	of	_
191-11	35460-35464	BDNF	_
191-12	35465-35468	and	_
191-13	35469-35478	decreased	_
191-14	35479-35492	amygdala-mPFC	_
191-15	35493-35503	functional	_
191-16	35504-35516	connectivity	_
191-17	35517-35523	during	_
191-18	35524-35532	U-threat	_
191-19	35533-35537	were	_
191-20	35538-35548	associated	_
191-21	35549-35553	with	_
191-22	35554-35558	more	_
191-23	35559-35564	binge	_
191-24	35565-35573	episodes	_
191-25	35574-35576	in	_
191-26	35577-35580	the	_
191-27	35581-35585	past	_
191-28	35586-35588	60	_
191-29	35589-35593	days	_
191-30	35594-35597	and	_
191-31	35598-35599	a	_
191-32	35600-35605	lower	_
191-33	35606-35609	age	_
191-34	35610-35612	of	_
191-35	35613-35616	AUD	_
191-36	35617-35622	onset	_
191-37	35622-35623	,	_
191-38	35624-35631	whereas	_
191-39	35632-35637	there	_
191-40	35638-35642	were	_
191-41	35643-35645	no	_
191-42	35646-35658	associations	_
191-43	35659-35663	with	_
191-44	35664-35672	drinking	_
191-45	35673-35682	behaviors	_
191-46	35683-35685	in	_
191-47	35686-35694	controls	_
191-48	35694-35695	.	_

#Text=One factor that may have contributed to the moderating effect of group is the fact that the controls reported very low levels of alcohol consumption, resulting in a restricted range of drinking behaviors, whereas individuals with AUD reported substantial variability in their patterns of alcohol use.
192-1	35696-35699	One	_
192-2	35700-35706	factor	_
192-3	35707-35711	that	_
192-4	35712-35715	may	_
192-5	35716-35720	have	_
192-6	35721-35732	contributed	_
192-7	35733-35735	to	_
192-8	35736-35739	the	_
192-9	35740-35750	moderating	_
192-10	35751-35757	effect	_
192-11	35758-35760	of	_
192-12	35761-35766	group	_
192-13	35767-35769	is	_
192-14	35770-35773	the	_
192-15	35774-35778	fact	_
192-16	35779-35783	that	_
192-17	35784-35787	the	_
192-18	35788-35796	controls	_
192-19	35797-35805	reported	_
192-20	35806-35810	very	_
192-21	35811-35814	low	_
192-22	35815-35821	levels	_
192-23	35822-35824	of	_
192-24	35825-35832	alcohol	_
192-25	35833-35844	consumption	_
192-26	35844-35845	,	_
192-27	35846-35855	resulting	_
192-28	35856-35858	in	_
192-29	35859-35860	a	_
192-30	35861-35871	restricted	_
192-31	35872-35877	range	_
192-32	35878-35880	of	_
192-33	35881-35889	drinking	_
192-34	35890-35899	behaviors	_
192-35	35899-35900	,	_
192-36	35901-35908	whereas	_
192-37	35909-35920	individuals	_
192-38	35921-35925	with	_
192-39	35926-35929	AUD	_
192-40	35930-35938	reported	_
192-41	35939-35950	substantial	_
192-42	35951-35962	variability	_
192-43	35963-35965	in	_
192-44	35966-35971	their	_
192-45	35972-35980	patterns	_
192-46	35981-35983	of	_
192-47	35984-35991	alcohol	_
192-48	35992-35995	use	_
192-49	35995-35996	.	_

#Text=Although the purpose of including both controls and individuals with AUD in the sample was to capture a normal variable distribution to increase statistical power for dimensional analyses, in terms of the drinking behaviors, almost all of the variability was found in those with AUD.
193-1	35997-36005	Although	_
193-2	36006-36009	the	_
193-3	36010-36017	purpose	_
193-4	36018-36020	of	_
193-5	36021-36030	including	_
193-6	36031-36035	both	_
193-7	36036-36044	controls	_
193-8	36045-36048	and	_
193-9	36049-36060	individuals	_
193-10	36061-36065	with	_
193-11	36066-36069	AUD	_
193-12	36070-36072	in	_
193-13	36073-36076	the	_
193-14	36077-36083	sample	_
193-15	36084-36087	was	_
193-16	36088-36090	to	_
193-17	36091-36098	capture	_
193-18	36099-36100	a	_
193-19	36101-36107	normal	_
193-20	36108-36116	variable	_
193-21	36117-36129	distribution	_
193-22	36130-36132	to	_
193-23	36133-36141	increase	_
193-24	36142-36153	statistical	_
193-25	36154-36159	power	_
193-26	36160-36163	for	_
193-27	36164-36175	dimensional	_
193-28	36176-36184	analyses	_
193-29	36184-36185	,	_
193-30	36186-36188	in	_
193-31	36189-36194	terms	_
193-32	36195-36197	of	_
193-33	36198-36201	the	_
193-34	36202-36210	drinking	_
193-35	36211-36220	behaviors	_
193-36	36220-36221	,	_
193-37	36222-36228	almost	_
193-38	36229-36232	all	_
193-39	36233-36235	of	_
193-40	36236-36239	the	_
193-41	36240-36251	variability	_
193-42	36252-36255	was	_
193-43	36256-36261	found	_
193-44	36262-36264	in	_
193-45	36265-36270	those	_
193-46	36271-36275	with	_
193-47	36276-36279	AUD	_
193-48	36279-36280	.	_

#Text=With that said, it is also worth highlighting that similarly found that plasma BDNF levels were negatively correlated with drinks consumed per day but only in individuals who exceeded 3 or more drinks per day.
194-1	36281-36285	With	_
194-2	36286-36290	that	_
194-3	36291-36295	said	_
194-4	36295-36296	,	_
194-5	36297-36299	it	_
194-6	36300-36302	is	_
194-7	36303-36307	also	_
194-8	36308-36313	worth	_
194-9	36314-36326	highlighting	_
194-10	36327-36331	that	_
194-11	36332-36341	similarly	_
194-12	36342-36347	found	_
194-13	36348-36352	that	_
194-14	36353-36359	plasma	_
194-15	36360-36364	BDNF	_
194-16	36365-36371	levels	_
194-17	36372-36376	were	_
194-18	36377-36387	negatively	_
194-19	36388-36398	correlated	_
194-20	36399-36403	with	_
194-21	36404-36410	drinks	_
194-22	36411-36419	consumed	_
194-23	36420-36423	per	_
194-24	36424-36427	day	_
194-25	36428-36431	but	_
194-26	36432-36436	only	_
194-27	36437-36439	in	_
194-28	36440-36451	individuals	_
194-29	36452-36455	who	_
194-30	36456-36464	exceeded	_
194-31	36465-36466	3	_
194-32	36467-36469	or	_
194-33	36470-36474	more	_
194-34	36475-36481	drinks	_
194-35	36482-36485	per	_
194-36	36486-36489	day	_
194-37	36489-36490	.	_

#Text=Thus, it is possible that specific associations between BDNF, neural function, and alcohol abuse are only observed in heavy drinkers.
195-1	36491-36495	Thus	_
195-2	36495-36496	,	_
195-3	36497-36499	it	_
195-4	36500-36502	is	_
195-5	36503-36511	possible	_
195-6	36512-36516	that	_
195-7	36517-36525	specific	_
195-8	36526-36538	associations	_
195-9	36539-36546	between	_
195-10	36547-36551	BDNF	_
195-11	36551-36552	,	_
195-12	36553-36559	neural	_
195-13	36560-36568	function	_
195-14	36568-36569	,	_
195-15	36570-36573	and	_
195-16	36574-36581	alcohol	_
195-17	36582-36587	abuse	_
195-18	36588-36591	are	_
195-19	36592-36596	only	_
195-20	36597-36605	observed	_
195-21	36606-36608	in	_
195-22	36609-36614	heavy	_
195-23	36615-36623	drinkers	_
195-24	36623-36624	.	_

#Text=Although BDNF and drinking variables were negatively associated with each other, we found that on average, individuals with AUD had higher levels of plasma BDNF compared with controls.
196-1	36625-36633	Although	_
196-2	36634-36638	BDNF	_
196-3	36639-36642	and	_
196-4	36643-36651	drinking	_
196-5	36652-36661	variables	_
196-6	36662-36666	were	_
196-7	36667-36677	negatively	_
196-8	36678-36688	associated	_
196-9	36689-36693	with	_
196-10	36694-36698	each	_
196-11	36699-36704	other	_
196-12	36704-36705	,	_
196-13	36706-36708	we	_
196-14	36709-36714	found	_
196-15	36715-36719	that	_
196-16	36720-36722	on	_
196-17	36723-36730	average	_
196-18	36730-36731	,	_
196-19	36732-36743	individuals	_
196-20	36744-36748	with	_
196-21	36749-36752	AUD	_
196-22	36753-36756	had	_
196-23	36757-36763	higher	_
196-24	36764-36770	levels	_
196-25	36771-36773	of	_
196-26	36774-36780	plasma	_
196-27	36781-36785	BDNF	_
196-28	36786-36794	compared	_
196-29	36795-36799	with	_
196-30	36800-36808	controls	_
196-31	36808-36809	.	_

#Text=This is consistent with a handful of other human studies and highlights the heterogeneous nature of the AUD diagnosis.
197-1	36810-36814	This	_
197-2	36815-36817	is	_
197-3	36818-36828	consistent	_
197-4	36829-36833	with	_
197-5	36834-36835	a	_
197-6	36836-36843	handful	_
197-7	36844-36846	of	_
197-8	36847-36852	other	_
197-9	36853-36858	human	_
197-10	36859-36866	studies	_
197-11	36867-36870	and	_
197-12	36871-36881	highlights	_
197-13	36882-36885	the	_
197-14	36886-36899	heterogeneous	_
197-15	36900-36906	nature	_
197-16	36907-36909	of	_
197-17	36910-36913	the	_
197-18	36914-36917	AUD	_
197-19	36918-36927	diagnosis	_
197-20	36927-36928	.	_

#Text=The current set of findings, as a whole, reinforces the utility of examining individual differences at the biological level to improve understanding of molecular, neural, and behavioral relationships.
198-1	36929-36932	The	_
198-2	36933-36940	current	_
198-3	36941-36944	set	_
198-4	36945-36947	of	_
198-5	36948-36956	findings	_
198-6	36956-36957	,	_
198-7	36958-36960	as	_
198-8	36961-36962	a	_
198-9	36963-36968	whole	_
198-10	36968-36969	,	_
198-11	36970-36980	reinforces	_
198-12	36981-36984	the	_
198-13	36985-36992	utility	_
198-14	36993-36995	of	_
198-15	36996-37005	examining	_
198-16	37006-37016	individual	_
198-17	37017-37028	differences	_
198-18	37029-37031	at	_
198-19	37032-37035	the	_
198-20	37036-37046	biological	_
198-21	37047-37052	level	_
198-22	37053-37055	to	_
198-23	37056-37063	improve	_
198-24	37064-37077	understanding	_
198-25	37078-37080	of	_
198-26	37081-37090	molecular	_
198-27	37090-37091	,	_
198-28	37092-37098	neural	_
198-29	37098-37099	,	_
198-30	37100-37103	and	_
198-31	37104-37114	behavioral	_
198-32	37115-37128	relationships	_
198-33	37128-37129	.	_

#Text=The links between the biological and alcohol-related variables in individuals with AUD are therefore important.
199-1	37130-37133	The	_
199-2	37134-37139	links	_
199-3	37140-37147	between	_
199-4	37148-37151	the	_
199-5	37152-37162	biological	_
199-6	37163-37166	and	_
199-7	37167-37182	alcohol-related	_
199-8	37183-37192	variables	_
199-9	37193-37195	in	_
199-10	37196-37207	individuals	_
199-11	37208-37212	with	_
199-12	37213-37216	AUD	_
199-13	37217-37220	are	_
199-14	37221-37230	therefore	_
199-15	37231-37240	important	_
199-16	37240-37241	.	_

#Text=Binge drinking and earlier age of AUD onset are 2 indicators of AUD severity as both variables are associated with poorer AUD prognosis and a host of negative biopsychosocial outcomes.
200-1	37242-37247	Binge	_
200-2	37248-37256	drinking	_
200-3	37257-37260	and	_
200-4	37261-37268	earlier	_
200-5	37269-37272	age	_
200-6	37273-37275	of	_
200-7	37276-37279	AUD	_
200-8	37280-37285	onset	_
200-9	37286-37289	are	_
200-10	37290-37291	2	_
200-11	37292-37302	indicators	_
200-12	37303-37305	of	_
200-13	37306-37309	AUD	_
200-14	37310-37318	severity	_
200-15	37319-37321	as	_
200-16	37322-37326	both	_
200-17	37327-37336	variables	_
200-18	37337-37340	are	_
200-19	37341-37351	associated	_
200-20	37352-37356	with	_
200-21	37357-37363	poorer	_
200-22	37364-37367	AUD	_
200-23	37368-37377	prognosis	_
200-24	37378-37381	and	_
200-25	37382-37383	a	_
200-26	37384-37388	host	_
200-27	37389-37391	of	_
200-28	37392-37400	negative	_
200-29	37401-37416	biopsychosocial	_
200-30	37417-37425	outcomes	_
200-31	37425-37426	.	_

#Text=Lower levels of plasma BDNF and decreased amygdala-PFC functional connectivity during U-threat may be 2 related individual difference factors that contribute to these specific aspects of AUD severity.
201-1	37427-37432	Lower	_
201-2	37433-37439	levels	_
201-3	37440-37442	of	_
201-4	37443-37449	plasma	_
201-5	37450-37454	BDNF	_
201-6	37455-37458	and	_
201-7	37459-37468	decreased	_
201-8	37469-37481	amygdala-PFC	_
201-9	37482-37492	functional	_
201-10	37493-37505	connectivity	_
201-11	37506-37512	during	_
201-12	37513-37521	U-threat	_
201-13	37522-37525	may	_
201-14	37526-37528	be	_
201-15	37529-37530	2	_
201-16	37531-37538	related	_
201-17	37539-37549	individual	_
201-18	37550-37560	difference	_
201-19	37561-37568	factors	_
201-20	37569-37573	that	_
201-21	37574-37584	contribute	_
201-22	37585-37587	to	_
201-23	37588-37593	these	_
201-24	37594-37602	specific	_
201-25	37603-37610	aspects	_
201-26	37611-37613	of	_
201-27	37614-37617	AUD	_
201-28	37618-37626	severity	_
201-29	37626-37627	.	_

#Text=Interestingly, separate studies have previously found associations between earlier age of AUD onset and lower levels of BDNF in amygdala and decreased amygdala-PFC functional connectivity.
202-1	37628-37641	Interestingly	_
202-2	37641-37642	,	_
202-3	37643-37651	separate	_
202-4	37652-37659	studies	_
202-5	37660-37664	have	_
202-6	37665-37675	previously	_
202-7	37676-37681	found	_
202-8	37682-37694	associations	_
202-9	37695-37702	between	_
202-10	37703-37710	earlier	_
202-11	37711-37714	age	_
202-12	37715-37717	of	_
202-13	37718-37721	AUD	_
202-14	37722-37727	onset	_
202-15	37728-37731	and	_
202-16	37732-37737	lower	_
202-17	37738-37744	levels	_
202-18	37745-37747	of	_
202-19	37748-37752	BDNF	_
202-20	37753-37755	in	_
202-21	37756-37764	amygdala	_
202-22	37765-37768	and	_
202-23	37769-37778	decreased	_
202-24	37779-37791	amygdala-PFC	_
202-25	37792-37802	functional	_
202-26	37803-37815	connectivity	_
202-27	37815-37816	.	_

#Text=Increased alcohol consumption has also previously been associated with decreased amygdala-PFC functional connectivity and lower peripheral BDNF levels, though the majority of human studies report no associations between BDNF levels and drinking behaviors (e.g.,).
203-1	37817-37826	Increased	_
203-2	37827-37834	alcohol	_
203-3	37835-37846	consumption	_
203-4	37847-37850	has	_
203-5	37851-37855	also	_
203-6	37856-37866	previously	_
203-7	37867-37871	been	_
203-8	37872-37882	associated	_
203-9	37883-37887	with	_
203-10	37888-37897	decreased	_
203-11	37898-37910	amygdala-PFC	_
203-12	37911-37921	functional	_
203-13	37922-37934	connectivity	_
203-14	37935-37938	and	_
203-15	37939-37944	lower	_
203-16	37945-37955	peripheral	_
203-17	37956-37960	BDNF	_
203-18	37961-37967	levels	_
203-19	37967-37968	,	_
203-20	37969-37975	though	_
203-21	37976-37979	the	_
203-22	37980-37988	majority	_
203-23	37989-37991	of	_
203-24	37992-37997	human	_
203-25	37998-38005	studies	_
203-26	38006-38012	report	_
203-27	38013-38015	no	_
203-28	38016-38028	associations	_
203-29	38029-38036	between	_
203-30	38037-38041	BDNF	_
203-31	38042-38048	levels	_
203-32	38049-38052	and	_
203-33	38053-38061	drinking	_
203-34	38062-38071	behaviors	_
203-35	38072-38073	(	_
203-36	38073-38076	e.g	_
203-37	38076-38077	.	_
203-38	38077-38078	,	_
203-39	38078-38079	)	_
203-40	38079-38080	.	_

#Text=The current study demonstrates for the first time, to our knowledge, associations across these variables within the same sample and suggests that within individuals with AUD, BDNF, and amygdala-mPFC functional connectivity during U-threat relate to more risky and chronic patterns of alcohol abuse.
204-1	38081-38084	The	_
204-2	38085-38092	current	_
204-3	38093-38098	study	_
204-4	38099-38111	demonstrates	_
204-5	38112-38115	for	_
204-6	38116-38119	the	_
204-7	38120-38125	first	_
204-8	38126-38130	time	_
204-9	38130-38131	,	_
204-10	38132-38134	to	_
204-11	38135-38138	our	_
204-12	38139-38148	knowledge	_
204-13	38148-38149	,	_
204-14	38150-38162	associations	_
204-15	38163-38169	across	_
204-16	38170-38175	these	_
204-17	38176-38185	variables	_
204-18	38186-38192	within	_
204-19	38193-38196	the	_
204-20	38197-38201	same	_
204-21	38202-38208	sample	_
204-22	38209-38212	and	_
204-23	38213-38221	suggests	_
204-24	38222-38226	that	_
204-25	38227-38233	within	_
204-26	38234-38245	individuals	_
204-27	38246-38250	with	_
204-28	38251-38254	AUD	_
204-29	38254-38255	,	_
204-30	38256-38260	BDNF	_
204-31	38260-38261	,	_
204-32	38262-38265	and	_
204-33	38266-38279	amygdala-mPFC	_
204-34	38280-38290	functional	_
204-35	38291-38303	connectivity	_
204-36	38304-38310	during	_
204-37	38311-38319	U-threat	_
204-38	38320-38326	relate	_
204-39	38327-38329	to	_
204-40	38330-38334	more	_
204-41	38335-38340	risky	_
204-42	38341-38344	and	_
204-43	38345-38352	chronic	_
204-44	38353-38361	patterns	_
204-45	38362-38364	of	_
204-46	38365-38372	alcohol	_
204-47	38373-38378	abuse	_
204-48	38378-38379	.	_

#Text=Given the current pattern of results, targeting amygdala-mPFC functional connectivity, particularly during anxiety, via BDNF expression (or other strategies) may improve drinking outcomes.
205-1	38380-38385	Given	_
205-2	38386-38389	the	_
205-3	38390-38397	current	_
205-4	38398-38405	pattern	_
205-5	38406-38408	of	_
205-6	38409-38416	results	_
205-7	38416-38417	,	_
205-8	38418-38427	targeting	_
205-9	38428-38441	amygdala-mPFC	_
205-10	38442-38452	functional	_
205-11	38453-38465	connectivity	_
205-12	38465-38466	,	_
205-13	38467-38479	particularly	_
205-14	38480-38486	during	_
205-15	38487-38494	anxiety	_
205-16	38494-38495	,	_
205-17	38496-38499	via	_
205-18	38500-38504	BDNF	_
205-19	38505-38515	expression	_
205-20	38516-38517	(	_
205-21	38517-38519	or	_
205-22	38520-38525	other	_
205-23	38526-38536	strategies	_
205-24	38536-38537	)	_
205-25	38538-38541	may	_
205-26	38542-38549	improve	_
205-27	38550-38558	drinking	_
205-28	38559-38567	outcomes	_
205-29	38567-38568	.	_

#Text=As briefly noted, decreased BDNF levels in the mPFC and amygdala have been implicated in excessive alcohol use.
206-1	38569-38571	As	_
206-2	38572-38579	briefly	_
206-3	38580-38585	noted	_
206-4	38585-38586	,	_
206-5	38587-38596	decreased	_
206-6	38597-38601	BDNF	_
206-7	38602-38608	levels	_
206-8	38609-38611	in	_
206-9	38612-38615	the	_
206-10	38616-38620	mPFC	_
206-11	38621-38624	and	_
206-12	38625-38633	amygdala	_
206-13	38634-38638	have	_
206-14	38639-38643	been	_
206-15	38644-38654	implicated	_
206-16	38655-38657	in	_
206-17	38658-38667	excessive	_
206-18	38668-38675	alcohol	_
206-19	38676-38679	use	_
206-20	38679-38680	.	_

#Text=In animals, infusion of BDNF or increasing BDNF via inhibition of miRNAs in the mPFC decreases alcohol consumption and cocaine self-administration, and BDNF infusion in the amygdala attenuated anxiety-like behaviors during ethanol withdrawal in rats.
207-1	38681-38683	In	_
207-2	38684-38691	animals	_
207-3	38691-38692	,	_
207-4	38693-38701	infusion	_
207-5	38702-38704	of	_
207-6	38705-38709	BDNF	_
207-7	38710-38712	or	_
207-8	38713-38723	increasing	_
207-9	38724-38728	BDNF	_
207-10	38729-38732	via	_
207-11	38733-38743	inhibition	_
207-12	38744-38746	of	_
207-13	38747-38753	miRNAs	_
207-14	38754-38756	in	_
207-15	38757-38760	the	_
207-16	38761-38765	mPFC	_
207-17	38766-38775	decreases	_
207-18	38776-38783	alcohol	_
207-19	38784-38795	consumption	_
207-20	38796-38799	and	_
207-21	38800-38807	cocaine	_
207-22	38808-38827	self-administration	_
207-23	38827-38828	,	_
207-24	38829-38832	and	_
207-25	38833-38837	BDNF	_
207-26	38838-38846	infusion	_
207-27	38847-38849	in	_
207-28	38850-38853	the	_
207-29	38854-38862	amygdala	_
207-30	38863-38873	attenuated	_
207-31	38874-38886	anxiety-like	_
207-32	38887-38896	behaviors	_
207-33	38897-38903	during	_
207-34	38904-38911	ethanol	_
207-35	38912-38922	withdrawal	_
207-36	38923-38925	in	_
207-37	38926-38930	rats	_
207-38	38930-38931	.	_

#Text=The amygdala-mPFC circuit is therefore a potential key treatment target for novel AUD interventions.
208-1	38932-38935	The	_
208-2	38936-38949	amygdala-mPFC	_
208-3	38950-38957	circuit	_
208-4	38958-38960	is	_
208-5	38961-38970	therefore	_
208-6	38971-38972	a	_
208-7	38973-38982	potential	_
208-8	38983-38986	key	_
208-9	38987-38996	treatment	_
208-10	38997-39003	target	_
208-11	39004-39007	for	_
208-12	39008-39013	novel	_
208-13	39014-39017	AUD	_
208-14	39018-39031	interventions	_
208-15	39031-39032	.	_

#Text=The relationship between plasma BDNF levels and amygdala-PFC connectivity during U-threat, but not P-threat, is noteworthy.
209-1	39033-39036	The	_
209-2	39037-39049	relationship	_
209-3	39050-39057	between	_
209-4	39058-39064	plasma	_
209-5	39065-39069	BDNF	_
209-6	39070-39076	levels	_
209-7	39077-39080	and	_
209-8	39081-39093	amygdala-PFC	_
209-9	39094-39106	connectivity	_
209-10	39107-39113	during	_
209-11	39114-39122	U-threat	_
209-12	39122-39123	,	_
209-13	39124-39127	but	_
209-14	39128-39131	not	_
209-15	39132-39140	P-threat	_
209-16	39140-39141	,	_
209-17	39142-39144	is	_
209-18	39145-39155	noteworthy	_
209-19	39155-39156	.	_

#Text=Anxiety and fear are separable aversive states, and accumulating research suggests that exaggerated anticipatory anxiety during U-threat is uniquely involved in the pathophysiology of AUD.
210-1	39157-39164	Anxiety	_
210-2	39165-39168	and	_
210-3	39169-39173	fear	_
210-4	39174-39177	are	_
210-5	39178-39187	separable	_
210-6	39188-39196	aversive	_
210-7	39197-39203	states	_
210-8	39203-39204	,	_
210-9	39205-39208	and	_
210-10	39209-39221	accumulating	_
210-11	39222-39230	research	_
210-12	39231-39239	suggests	_
210-13	39240-39244	that	_
210-14	39245-39256	exaggerated	_
210-15	39257-39269	anticipatory	_
210-16	39270-39277	anxiety	_
210-17	39278-39284	during	_
210-18	39285-39293	U-threat	_
210-19	39294-39296	is	_
210-20	39297-39305	uniquely	_
210-21	39306-39314	involved	_
210-22	39315-39317	in	_
210-23	39318-39321	the	_
210-24	39322-39337	pathophysiology	_
210-25	39338-39340	of	_
210-26	39341-39344	AUD	_
210-27	39344-39345	.	_

#Text=We have repeatedly demonstrated that individuals with both current and remitted AUD display exaggerated behavioral and neural reactivity to U-threat, but not P-threat, compared with controls (; Gorka et al., in press).
211-1	39346-39348	We	_
211-2	39349-39353	have	_
211-3	39354-39364	repeatedly	_
211-4	39365-39377	demonstrated	_
211-5	39378-39382	that	_
211-6	39383-39394	individuals	_
211-7	39395-39399	with	_
211-8	39400-39404	both	_
211-9	39405-39412	current	_
211-10	39413-39416	and	_
211-11	39417-39425	remitted	_
211-12	39426-39429	AUD	_
211-13	39430-39437	display	_
211-14	39438-39449	exaggerated	_
211-15	39450-39460	behavioral	_
211-16	39461-39464	and	_
211-17	39465-39471	neural	_
211-18	39472-39482	reactivity	_
211-19	39483-39485	to	_
211-20	39486-39494	U-threat	_
211-21	39494-39495	,	_
211-22	39496-39499	but	_
211-23	39500-39503	not	_
211-24	39504-39512	P-threat	_
211-25	39512-39513	,	_
211-26	39514-39522	compared	_
211-27	39523-39527	with	_
211-28	39528-39536	controls	_
211-29	39537-39538	(	_
211-30	39538-39539	;	_
211-31	39540-39545	Gorka	_
211-32	39546-39548	et	_
211-33	39549-39551	al	_
211-34	39551-39552	.	_
211-35	39552-39553	,	_
211-36	39554-39556	in	_
211-37	39557-39562	press	_
211-38	39562-39563	)	_
211-39	39563-39564	.	_

#Text=It has also been shown in humans that acute alcohol administration selectively and preferentially dampens aversive reactivity to U-threat relative to P-threat.
212-1	39565-39567	It	_
212-2	39568-39571	has	_
212-3	39572-39576	also	_
212-4	39577-39581	been	_
212-5	39582-39587	shown	_
212-6	39588-39590	in	_
212-7	39591-39597	humans	_
212-8	39598-39602	that	_
212-9	39603-39608	acute	_
212-10	39609-39616	alcohol	_
212-11	39617-39631	administration	_
212-12	39632-39643	selectively	_
212-13	39644-39647	and	_
212-14	39648-39662	preferentially	_
212-15	39663-39670	dampens	_
212-16	39671-39679	aversive	_
212-17	39680-39690	reactivity	_
212-18	39691-39693	to	_
212-19	39694-39702	U-threat	_
212-20	39703-39711	relative	_
212-21	39712-39714	to	_
212-22	39715-39723	P-threat	_
212-23	39723-39724	.	_

#Text=Targeting neural dysfunction during U-threat, specifically, may therefore have the most robust impact on alcohol behaviors.
213-1	39725-39734	Targeting	_
213-2	39735-39741	neural	_
213-3	39742-39753	dysfunction	_
213-4	39754-39760	during	_
213-5	39761-39769	U-threat	_
213-6	39769-39770	,	_
213-7	39771-39783	specifically	_
213-8	39783-39784	,	_
213-9	39785-39788	may	_
213-10	39789-39798	therefore	_
213-11	39799-39803	have	_
213-12	39804-39807	the	_
213-13	39808-39812	most	_
213-14	39813-39819	robust	_
213-15	39820-39826	impact	_
213-16	39827-39829	on	_
213-17	39830-39837	alcohol	_
213-18	39838-39847	behaviors	_
213-19	39847-39848	.	_

#Text=The current study had numerous strengths but also several limitations.
214-1	39849-39852	The	_
214-2	39853-39860	current	_
214-3	39861-39866	study	_
214-4	39867-39870	had	_
214-5	39871-39879	numerous	_
214-6	39880-39889	strengths	_
214-7	39890-39893	but	_
214-8	39894-39898	also	_
214-9	39899-39906	several	_
214-10	39907-39918	limitations	_
214-11	39918-39919	.	_

#Text=First, blood samples for plasma BDNF extraction were collected 1–7 days prior to the fMRI session, and this time lag in data collection may have introduced unknown confounds in the association between BDNF levels and amygdala reactivity and connectivity.
215-1	39920-39925	First	_
215-2	39925-39926	,	_
215-3	39927-39932	blood	_
215-4	39933-39940	samples	_
215-5	39941-39944	for	_
215-6	39945-39951	plasma	_
215-7	39952-39956	BDNF	_
215-8	39957-39967	extraction	_
215-9	39968-39972	were	_
215-10	39973-39982	collected	_
215-11	39983-39984	1	_
215-12	39984-39985	–	_
215-13	39985-39986	7	_
215-14	39987-39991	days	_
215-15	39992-39997	prior	_
215-16	39998-40000	to	_
215-17	40001-40004	the	_
215-18	40005-40009	fMRI	_
215-19	40010-40017	session	_
215-20	40017-40018	,	_
215-21	40019-40022	and	_
215-22	40023-40027	this	_
215-23	40028-40032	time	_
215-24	40033-40036	lag	_
215-25	40037-40039	in	_
215-26	40040-40044	data	_
215-27	40045-40055	collection	_
215-28	40056-40059	may	_
215-29	40060-40064	have	_
215-30	40065-40075	introduced	_
215-31	40076-40083	unknown	_
215-32	40084-40093	confounds	_
215-33	40094-40096	in	_
215-34	40097-40100	the	_
215-35	40101-40112	association	_
215-36	40113-40120	between	_
215-37	40121-40125	BDNF	_
215-38	40126-40132	levels	_
215-39	40133-40136	and	_
215-40	40137-40145	amygdala	_
215-41	40146-40156	reactivity	_
215-42	40157-40160	and	_
215-43	40161-40173	connectivity	_
215-44	40173-40174	.	_

#Text=There were also unmeasured factors, known to influence BDNF expression, which could have contributed to BDNF levels on the day of extraction (e.g., sleep deprivation).
216-1	40175-40180	There	_
216-2	40181-40185	were	_
216-3	40186-40190	also	_
216-4	40191-40201	unmeasured	_
216-5	40202-40209	factors	_
216-6	40209-40210	,	_
216-7	40211-40216	known	_
216-8	40217-40219	to	_
216-9	40220-40229	influence	_
216-10	40230-40234	BDNF	_
216-11	40235-40245	expression	_
216-12	40245-40246	,	_
216-13	40247-40252	which	_
216-14	40253-40258	could	_
216-15	40259-40263	have	_
216-16	40264-40275	contributed	_
216-17	40276-40278	to	_
216-18	40279-40283	BDNF	_
216-19	40284-40290	levels	_
216-20	40291-40293	on	_
216-21	40294-40297	the	_
216-22	40298-40301	day	_
216-23	40302-40304	of	_
216-24	40305-40315	extraction	_
216-25	40316-40317	(	_
216-26	40317-40320	e.g	_
216-27	40320-40321	.	_
216-28	40321-40322	,	_
216-29	40323-40328	sleep	_
216-30	40329-40340	deprivation	_
216-31	40340-40341	)	_
216-32	40341-40342	.	_

#Text=To capture a more reliable estimate of BDNF levels, repeated measurements, spaced in time, would be beneficial.
217-1	40343-40345	To	_
217-2	40346-40353	capture	_
217-3	40354-40355	a	_
217-4	40356-40360	more	_
217-5	40361-40369	reliable	_
217-6	40370-40378	estimate	_
217-7	40379-40381	of	_
217-8	40382-40386	BDNF	_
217-9	40387-40393	levels	_
217-10	40393-40394	,	_
217-11	40395-40403	repeated	_
217-12	40404-40416	measurements	_
217-13	40416-40417	,	_
217-14	40418-40424	spaced	_
217-15	40425-40427	in	_
217-16	40428-40432	time	_
217-17	40432-40433	,	_
217-18	40434-40439	would	_
217-19	40440-40442	be	_
217-20	40443-40453	beneficial	_
217-21	40453-40454	.	_

#Text=Second, we restricted our analyses to the amygdala and amygdala-PFC circuit given the robust animal literature implicating dysfunction in these areas; however, it is possible that other neural regions and circuits are also related to individual differences in plasma BDNF.
218-1	40455-40461	Second	_
218-2	40461-40462	,	_
218-3	40463-40465	we	_
218-4	40466-40476	restricted	_
218-5	40477-40480	our	_
218-6	40481-40489	analyses	_
218-7	40490-40492	to	_
218-8	40493-40496	the	_
218-9	40497-40505	amygdala	_
218-10	40506-40509	and	_
218-11	40510-40522	amygdala-PFC	_
218-12	40523-40530	circuit	_
218-13	40531-40536	given	_
218-14	40537-40540	the	_
218-15	40541-40547	robust	_
218-16	40548-40554	animal	_
218-17	40555-40565	literature	_
218-18	40566-40577	implicating	_
218-19	40578-40589	dysfunction	_
218-20	40590-40592	in	_
218-21	40593-40598	these	_
218-22	40599-40604	areas	_
218-23	40604-40605	;	_
218-24	40606-40613	however	_
218-25	40613-40614	,	_
218-26	40615-40617	it	_
218-27	40618-40620	is	_
218-28	40621-40629	possible	_
218-29	40630-40634	that	_
218-30	40635-40640	other	_
218-31	40641-40647	neural	_
218-32	40648-40655	regions	_
218-33	40656-40659	and	_
218-34	40660-40668	circuits	_
218-35	40669-40672	are	_
218-36	40673-40677	also	_
218-37	40678-40685	related	_
218-38	40686-40688	to	_
218-39	40689-40699	individual	_
218-40	40700-40711	differences	_
218-41	40712-40714	in	_
218-42	40715-40721	plasma	_
218-43	40722-40726	BDNF	_
218-44	40726-40727	.	_

#Text=Third, the total sample size was modest and subgroup cell sizes for AUD compared with controls was small.
219-1	40728-40733	Third	_
219-2	40733-40734	,	_
219-3	40735-40738	the	_
219-4	40739-40744	total	_
219-5	40745-40751	sample	_
219-6	40752-40756	size	_
219-7	40757-40760	was	_
219-8	40761-40767	modest	_
219-9	40768-40771	and	_
219-10	40772-40780	subgroup	_
219-11	40781-40785	cell	_
219-12	40786-40791	sizes	_
219-13	40792-40795	for	_
219-14	40796-40799	AUD	_
219-15	40800-40808	compared	_
219-16	40809-40813	with	_
219-17	40814-40822	controls	_
219-18	40823-40826	was	_
219-19	40827-40832	small	_
219-20	40832-40833	.	_

#Text=This issue limited statistical power and may have prevented the detection of additional associations.
220-1	40834-40838	This	_
220-2	40839-40844	issue	_
220-3	40845-40852	limited	_
220-4	40853-40864	statistical	_
220-5	40865-40870	power	_
220-6	40871-40874	and	_
220-7	40875-40878	may	_
220-8	40879-40883	have	_
220-9	40884-40893	prevented	_
220-10	40894-40897	the	_
220-11	40898-40907	detection	_
220-12	40908-40910	of	_
220-13	40911-40921	additional	_
220-14	40922-40934	associations	_
220-15	40934-40935	.	_

#Text=Lastly, the current study was correlational, and we are unable to make inferences about the directionality of the associations between BDNF, functional connectivity, and drinking behaviors.
221-1	40936-40942	Lastly	_
221-2	40942-40943	,	_
221-3	40944-40947	the	_
221-4	40948-40955	current	_
221-5	40956-40961	study	_
221-6	40962-40965	was	_
221-7	40966-40979	correlational	_
221-8	40979-40980	,	_
221-9	40981-40984	and	_
221-10	40985-40987	we	_
221-11	40988-40991	are	_
221-12	40992-40998	unable	_
221-13	40999-41001	to	_
221-14	41002-41006	make	_
221-15	41007-41017	inferences	_
221-16	41018-41023	about	_
221-17	41024-41027	the	_
221-18	41028-41042	directionality	_
221-19	41043-41045	of	_
221-20	41046-41049	the	_
221-21	41050-41062	associations	_
221-22	41063-41070	between	_
221-23	41071-41075	BDNF	_
221-24	41075-41076	,	_
221-25	41077-41087	functional	_
221-26	41088-41100	connectivity	_
221-27	41100-41101	,	_
221-28	41102-41105	and	_
221-29	41106-41114	drinking	_
221-30	41115-41124	behaviors	_
221-31	41124-41125	.	_

#Text=Related, to comprehensively test associations across study measures, corrections for multiple comparison were not applied to the correlations between biological variables and drinking behaviors.
222-1	41126-41133	Related	_
222-2	41133-41134	,	_
222-3	41135-41137	to	_
222-4	41138-41153	comprehensively	_
222-5	41154-41158	test	_
222-6	41159-41171	associations	_
222-7	41172-41178	across	_
222-8	41179-41184	study	_
222-9	41185-41193	measures	_
222-10	41193-41194	,	_
222-11	41195-41206	corrections	_
222-12	41207-41210	for	_
222-13	41211-41219	multiple	_
222-14	41220-41230	comparison	_
222-15	41231-41235	were	_
222-16	41236-41239	not	_
222-17	41240-41247	applied	_
222-18	41248-41250	to	_
222-19	41251-41254	the	_
222-20	41255-41267	correlations	_
222-21	41268-41275	between	_
222-22	41276-41286	biological	_
222-23	41287-41296	variables	_
222-24	41297-41300	and	_
222-25	41301-41309	drinking	_
222-26	41310-41319	behaviors	_
222-27	41319-41320	.	_

#Text=These results should therefore be interpreted with caution and require replication.
223-1	41321-41326	These	_
223-2	41327-41334	results	_
223-3	41335-41341	should	_
223-4	41342-41351	therefore	_
223-5	41352-41354	be	_
223-6	41355-41366	interpreted	_
223-7	41367-41371	with	_
223-8	41372-41379	caution	_
223-9	41380-41383	and	_
223-10	41384-41391	require	_
223-11	41392-41403	replication	_
223-12	41403-41404	.	_

#Text=Results from the current study suggest that lower levels of plasma BDNF are associated with disruptions in amygdala-PFC functional connectivity during anticipatory anxiety and that these biological individual difference factors may contribute to risky patterns of alcohol use within individuals with AUD and may serve as a biomarker for AUD.
224-1	41405-41412	Results	_
224-2	41413-41417	from	_
224-3	41418-41421	the	_
224-4	41422-41429	current	_
224-5	41430-41435	study	_
224-6	41436-41443	suggest	_
224-7	41444-41448	that	_
224-8	41449-41454	lower	_
224-9	41455-41461	levels	_
224-10	41462-41464	of	_
224-11	41465-41471	plasma	_
224-12	41472-41476	BDNF	_
224-13	41477-41480	are	_
224-14	41481-41491	associated	_
224-15	41492-41496	with	_
224-16	41497-41508	disruptions	_
224-17	41509-41511	in	_
224-18	41512-41524	amygdala-PFC	_
224-19	41525-41535	functional	_
224-20	41536-41548	connectivity	_
224-21	41549-41555	during	_
224-22	41556-41568	anticipatory	_
224-23	41569-41576	anxiety	_
224-24	41577-41580	and	_
224-25	41581-41585	that	_
224-26	41586-41591	these	_
224-27	41592-41602	biological	_
224-28	41603-41613	individual	_
224-29	41614-41624	difference	_
224-30	41625-41632	factors	_
224-31	41633-41636	may	_
224-32	41637-41647	contribute	_
224-33	41648-41650	to	_
224-34	41651-41656	risky	_
224-35	41657-41665	patterns	_
224-36	41666-41668	of	_
224-37	41669-41676	alcohol	_
224-38	41677-41680	use	_
224-39	41681-41687	within	_
224-40	41688-41699	individuals	_
224-41	41700-41704	with	_
224-42	41705-41708	AUD	_
224-43	41709-41712	and	_
224-44	41713-41716	may	_
224-45	41717-41722	serve	_
224-46	41723-41725	as	_
224-47	41726-41727	a	_
224-48	41728-41737	biomarker	_
224-49	41738-41741	for	_
224-50	41742-41745	AUD	_
224-51	41745-41746	.	_

#Text=Converging evidence across human and animal research suggests that the amygdala-PFC circuit is an important AUD treatment target, which may be modulated by BDNF expression.
225-1	41747-41757	Converging	_
225-2	41758-41766	evidence	_
225-3	41767-41773	across	_
225-4	41774-41779	human	_
225-5	41780-41783	and	_
225-6	41784-41790	animal	_
225-7	41791-41799	research	_
225-8	41800-41808	suggests	_
225-9	41809-41813	that	_
225-10	41814-41817	the	_
225-11	41818-41830	amygdala-PFC	_
225-12	41831-41838	circuit	_
225-13	41839-41841	is	_
225-14	41842-41844	an	_
225-15	41845-41854	important	_
225-16	41855-41858	AUD	_
225-17	41859-41868	treatment	_
225-18	41869-41875	target	_
225-19	41875-41876	,	_
225-20	41877-41882	which	_
225-21	41883-41886	may	_
225-22	41887-41889	be	_
225-23	41890-41899	modulated	_
225-24	41900-41902	by	_
225-25	41903-41907	BDNF	_
225-26	41908-41918	expression	_
225-27	41918-41919	.	_

#Text=Interest Statement
#Text=None.
226-1	41920-41928	Interest	_
226-2	41929-41938	Statement	_
226-3	41939-41943	None	_
226-4	41943-41944	.	_

#Text=References
#Text=
#Text=Phasic and sustained fear in humans elicits distinct patterns of brain activity
#Text=BDNF-TrkB receptor regulation of distributed adult neural plasticity, memory formation, and psychiatric disorders
#Text=Brain-derived neurotrophic factor and neuropsychiatric disorders
#Text=Types of alcoholics: concurrent and predictive validity of some common classification schemes
#Text=Amygdala-frontal connectivity during emotion regulation
#Text=A BDNF infusion into the medial prefrontal cortex suppresses cocaine seeking in rats
#Text=Emerging role of epigenetic mechanisms in alcohol addiction
#Text=The lncRNA BDNF-AS is an epigenetic regulator in the human amygdala in early onset alcohol use disorders
#Text=Combining region- and network-level brain-behavior relationships in a structural equation model
#Text=How bad could it be?
227-1	41945-41955	References	_
227-2	41957-41963	Phasic	_
227-3	41964-41967	and	_
227-4	41968-41977	sustained	_
227-5	41978-41982	fear	_
227-6	41983-41985	in	_
227-7	41986-41992	humans	_
227-8	41993-42000	elicits	_
227-9	42001-42009	distinct	_
227-10	42010-42018	patterns	_
227-11	42019-42021	of	_
227-12	42022-42027	brain	_
227-13	42028-42036	activity	_
227-14	42037-42046	BDNF-TrkB	_
227-15	42047-42055	receptor	_
227-16	42056-42066	regulation	_
227-17	42067-42069	of	_
227-18	42070-42081	distributed	_
227-19	42082-42087	adult	_
227-20	42088-42094	neural	_
227-21	42095-42105	plasticity	_
227-22	42105-42106	,	_
227-23	42107-42113	memory	_
227-24	42114-42123	formation	_
227-25	42123-42124	,	_
227-26	42125-42128	and	_
227-27	42129-42140	psychiatric	_
227-28	42141-42150	disorders	_
227-29	42151-42164	Brain-derived	_
227-30	42165-42177	neurotrophic	_
227-31	42178-42184	factor	_
227-32	42185-42188	and	_
227-33	42189-42205	neuropsychiatric	_
227-34	42206-42215	disorders	_
227-35	42216-42221	Types	_
227-36	42222-42224	of	_
227-37	42225-42235	alcoholics	_
227-38	42235-42236	:	_
227-39	42237-42247	concurrent	_
227-40	42248-42251	and	_
227-41	42252-42262	predictive	_
227-42	42263-42271	validity	_
227-43	42272-42274	of	_
227-44	42275-42279	some	_
227-45	42280-42286	common	_
227-46	42287-42301	classification	_
227-47	42302-42309	schemes	_
227-48	42310-42326	Amygdala-frontal	_
227-49	42327-42339	connectivity	_
227-50	42340-42346	during	_
227-51	42347-42354	emotion	_
227-52	42355-42365	regulation	_
227-53	42366-42367	A	_
227-54	42368-42372	BDNF	_
227-55	42373-42381	infusion	_
227-56	42382-42386	into	_
227-57	42387-42390	the	_
227-58	42391-42397	medial	_
227-59	42398-42408	prefrontal	_
227-60	42409-42415	cortex	_
227-61	42416-42426	suppresses	_
227-62	42427-42434	cocaine	_
227-63	42435-42442	seeking	_
227-64	42443-42445	in	_
227-65	42446-42450	rats	_
227-66	42451-42459	Emerging	_
227-67	42460-42464	role	_
227-68	42465-42467	of	_
227-69	42468-42478	epigenetic	_
227-70	42479-42489	mechanisms	_
227-71	42490-42492	in	_
227-72	42493-42500	alcohol	_
227-73	42501-42510	addiction	_
227-74	42511-42514	The	_
227-75	42515-42521	lncRNA	_
227-76	42522-42529	BDNF-AS	_
227-77	42530-42532	is	_
227-78	42533-42535	an	_
227-79	42536-42546	epigenetic	_
227-80	42547-42556	regulator	_
227-81	42557-42559	in	_
227-82	42560-42563	the	_
227-83	42564-42569	human	_
227-84	42570-42578	amygdala	_
227-85	42579-42581	in	_
227-86	42582-42587	early	_
227-87	42588-42593	onset	_
227-88	42594-42601	alcohol	_
227-89	42602-42605	use	_
227-90	42606-42615	disorders	_
227-91	42616-42625	Combining	_
227-92	42626-42632	region	_
227-93	42632-42633	-	_
227-94	42634-42637	and	_
227-95	42638-42651	network-level	_
227-96	42652-42666	brain-behavior	_
227-97	42667-42680	relationships	_
227-98	42681-42683	in	_
227-99	42684-42685	a	_
227-100	42686-42696	structural	_
227-101	42697-42705	equation	_
227-102	42706-42711	model	_
227-103	42712-42715	How	_
227-104	42716-42719	bad	_
227-105	42720-42725	could	_
227-106	42726-42728	it	_
227-107	42729-42731	be	_
227-108	42731-42732	?	_

#Text=Alcohol dampens stress responses to threat of uncertain intensity
#Text=Disinhibited characteristics and binge drinking among university student drinkers
#Text=Relation between plasma brain-derived neurotrophic factor and nerve growth factor in the male patients with alcohol dependence
#Text=BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults
#Text=Brain-derived neurotrophic factor serum levels in alcohol-dependent subjects 6 months after alcohol withdrawal
#Text=FMRI clustering in AFNI: false-positive rates redux
#Text=Brain pathways to recovery from alcohol dependence
#Text=MicroRNA-30a-5p in the prefrontal cortex controls the transition from moderate to excessive alcohol consumption
#Text=Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety
#Text=Association between BDNF val66 met genotype and episodic memory
#Text=Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder
#Text=Serum and plasma brain-derived neurotrophic factor (BDNF) in abstinent alcoholics and social drinkers
#Text=The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
#Text=Trajectories of alcohol initiation and use during adolescence: the role of stress and amygdala reactivity
#Text=Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders
#Text=Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders
#Text=Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation
#Text=Reduced amygdala activation in young adults at high risk of alcoholism: studies from the Oklahoma Family Health Patterns Project
#Text=Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol
#Text=Alcohol attenuates amygdala-frontal connectivity during processing social signals in heavy social drinkers: a preliminary pharmaco-fMRI study
#Text=Reactivity to uncertain threat as a familial vulnerability factor for alcohol use disorder
#Text=Association between problematic alcohol use and reactivity to uncertain threat in two independent samples
#Text=Preliminary evidence that reactivity to uncertain threat is an endophenotype for alcohol use disorder
#Text=Behavioral and neural sensitivity to uncertain threat in individuals with alcohol use disorder: associations with drinking behaviors and motives
#Text=Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III
#Text=Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
#Text=BDNF and GDNF serum levels in alcohol-dependent patients during withdrawal
#Text=Ethanol consumption and serotonin-1A (5-HT1A) receptor function in heterozygous BDNF (+/-) mice
#Text=Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers
#Text=Resting state functional connectivity of the amygdala and problem drinking in non-dependent alcohol drinkers
#Text=Neural systems responding to degrees of uncertainty in human decision-making
#Text=The impact of genetic variation in comt and bdnf on resting‐state functional connectivity
#Text=Decreased plasma brain-derived neurotrophic factor levels in patients with alcohol dependence
#Text=Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets
#Text=The effects of alcohol abstinence on BDNF, ghrelin, and leptin secretions in alcohol-dependent patients with glucose intolerance
#Text=Serum brain-derived neurotrophic factor and nerve growth factor concentrations change after alcohol withdrawal: preliminary data of a case-control comparison
#Text=Multiple functions of precursor BDNF to CNS neurons: negative regulation of neurite growth, spine formation and cell survival
#Text=Molecular mechanisms of synaptic remodeling in alcoholism
#Text=Neural representation of subjective value under risk and ambiguity
#Text=Increased serum neurotrophin levels related to alcohol use disorder in a young population sample
#Text=Medial prefrontal cortex: adding value to imagined scenarios
#Text=Corticostriatal BDNF and alcohol addiction
#Text=RACK1 and brain-derived neurotrophic factor: a homeostatic pathway that regulates alcohol addiction
#Text=A generalized form of context-dependent psychophysiological interactions (gPPI): a comparison to standard approaches
#Text=Intermediate phenotypes and genetic mechanisms of psychiatric disorders
#Text=Increased startle potentiation to unpredictable stressors in alcohol dependence: possible stress neuroadaptation in humans
#Text=Neuroscience of alcoholism: molecular and cellular mechanisms
#Text=The role of amygdaloid brain‐derived neurotrophic factor, activity‐regulated cytoskeleton‐associated protein and dendritic spines in anxiety and alcoholism
#Text=Alcohol selectively reduces anxiety but not fear: startle response during unpredictable versus predictable threat
#Text=Serum BDNF correlates with connectivity in the (pre)motor hub in the aging human brain–a resting-state fMRI pilot study
#Text=Effects of the BDNF Val66Met polymorphism on neural responses to facial emotion
#Text=Functional imaging studies of emotion regulation: a synthetic review and evolving model of the cognitive control of emotion
#Text=A critical role of brain-derived neurotrophic factor in alcohol consumption
#Text=Partial deletion of the cAMP response element-binding protein gene promotes alcohol-drinking behaviors
#Text=Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors
#Text=Effector immediate-early gene arc in the amygdala plays a critical role in alcoholism
#Text=The link between testosterone and amygdala-orbitofrontal cortex connectivity in adolescent alcohol use
#Text=Amygdala–orbitofrontal connectivity predicts alcohol use two years later: a longitudinal neuroimaging study on alcohol use in adolescence
#Text=Aberrant amygdala-frontal cortex connectivity during perception of fearful faces and at rest in generalized social anxiety disorder
#Text=A comparison of dexmedetomidine and placebo on the plasma concentrations of NGF, BDNF, GDNF, and epinephrine during severe alcohol withdrawal
#Text=Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test)
#Text=A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder
#Text=Timeline follow-back.
228-1	42733-42740	Alcohol	_
228-2	42741-42748	dampens	_
228-3	42749-42755	stress	_
228-4	42756-42765	responses	_
228-5	42766-42768	to	_
228-6	42769-42775	threat	_
228-7	42776-42778	of	_
228-8	42779-42788	uncertain	_
228-9	42789-42798	intensity	_
228-10	42799-42811	Disinhibited	_
228-11	42812-42827	characteristics	_
228-12	42828-42831	and	_
228-13	42832-42837	binge	_
228-14	42838-42846	drinking	_
228-15	42847-42852	among	_
228-16	42853-42863	university	_
228-17	42864-42871	student	_
228-18	42872-42880	drinkers	_
228-19	42881-42889	Relation	_
228-20	42890-42897	between	_
228-21	42898-42904	plasma	_
228-22	42905-42918	brain-derived	_
228-23	42919-42931	neurotrophic	_
228-24	42932-42938	factor	_
228-25	42939-42942	and	_
228-26	42943-42948	nerve	_
228-27	42949-42955	growth	_
228-28	42956-42962	factor	_
228-29	42963-42965	in	_
228-30	42966-42969	the	_
228-31	42970-42974	male	_
228-32	42975-42983	patients	_
228-33	42984-42988	with	_
228-34	42989-42996	alcohol	_
228-35	42997-43007	dependence	_
228-36	43008-43012	BDNF	_
228-37	43013-43021	Val66Met	_
228-38	43022-43034	polymorphism	_
228-39	43035-43037	is	_
228-40	43038-43048	associated	_
228-41	43049-43053	with	_
228-42	43054-43060	higher	_
228-43	43061-43073	anticipatory	_
228-44	43074-43082	cortisol	_
228-45	43083-43089	stress	_
228-46	43090-43098	response	_
228-47	43098-43099	,	_
228-48	43100-43107	anxiety	_
228-49	43107-43108	,	_
228-50	43109-43112	and	_
228-51	43113-43120	alcohol	_
228-52	43121-43132	consumption	_
228-53	43133-43135	in	_
228-54	43136-43143	healthy	_
228-55	43144-43150	adults	_
228-56	43151-43164	Brain-derived	_
228-57	43165-43177	neurotrophic	_
228-58	43178-43184	factor	_
228-59	43185-43190	serum	_
228-60	43191-43197	levels	_
228-61	43198-43200	in	_
228-62	43201-43218	alcohol-dependent	_
228-63	43219-43227	subjects	_
228-64	43228-43229	6	_
228-65	43230-43236	months	_
228-66	43237-43242	after	_
228-67	43243-43250	alcohol	_
228-68	43251-43261	withdrawal	_
228-69	43262-43266	FMRI	_
228-70	43267-43277	clustering	_
228-71	43278-43280	in	_
228-72	43281-43285	AFNI	_
228-73	43285-43286	:	_
228-74	43287-43301	false-positive	_
228-75	43302-43307	rates	_
228-76	43308-43313	redux	_
228-77	43314-43319	Brain	_
228-78	43320-43328	pathways	_
228-79	43329-43331	to	_
228-80	43332-43340	recovery	_
228-81	43341-43345	from	_
228-82	43346-43353	alcohol	_
228-83	43354-43364	dependence	_
228-84	43365-43373	MicroRNA	_
228-85	43373-43374	-	_
228-86	43374-43377	30a	_
228-87	43377-43378	-	_
228-88	43378-43380	5p	_
228-89	43381-43383	in	_
228-90	43384-43387	the	_
228-91	43388-43398	prefrontal	_
228-92	43399-43405	cortex	_
228-93	43406-43414	controls	_
228-94	43415-43418	the	_
228-95	43419-43429	transition	_
228-96	43430-43434	from	_
228-97	43435-43443	moderate	_
228-98	43444-43446	to	_
228-99	43447-43456	excessive	_
228-100	43457-43464	alcohol	_
228-101	43465-43476	consumption	_
228-102	43477-43483	Phasic	_
228-103	43484-43486	vs	_
228-104	43487-43496	sustained	_
228-105	43497-43501	fear	_
228-106	43502-43504	in	_
228-107	43505-43509	rats	_
228-108	43510-43513	and	_
228-109	43514-43520	humans	_
228-110	43520-43521	:	_
228-111	43522-43526	role	_
228-112	43527-43529	of	_
228-113	43530-43533	the	_
228-114	43534-43542	extended	_
228-115	43543-43551	amygdala	_
228-116	43552-43554	in	_
228-117	43555-43559	fear	_
228-118	43560-43562	vs	_
228-119	43563-43570	anxiety	_
228-120	43571-43582	Association	_
228-121	43583-43590	between	_
228-122	43591-43595	BDNF	_
228-123	43596-43601	val66	_
228-124	43602-43605	met	_
228-125	43606-43614	genotype	_
228-126	43615-43618	and	_
228-127	43619-43627	episodic	_
228-128	43628-43634	memory	_
228-129	43635-43645	Modulation	_
228-130	43646-43648	of	_
228-131	43649-43662	resting-state	_
228-132	43663-43679	amygdala-frontal	_
228-133	43680-43690	functional	_
228-134	43691-43703	connectivity	_
228-135	43704-43706	by	_
228-136	43707-43715	oxytocin	_
228-137	43716-43718	in	_
228-138	43719-43730	generalized	_
228-139	43731-43737	social	_
228-140	43738-43745	anxiety	_
228-141	43746-43754	disorder	_
228-142	43755-43760	Serum	_
228-143	43761-43764	and	_
228-144	43765-43771	plasma	_
228-145	43772-43785	brain-derived	_
228-146	43786-43798	neurotrophic	_
228-147	43799-43805	factor	_
228-148	43806-43807	(	_
228-149	43807-43811	BDNF	_
228-150	43811-43812	)	_
228-151	43813-43815	in	_
228-152	43816-43825	abstinent	_
228-153	43826-43836	alcoholics	_
228-154	43837-43840	and	_
228-155	43841-43847	social	_
228-156	43848-43856	drinkers	_
228-157	43857-43860	The	_
228-158	43861-43865	BDNF	_
228-159	43866-43874	val66met	_
228-160	43875-43887	polymorphism	_
228-161	43888-43895	affects	_
228-162	43896-43914	activity-dependent	_
228-163	43915-43924	secretion	_
228-164	43925-43927	of	_
228-165	43928-43932	BDNF	_
228-166	43933-43936	and	_
228-167	43937-43942	human	_
228-168	43943-43949	memory	_
228-169	43950-43953	and	_
228-170	43954-43965	hippocampal	_
228-171	43966-43974	function	_
228-172	43975-43987	Trajectories	_
228-173	43988-43990	of	_
228-174	43991-43998	alcohol	_
228-175	43999-44009	initiation	_
228-176	44010-44013	and	_
228-177	44014-44017	use	_
228-178	44018-44024	during	_
228-179	44025-44036	adolescence	_
228-180	44036-44037	:	_
228-181	44038-44041	the	_
228-182	44042-44046	role	_
228-183	44047-44049	of	_
228-184	44050-44056	stress	_
228-185	44057-44060	and	_
228-186	44061-44069	amygdala	_
228-187	44070-44080	reactivity	_
228-188	44081-44084	Age	_
228-189	44085-44087	of	_
228-190	44088-44093	onset	_
228-191	44094-44097	and	_
228-192	44098-44106	temporal	_
228-193	44107-44117	sequencing	_
228-194	44118-44120	of	_
228-195	44121-44129	lifetime	_
228-196	44130-44136	DSM-IV	_
228-197	44137-44144	alcohol	_
228-198	44145-44148	use	_
228-199	44149-44158	disorders	_
228-200	44159-44167	relative	_
228-201	44168-44170	to	_
228-202	44171-44179	comorbid	_
228-203	44180-44184	mood	_
228-204	44185-44188	and	_
228-205	44189-44196	anxiety	_
228-206	44197-44206	disorders	_
228-207	44207-44216	Decreased	_
228-208	44217-44223	plasma	_
228-209	44224-44238	concentrations	_
228-210	44239-44241	of	_
228-211	44242-44246	BDNF	_
228-212	44247-44250	and	_
228-213	44251-44254	IGF	_
228-214	44254-44255	-	_
228-215	44255-44256	1	_
228-216	44257-44259	in	_
228-217	44260-44269	abstinent	_
228-218	44270-44278	patients	_
228-219	44279-44283	with	_
228-220	44284-44291	alcohol	_
228-221	44292-44295	use	_
228-222	44296-44305	disorders	_
228-223	44306-44310	Fast	_
228-224	44311-44315	BDNF	_
228-225	44316-44321	serum	_
228-226	44322-44327	level	_
228-227	44328-44336	increase	_
228-228	44337-44340	and	_
228-229	44341-44348	diurnal	_
228-230	44349-44353	BDNF	_
228-231	44354-44366	oscillations	_
228-232	44367-44370	are	_
228-233	44371-44381	associated	_
228-234	44382-44386	with	_
228-235	44387-44398	therapeutic	_
228-236	44399-44407	response	_
228-237	44408-44413	after	_
228-238	44414-44421	partial	_
228-239	44422-44427	sleep	_
228-240	44428-44439	deprivation	_
228-241	44440-44447	Reduced	_
228-242	44448-44456	amygdala	_
228-243	44457-44467	activation	_
228-244	44468-44470	in	_
228-245	44471-44476	young	_
228-246	44477-44483	adults	_
228-247	44484-44486	at	_
228-248	44487-44491	high	_
228-249	44492-44496	risk	_
228-250	44497-44499	of	_
228-251	44500-44510	alcoholism	_
228-252	44510-44511	:	_
228-253	44512-44519	studies	_
228-254	44520-44524	from	_
228-255	44525-44528	the	_
228-256	44529-44537	Oklahoma	_
228-257	44538-44544	Family	_
228-258	44545-44551	Health	_
228-259	44552-44560	Patterns	_
228-260	44561-44568	Project	_
228-261	44569-44572	Why	_
228-262	44573-44575	we	_
228-263	44576-44580	like	_
228-264	44581-44583	to	_
228-265	44584-44589	drink	_
228-266	44589-44590	:	_
228-267	44591-44592	a	_
228-268	44593-44603	functional	_
228-269	44604-44612	magnetic	_
228-270	44613-44622	resonance	_
228-271	44623-44630	imaging	_
228-272	44631-44636	study	_
228-273	44637-44639	of	_
228-274	44640-44643	the	_
228-275	44644-44653	rewarding	_
228-276	44654-44657	and	_
228-277	44658-44668	anxiolytic	_
228-278	44669-44676	effects	_
228-279	44677-44679	of	_
228-280	44680-44687	alcohol	_
228-281	44688-44695	Alcohol	_
228-282	44696-44706	attenuates	_
228-283	44707-44723	amygdala-frontal	_
228-284	44724-44736	connectivity	_
228-285	44737-44743	during	_
228-286	44744-44754	processing	_
228-287	44755-44761	social	_
228-288	44762-44769	signals	_
228-289	44770-44772	in	_
228-290	44773-44778	heavy	_
228-291	44779-44785	social	_
228-292	44786-44794	drinkers	_
228-293	44794-44795	:	_
228-294	44796-44797	a	_
228-295	44798-44809	preliminary	_
228-296	44810-44823	pharmaco-fMRI	_
228-297	44824-44829	study	_
228-298	44830-44840	Reactivity	_
228-299	44841-44843	to	_
228-300	44844-44853	uncertain	_
228-301	44854-44860	threat	_
228-302	44861-44863	as	_
228-303	44864-44865	a	_
228-304	44866-44874	familial	_
228-305	44875-44888	vulnerability	_
228-306	44889-44895	factor	_
228-307	44896-44899	for	_
228-308	44900-44907	alcohol	_
228-309	44908-44911	use	_
228-310	44912-44920	disorder	_
228-311	44921-44932	Association	_
228-312	44933-44940	between	_
228-313	44941-44952	problematic	_
228-314	44953-44960	alcohol	_
228-315	44961-44964	use	_
228-316	44965-44968	and	_
228-317	44969-44979	reactivity	_
228-318	44980-44982	to	_
228-319	44983-44992	uncertain	_
228-320	44993-44999	threat	_
228-321	45000-45002	in	_
228-322	45003-45006	two	_
228-323	45007-45018	independent	_
228-324	45019-45026	samples	_
228-325	45027-45038	Preliminary	_
228-326	45039-45047	evidence	_
228-327	45048-45052	that	_
228-328	45053-45063	reactivity	_
228-329	45064-45066	to	_
228-330	45067-45076	uncertain	_
228-331	45077-45083	threat	_
228-332	45084-45086	is	_
228-333	45087-45089	an	_
228-334	45090-45103	endophenotype	_
228-335	45104-45107	for	_
228-336	45108-45115	alcohol	_
228-337	45116-45119	use	_
228-338	45120-45128	disorder	_
228-339	45129-45139	Behavioral	_
228-340	45140-45143	and	_
228-341	45144-45150	neural	_
228-342	45151-45162	sensitivity	_
228-343	45163-45165	to	_
228-344	45166-45175	uncertain	_
228-345	45176-45182	threat	_
228-346	45183-45185	in	_
228-347	45186-45197	individuals	_
228-348	45198-45202	with	_
228-349	45203-45210	alcohol	_
228-350	45211-45214	use	_
228-351	45215-45223	disorder	_
228-352	45223-45224	:	_
228-353	45225-45237	associations	_
228-354	45238-45242	with	_
228-355	45243-45251	drinking	_
228-356	45252-45261	behaviors	_
228-357	45262-45265	and	_
228-358	45266-45273	motives	_
228-359	45274-45286	Epidemiology	_
228-360	45287-45289	of	_
228-361	45290-45293	DSM	_
228-362	45293-45294	-	_
228-363	45294-45295	5	_
228-364	45296-45303	alcohol	_
228-365	45304-45307	use	_
228-366	45308-45316	disorder	_
228-367	45316-45317	:	_
228-368	45318-45325	results	_
228-369	45326-45330	from	_
228-370	45331-45334	the	_
228-371	45335-45343	national	_
228-372	45344-45357	epidemiologic	_
228-373	45358-45364	survey	_
228-374	45365-45367	on	_
228-375	45368-45375	alcohol	_
228-376	45376-45379	and	_
228-377	45380-45387	related	_
228-378	45388-45398	conditions	_
228-379	45399-45402	III	_
228-380	45403-45410	Alcohol	_
228-381	45411-45414	use	_
228-382	45415-45418	and	_
228-383	45419-45425	burden	_
228-384	45426-45429	for	_
228-385	45430-45433	195	_
228-386	45434-45443	countries	_
228-387	45444-45447	and	_
228-388	45448-45459	territories	_
228-389	45459-45460	,	_
228-390	45461-45465	1990	_
228-391	45465-45466	–	_
228-392	45466-45470	2016	_
228-393	45470-45471	:	_
228-394	45472-45473	a	_
228-395	45474-45484	systematic	_
228-396	45485-45493	analysis	_
228-397	45494-45497	for	_
228-398	45498-45501	the	_
228-399	45502-45508	Global	_
228-400	45509-45515	Burden	_
228-401	45516-45518	of	_
228-402	45519-45526	Disease	_
228-403	45527-45532	Study	_
228-404	45533-45537	2016	_
228-405	45538-45542	BDNF	_
228-406	45543-45546	and	_
228-407	45547-45551	GDNF	_
228-408	45552-45557	serum	_
228-409	45558-45564	levels	_
228-410	45565-45567	in	_
228-411	45568-45585	alcohol-dependent	_
228-412	45586-45594	patients	_
228-413	45595-45601	during	_
228-414	45602-45612	withdrawal	_
228-415	45613-45620	Ethanol	_
228-416	45621-45632	consumption	_
228-417	45633-45636	and	_
228-418	45637-45646	serotonin	_
228-419	45646-45647	-	_
228-420	45647-45649	1A	_
228-421	45650-45651	(	_
228-422	45651-45652	5	_
228-423	45652-45653	-	_
228-424	45653-45657	HT1A	_
228-425	45657-45658	)	_
228-426	45659-45667	receptor	_
228-427	45668-45676	function	_
228-428	45677-45679	in	_
228-429	45680-45692	heterozygous	_
228-430	45693-45697	BDNF	_
228-431	45698-45699	(	_
228-432	45699-45700	+	_
228-433	45700-45701	/	_
228-434	45701-45702	-	_
228-435	45702-45703	)	_
228-436	45704-45708	mice	_
228-437	45709-45718	Cognitive	_
228-438	45719-45722	and	_
228-439	45723-45731	magnetic	_
228-440	45732-45741	resonance	_
228-441	45742-45749	imaging	_
228-442	45750-45755	brain	_
228-443	45756-45768	morphometric	_
228-444	45769-45779	correlates	_
228-445	45780-45782	of	_
228-446	45783-45796	brain-derived	_
228-447	45797-45809	neurotrophic	_
228-448	45810-45816	factor	_
228-449	45817-45825	Val66Met	_
228-450	45826-45830	gene	_
228-451	45831-45843	polymorphism	_
228-452	45844-45846	in	_
228-453	45847-45855	patients	_
228-454	45856-45860	with	_
228-455	45861-45874	schizophrenia	_
228-456	45875-45878	and	_
228-457	45879-45886	healthy	_
228-458	45887-45897	volunteers	_
228-459	45898-45905	Resting	_
228-460	45906-45911	state	_
228-461	45912-45922	functional	_
228-462	45923-45935	connectivity	_
228-463	45936-45938	of	_
228-464	45939-45942	the	_
228-465	45943-45951	amygdala	_
228-466	45952-45955	and	_
228-467	45956-45963	problem	_
228-468	45964-45972	drinking	_
228-469	45973-45975	in	_
228-470	45976-45989	non-dependent	_
228-471	45990-45997	alcohol	_
228-472	45998-46006	drinkers	_
228-473	46007-46013	Neural	_
228-474	46014-46021	systems	_
228-475	46022-46032	responding	_
228-476	46033-46035	to	_
228-477	46036-46043	degrees	_
228-478	46044-46046	of	_
228-479	46047-46058	uncertainty	_
228-480	46059-46061	in	_
228-481	46062-46067	human	_
228-482	46068-46083	decision-making	_
228-483	46084-46087	The	_
228-484	46088-46094	impact	_
228-485	46095-46097	of	_
228-486	46098-46105	genetic	_
228-487	46106-46115	variation	_
228-488	46116-46118	in	_
228-489	46119-46123	comt	_
228-490	46124-46127	and	_
228-491	46128-46132	bdnf	_
228-492	46133-46135	on	_
228-493	46136-46149	resting‐state	_
228-494	46150-46160	functional	_
228-495	46161-46173	connectivity	_
228-496	46174-46183	Decreased	_
228-497	46184-46190	plasma	_
228-498	46191-46204	brain-derived	_
228-499	46205-46217	neurotrophic	_
228-500	46218-46224	factor	_
228-501	46225-46231	levels	_
228-502	46232-46234	in	_
228-503	46235-46243	patients	_
228-504	46244-46248	with	_
228-505	46249-46256	alcohol	_
228-506	46257-46267	dependence	_
228-507	46268-46277	Postnatal	_
228-508	46278-46291	developmental	_
228-509	46292-46299	profile	_
228-510	46300-46302	of	_
228-511	46303-46316	brain-derived	_
228-512	46317-46329	neurotrophic	_
228-513	46330-46336	factor	_
228-514	46337-46339	in	_
228-515	46340-46343	rat	_
228-516	46344-46349	brain	_
228-517	46350-46353	and	_
228-518	46354-46363	platelets	_
228-519	46364-46367	The	_
228-520	46368-46375	effects	_
228-521	46376-46378	of	_
228-522	46379-46386	alcohol	_
228-523	46387-46397	abstinence	_
228-524	46398-46400	on	_
228-525	46401-46405	BDNF	_
228-526	46405-46406	,	_
228-527	46407-46414	ghrelin	_
228-528	46414-46415	,	_
228-529	46416-46419	and	_
228-530	46420-46426	leptin	_
228-531	46427-46437	secretions	_
228-532	46438-46440	in	_
228-533	46441-46458	alcohol-dependent	_
228-534	46459-46467	patients	_
228-535	46468-46472	with	_
228-536	46473-46480	glucose	_
228-537	46481-46492	intolerance	_
228-538	46493-46498	Serum	_
228-539	46499-46512	brain-derived	_
228-540	46513-46525	neurotrophic	_
228-541	46526-46532	factor	_
228-542	46533-46536	and	_
228-543	46537-46542	nerve	_
228-544	46543-46549	growth	_
228-545	46550-46556	factor	_
228-546	46557-46571	concentrations	_
228-547	46572-46578	change	_
228-548	46579-46584	after	_
228-549	46585-46592	alcohol	_
228-550	46593-46603	withdrawal	_
228-551	46603-46604	:	_
228-552	46605-46616	preliminary	_
228-553	46617-46621	data	_
228-554	46622-46624	of	_
228-555	46625-46626	a	_
228-556	46627-46639	case-control	_
228-557	46640-46650	comparison	_
228-558	46651-46659	Multiple	_
228-559	46660-46669	functions	_
228-560	46670-46672	of	_
228-561	46673-46682	precursor	_
228-562	46683-46687	BDNF	_
228-563	46688-46690	to	_
228-564	46691-46694	CNS	_
228-565	46695-46702	neurons	_
228-566	46702-46703	:	_
228-567	46704-46712	negative	_
228-568	46713-46723	regulation	_
228-569	46724-46726	of	_
228-570	46727-46734	neurite	_
228-571	46735-46741	growth	_
228-572	46741-46742	,	_
228-573	46743-46748	spine	_
228-574	46749-46758	formation	_
228-575	46759-46762	and	_
228-576	46763-46767	cell	_
228-577	46768-46776	survival	_
228-578	46777-46786	Molecular	_
228-579	46787-46797	mechanisms	_
228-580	46798-46800	of	_
228-581	46801-46809	synaptic	_
228-582	46810-46820	remodeling	_
228-583	46821-46823	in	_
228-584	46824-46834	alcoholism	_
228-585	46835-46841	Neural	_
228-586	46842-46856	representation	_
228-587	46857-46859	of	_
228-588	46860-46870	subjective	_
228-589	46871-46876	value	_
228-590	46877-46882	under	_
228-591	46883-46887	risk	_
228-592	46888-46891	and	_
228-593	46892-46901	ambiguity	_
228-594	46902-46911	Increased	_
228-595	46912-46917	serum	_
228-596	46918-46930	neurotrophin	_
228-597	46931-46937	levels	_
228-598	46938-46945	related	_
228-599	46946-46948	to	_
228-600	46949-46956	alcohol	_
228-601	46957-46960	use	_
228-602	46961-46969	disorder	_
228-603	46970-46972	in	_
228-604	46973-46974	a	_
228-605	46975-46980	young	_
228-606	46981-46991	population	_
228-607	46992-46998	sample	_
228-608	46999-47005	Medial	_
228-609	47006-47016	prefrontal	_
228-610	47017-47023	cortex	_
228-611	47023-47024	:	_
228-612	47025-47031	adding	_
228-613	47032-47037	value	_
228-614	47038-47040	to	_
228-615	47041-47049	imagined	_
228-616	47050-47059	scenarios	_
228-617	47060-47075	Corticostriatal	_
228-618	47076-47080	BDNF	_
228-619	47081-47084	and	_
228-620	47085-47092	alcohol	_
228-621	47093-47102	addiction	_
228-622	47103-47108	RACK1	_
228-623	47109-47112	and	_
228-624	47113-47126	brain-derived	_
228-625	47127-47139	neurotrophic	_
228-626	47140-47146	factor	_
228-627	47146-47147	:	_
228-628	47148-47149	a	_
228-629	47150-47161	homeostatic	_
228-630	47162-47169	pathway	_
228-631	47170-47174	that	_
228-632	47175-47184	regulates	_
228-633	47185-47192	alcohol	_
228-634	47193-47202	addiction	_
228-635	47203-47204	A	_
228-636	47205-47216	generalized	_
228-637	47217-47221	form	_
228-638	47222-47224	of	_
228-639	47225-47242	context-dependent	_
228-640	47243-47262	psychophysiological	_
228-641	47263-47275	interactions	_
228-642	47276-47277	(	_
228-643	47277-47281	gPPI	_
228-644	47281-47282	)	_
228-645	47282-47283	:	_
228-646	47284-47285	a	_
228-647	47286-47296	comparison	_
228-648	47297-47299	to	_
228-649	47300-47308	standard	_
228-650	47309-47319	approaches	_
228-651	47320-47332	Intermediate	_
228-652	47333-47343	phenotypes	_
228-653	47344-47347	and	_
228-654	47348-47355	genetic	_
228-655	47356-47366	mechanisms	_
228-656	47367-47369	of	_
228-657	47370-47381	psychiatric	_
228-658	47382-47391	disorders	_
228-659	47392-47401	Increased	_
228-660	47402-47409	startle	_
228-661	47410-47422	potentiation	_
228-662	47423-47425	to	_
228-663	47426-47439	unpredictable	_
228-664	47440-47449	stressors	_
228-665	47450-47452	in	_
228-666	47453-47460	alcohol	_
228-667	47461-47471	dependence	_
228-668	47471-47472	:	_
228-669	47473-47481	possible	_
228-670	47482-47488	stress	_
228-671	47489-47504	neuroadaptation	_
228-672	47505-47507	in	_
228-673	47508-47514	humans	_
228-674	47515-47527	Neuroscience	_
228-675	47528-47530	of	_
228-676	47531-47541	alcoholism	_
228-677	47541-47542	:	_
228-678	47543-47552	molecular	_
228-679	47553-47556	and	_
228-680	47557-47565	cellular	_
228-681	47566-47576	mechanisms	_
228-682	47577-47580	The	_
228-683	47581-47585	role	_
228-684	47586-47588	of	_
228-685	47589-47599	amygdaloid	_
228-686	47600-47613	brain‐derived	_
228-687	47614-47626	neurotrophic	_
228-688	47627-47633	factor	_
228-689	47633-47634	,	_
228-690	47635-47653	activity‐regulated	_
228-691	47654-47677	cytoskeleton‐associated	_
228-692	47678-47685	protein	_
228-693	47686-47689	and	_
228-694	47690-47699	dendritic	_
228-695	47700-47706	spines	_
228-696	47707-47709	in	_
228-697	47710-47717	anxiety	_
228-698	47718-47721	and	_
228-699	47722-47732	alcoholism	_
228-700	47733-47740	Alcohol	_
228-701	47741-47752	selectively	_
228-702	47753-47760	reduces	_
228-703	47761-47768	anxiety	_
228-704	47769-47772	but	_
228-705	47773-47776	not	_
228-706	47777-47781	fear	_
228-707	47781-47782	:	_
228-708	47783-47790	startle	_
228-709	47791-47799	response	_
228-710	47800-47806	during	_
228-711	47807-47820	unpredictable	_
228-712	47821-47827	versus	_
228-713	47828-47839	predictable	_
228-714	47840-47846	threat	_
228-715	47847-47852	Serum	_
228-716	47853-47857	BDNF	_
228-717	47858-47868	correlates	_
228-718	47869-47873	with	_
228-719	47874-47886	connectivity	_
228-720	47887-47889	in	_
228-721	47890-47893	the	_
228-722	47894-47895	(	_
228-723	47895-47898	pre	_
228-724	47898-47899	)	_
228-725	47899-47904	motor	_
228-726	47905-47908	hub	_
228-727	47909-47911	in	_
228-728	47912-47915	the	_
228-729	47916-47921	aging	_
228-730	47922-47927	human	_
228-731	47928-47935	brain–a	_
228-732	47936-47949	resting-state	_
228-733	47950-47954	fMRI	_
228-734	47955-47960	pilot	_
228-735	47961-47966	study	_
228-736	47967-47974	Effects	_
228-737	47975-47977	of	_
228-738	47978-47981	the	_
228-739	47982-47986	BDNF	_
228-740	47987-47995	Val66Met	_
228-741	47996-48008	polymorphism	_
228-742	48009-48011	on	_
228-743	48012-48018	neural	_
228-744	48019-48028	responses	_
228-745	48029-48031	to	_
228-746	48032-48038	facial	_
228-747	48039-48046	emotion	_
228-748	48047-48057	Functional	_
228-749	48058-48065	imaging	_
228-750	48066-48073	studies	_
228-751	48074-48076	of	_
228-752	48077-48084	emotion	_
228-753	48085-48095	regulation	_
228-754	48095-48096	:	_
228-755	48097-48098	a	_
228-756	48099-48108	synthetic	_
228-757	48109-48115	review	_
228-758	48116-48119	and	_
228-759	48120-48128	evolving	_
228-760	48129-48134	model	_
228-761	48135-48137	of	_
228-762	48138-48141	the	_
228-763	48142-48151	cognitive	_
228-764	48152-48159	control	_
228-765	48160-48162	of	_
228-766	48163-48170	emotion	_
228-767	48171-48172	A	_
228-768	48173-48181	critical	_
228-769	48182-48186	role	_
228-770	48187-48189	of	_
228-771	48190-48203	brain-derived	_
228-772	48204-48216	neurotrophic	_
228-773	48217-48223	factor	_
228-774	48224-48226	in	_
228-775	48227-48234	alcohol	_
228-776	48235-48246	consumption	_
228-777	48247-48254	Partial	_
228-778	48255-48263	deletion	_
228-779	48264-48266	of	_
228-780	48267-48270	the	_
228-781	48271-48275	cAMP	_
228-782	48276-48284	response	_
228-783	48285-48300	element-binding	_
228-784	48301-48308	protein	_
228-785	48309-48313	gene	_
228-786	48314-48322	promotes	_
228-787	48323-48339	alcohol-drinking	_
228-788	48340-48349	behaviors	_
228-789	48350-48357	Central	_
228-790	48358-48361	and	_
228-791	48362-48368	medial	_
228-792	48369-48379	amygdaloid	_
228-793	48380-48393	brain-derived	_
228-794	48394-48406	neurotrophic	_
228-795	48407-48413	factor	_
228-796	48414-48423	signaling	_
228-797	48424-48429	plays	_
228-798	48430-48431	a	_
228-799	48432-48440	critical	_
228-800	48441-48445	role	_
228-801	48446-48448	in	_
228-802	48449-48465	alcohol-drinking	_
228-803	48466-48469	and	_
228-804	48470-48482	anxiety-like	_
228-805	48483-48492	behaviors	_
228-806	48493-48501	Effector	_
228-807	48502-48517	immediate-early	_
228-808	48518-48522	gene	_
228-809	48523-48526	arc	_
228-810	48527-48529	in	_
228-811	48530-48533	the	_
228-812	48534-48542	amygdala	_
228-813	48543-48548	plays	_
228-814	48549-48550	a	_
228-815	48551-48559	critical	_
228-816	48560-48564	role	_
228-817	48565-48567	in	_
228-818	48568-48578	alcoholism	_
228-819	48579-48582	The	_
228-820	48583-48587	link	_
228-821	48588-48595	between	_
228-822	48596-48608	testosterone	_
228-823	48609-48612	and	_
228-824	48613-48635	amygdala-orbitofrontal	_
228-825	48636-48642	cortex	_
228-826	48643-48655	connectivity	_
228-827	48656-48658	in	_
228-828	48659-48669	adolescent	_
228-829	48670-48677	alcohol	_
228-830	48678-48681	use	_
228-831	48682-48704	Amygdala–orbitofrontal	_
228-832	48705-48717	connectivity	_
228-833	48718-48726	predicts	_
228-834	48727-48734	alcohol	_
228-835	48735-48738	use	_
228-836	48739-48742	two	_
228-837	48743-48748	years	_
228-838	48749-48754	later	_
228-839	48754-48755	:	_
228-840	48756-48757	a	_
228-841	48758-48770	longitudinal	_
228-842	48771-48783	neuroimaging	_
228-843	48784-48789	study	_
228-844	48790-48792	on	_
228-845	48793-48800	alcohol	_
228-846	48801-48804	use	_
228-847	48805-48807	in	_
228-848	48808-48819	adolescence	_
228-849	48820-48828	Aberrant	_
228-850	48829-48845	amygdala-frontal	_
228-851	48846-48852	cortex	_
228-852	48853-48865	connectivity	_
228-853	48866-48872	during	_
228-854	48873-48883	perception	_
228-855	48884-48886	of	_
228-856	48887-48894	fearful	_
228-857	48895-48900	faces	_
228-858	48901-48904	and	_
228-859	48905-48907	at	_
228-860	48908-48912	rest	_
228-861	48913-48915	in	_
228-862	48916-48927	generalized	_
228-863	48928-48934	social	_
228-864	48935-48942	anxiety	_
228-865	48943-48951	disorder	_
228-866	48952-48953	A	_
228-867	48954-48964	comparison	_
228-868	48965-48967	of	_
228-869	48968-48983	dexmedetomidine	_
228-870	48984-48987	and	_
228-871	48988-48995	placebo	_
228-872	48996-48998	on	_
228-873	48999-49002	the	_
228-874	49003-49009	plasma	_
228-875	49010-49024	concentrations	_
228-876	49025-49027	of	_
228-877	49028-49031	NGF	_
228-878	49031-49032	,	_
228-879	49033-49037	BDNF	_
228-880	49037-49038	,	_
228-881	49039-49043	GDNF	_
228-882	49043-49044	,	_
228-883	49045-49048	and	_
228-884	49049-49060	epinephrine	_
228-885	49061-49067	during	_
228-886	49068-49074	severe	_
228-887	49075-49082	alcohol	_
228-888	49083-49093	withdrawal	_
228-889	49094-49103	Assessing	_
228-890	49104-49108	fear	_
228-891	49109-49112	and	_
228-892	49113-49120	anxiety	_
228-893	49121-49123	in	_
228-894	49124-49130	humans	_
228-895	49131-49136	using	_
228-896	49137-49140	the	_
228-897	49141-49147	threat	_
228-898	49148-49150	of	_
228-899	49151-49162	predictable	_
228-900	49163-49166	and	_
228-901	49167-49180	unpredictable	_
228-902	49181-49189	aversive	_
228-903	49190-49196	events	_
228-904	49197-49198	(	_
228-905	49198-49201	the	_
228-906	49202-49212	NPU-threat	_
228-907	49213-49217	test	_
228-908	49217-49218	)	_
228-909	49219-49220	A	_
228-910	49221-49231	functional	_
228-911	49232-49240	magnetic	_
228-912	49241-49250	resonance	_
228-913	49251-49258	imaging	_
228-914	49259-49264	study	_
228-915	49265-49267	of	_
228-916	49268-49276	amygdala	_
228-917	49277-49280	and	_
228-918	49281-49287	medial	_
228-919	49288-49298	prefrontal	_
228-920	49299-49305	cortex	_
228-921	49306-49315	responses	_
228-922	49316-49318	to	_
228-923	49319-49326	overtly	_
228-924	49327-49336	presented	_
228-925	49337-49344	fearful	_
228-926	49345-49350	faces	_
228-927	49351-49353	in	_
228-928	49354-49367	posttraumatic	_
228-929	49368-49374	stress	_
228-930	49375-49383	disorder	_
228-931	49384-49392	Timeline	_
228-932	49393-49404	follow-back	_
228-933	49404-49405	.	_

#Text=Effects of alcohol on brain responses to social signals of threat in humans
#Text=Neurotrophins and activity-dependent plasticity
#Text=BDNF genotype modulates resting functional connectivity in children
#Text=Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity
#Text=BDNF-dependent effects on amygdala-cortical circuitry and depression risk in children and youth
#Text=Functional dissociations of risk and reward processing in the medial prefrontal cortex
#Text=Alterations of brain‐derived neurotrophic factor serum levels in patients with alcohol dependence
#Text= 1We conducted an additional set of analyses where the U- and P- shocks were included as regressors in the first level model.
229-1	49406-49413	Effects	_
229-2	49414-49416	of	_
229-3	49417-49424	alcohol	_
229-4	49425-49427	on	_
229-5	49428-49433	brain	_
229-6	49434-49443	responses	_
229-7	49444-49446	to	_
229-8	49447-49453	social	_
229-9	49454-49461	signals	_
229-10	49462-49464	of	_
229-11	49465-49471	threat	_
229-12	49472-49474	in	_
229-13	49475-49481	humans	_
229-14	49482-49495	Neurotrophins	_
229-15	49496-49499	and	_
229-16	49500-49518	activity-dependent	_
229-17	49519-49529	plasticity	_
229-18	49530-49534	BDNF	_
229-19	49535-49543	genotype	_
229-20	49544-49553	modulates	_
229-21	49554-49561	resting	_
229-22	49562-49572	functional	_
229-23	49573-49585	connectivity	_
229-24	49586-49588	in	_
229-25	49589-49597	children	_
229-26	49598-49604	Dosage	_
229-27	49605-49612	effects	_
229-28	49613-49615	of	_
229-29	49616-49620	BDNF	_
229-30	49621-49629	Val66Met	_
229-31	49630-49642	polymorphism	_
229-32	49643-49645	on	_
229-33	49646-49654	cortical	_
229-34	49655-49662	surface	_
229-35	49663-49667	area	_
229-36	49668-49671	and	_
229-37	49672-49682	functional	_
229-38	49683-49695	connectivity	_
229-39	49696-49710	BDNF-dependent	_
229-40	49711-49718	effects	_
229-41	49719-49721	on	_
229-42	49722-49739	amygdala-cortical	_
229-43	49740-49749	circuitry	_
229-44	49750-49753	and	_
229-45	49754-49764	depression	_
229-46	49765-49769	risk	_
229-47	49770-49772	in	_
229-48	49773-49781	children	_
229-49	49782-49785	and	_
229-50	49786-49791	youth	_
229-51	49792-49802	Functional	_
229-52	49803-49816	dissociations	_
229-53	49817-49819	of	_
229-54	49820-49824	risk	_
229-55	49825-49828	and	_
229-56	49829-49835	reward	_
229-57	49836-49846	processing	_
229-58	49847-49849	in	_
229-59	49850-49853	the	_
229-60	49854-49860	medial	_
229-61	49861-49871	prefrontal	_
229-62	49872-49878	cortex	_
229-63	49879-49890	Alterations	_
229-64	49891-49893	of	_
229-65	49894-49907	brain‐derived	_
229-66	49908-49920	neurotrophic	_
229-67	49921-49927	factor	_
229-68	49928-49933	serum	_
229-69	49934-49940	levels	_
229-70	49941-49943	in	_
229-71	49944-49952	patients	_
229-72	49953-49957	with	_
229-73	49958-49965	alcohol	_
229-74	49966-49976	dependence	_
229-75	49978-49981	1We	_
229-76	49982-49991	conducted	_
229-77	49992-49994	an	_
229-78	49995-50005	additional	_
229-79	50006-50009	set	_
229-80	50010-50012	of	_
229-81	50013-50021	analyses	_
229-82	50022-50027	where	_
229-83	50028-50031	the	_
229-84	50032-50033	U	_
229-85	50033-50034	-	_
229-86	50035-50038	and	_
229-87	50039-50040	P	_
229-88	50040-50041	-	_
229-89	50042-50048	shocks	_
229-90	50049-50053	were	_
229-91	50054-50062	included	_
229-92	50063-50065	as	_
229-93	50066-50076	regressors	_
229-94	50077-50079	in	_
229-95	50080-50083	the	_
229-96	50084-50089	first	_
229-97	50090-50095	level	_
229-98	50096-50101	model	_
229-99	50101-50102	.	_

#Text=The results of the paper were consistent whether shocks were included or excluded from the model.
230-1	50103-50106	The	_
230-2	50107-50114	results	_
230-3	50115-50117	of	_
230-4	50118-50121	the	_
230-5	50122-50127	paper	_
230-6	50128-50132	were	_
230-7	50133-50143	consistent	_
230-8	50144-50151	whether	_
230-9	50152-50158	shocks	_
230-10	50159-50163	were	_
230-11	50164-50172	included	_
230-12	50173-50175	or	_
230-13	50176-50184	excluded	_
230-14	50185-50189	from	_
230-15	50190-50193	the	_
230-16	50194-50199	model	_
230-17	50199-50200	.	_
